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ABSTRACT
Introduction: Bacterial-platelet-fibrin complexes (vegetations), form on cardiac
valves in infective endocarditis and are associated with increased morbidity and 
mortality. Although the mechanisms o f bacterium-platelet adhesion, platelet 
activation and aggregation that are likely to contribute to vegetation formation have 
been identified, experimental conditions employed in these studies do not accurately 
reflect bacterial growth in the human vasculature. In addition, the contribution o f 
host genetic factors such as platelet receptor polymorphisms to the pathogenesis o f 
infective endocarditis is unknown. Considering that Staphylococcus aureus is now 
the most common cause o f infective endocarditis associated with a poor prognosis, 
the contribution o f bacterial and host factors to bacterium-platelet interactions, 
platelet activation and severity o f infective endocarditis were analysed.
Methods and results:
Influence o f bacterial growth environment on S. aureus -platelet interactions
Platelet aggregometry was performed with a range o f S. aureus clinical and 
genetically modified isolates grown in nutrient broth and whole human blood. Some 
strains grown in nutrient broth failed to induce platelet aggregation, whereas all S. 
aureus isolates induced platelet aggregation after growth in blood. S. aureus surface 
proteins clumping factors A and B, serine-aspartate repeats C, D and E, iron- 
regulated surface determinants A and B and staphylococcal protein A were not 
essential for platelet aggregation induced by S. aureus grown in human blood, but 
the lag time to aggregation was increased in a strain containing mutations in genes 
encoding fibronectin-binding proteins A and B.
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Correlation between platelet activation and susceptibility to infective endocarditis
Platelet activation was determined in patients with infective endocarditis using flow 
cytometry. Platelet P-selectin expression was reduced in patients with infective 
endocarditis as compared to healthy volunteers, but was higher in patients requiring 
surgery.
Influence o f  host genetic polymorphisms on S. aureus-platelet interactions and 
outcome in infective endocarditis
Flow cytometry and platelet aggregometry were performed to determine the role o f 
specific platelet receptor GPIIIa p iAI/A2? GPIb Kozak sequence, human platelet 
antigen (HPA)-2, variable number o f tandem repeats (VNTR) and FcyRIIa H131R 
polymorphisms in S. aureus-platelet interactions. The GPIIIa p jA1/A1 genotype, 
FcyRIIa H allele and GPIb Kozak sequence polymorphism were associated with 
increased S. aureus-induced platelet aggregation. GPIb VNTR alleles influenced 
aggregate formation in vitro and development o f vegetations in patients with 
infective endocarditis. The GPIb HPA-2a/2a genotype was associated with increased 
incidence o f the composite clinical end-point o f embolism, heart failure, need for 
surgery and mortality in patients with infective endocarditis.
Conclusions: These studies have indicated that host and bacterial factors influence 
infective endocarditis and S. awrews-platelet interactions under conditions reflective 
o f the host environment. Bacterial factors expressed during growth in human blood, 
host platelet activation levels and platelet receptor polymorphisms may represent 
novel prognostic markers and therapeutic targets in infective endocarditis.
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1.1 Infections of the cardiovascular system
Recent evidence has suggested an association between infection and the development 
o f a wide range o f  cardiovascular disorders. For example, a number o f organisms 
including Coxsackie B, hepatitis C and adeno-viruses have been implicated in the 
pathogenesis o f  both myocarditis and pericarditis (Magnani & Dec, 2006). In 
addition, Helicobacter pylori, Chlamydophila pneumoniae, Porphyromonas 
gingivalis, herpes simplex virus and cytomegalovirus have been associated with the 
development o f coronary artery disease (Kalvegren et al., 2003, Vercellotti, 2001). 
However, in many cases there is no convincing evidence for an infective aetiology. 
A definitive link between infection and fatal cardiac disease is seen in infective 
endocarditis, a condition that develops following infection o f  the endocardium. The 
term infective endocarditis encompasses infection o f native and prosthetic heart 
valves, implanted medical devices and large vessels (Horstkotte et al., 2004).
1.2 Clinical aspects of infective endocarditis
1.2.1 Epidemiology of infective endocarditis
Infective endocarditis is a serious condition with an incidence o f 2.43 to 9.29 per 
100,000 person-years and predominantly affects men (Bashore et al., 2006). 
Congestive cardiac failure is the most common complication, developing in up to 
44% o f patients, and is associated with an approximate two-fold increase in mortality 
(Heiro et al., 2008, Murdoch et al., 2009). Infective endocarditis may also be 
complicated by septic embolism in 21% to 34% o f patients, with a resultant two- to 
three-fold increase in mortality (Chu et al., 2004, Fabri et al., 2006, Fowler et al., 
2005b, Heiro et al., 2008, Thuny et al., 2005). Between 0.3% to 3.3% o f cases 
relapse and one or more recurrences occur in 6.6% to 12.3% o f individuals (Heiro et 
al., 2008, Mansur et al., 2001). Despite current treatment options, the overall 1-year 
mortality rate o f infective endocarditis has not changed in the past 30 years and
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remains high at 12% to 31% (Habib et al., 2009, Heiro et al., 2008, M ansur et al., 
2001, Murdoch et al., 2009).
It is already known that age, intravenous drug abuse and pre-existing valvular heart 
disease increase the risk o f infective endocarditis (Bashore et al., 2006). However, 
14% of patients with infective endocarditis have no underlying risk factors, and this 
increases to over 50% in those with Staphylococcus aureus infective endocarditis 
(Fowler et al., 1999, Murdoch et al., 2009, Netzer et al., 2000). Considering the high 
morbidity and mortality associated with infective endocarditis, it is important to 
elucidate why it occurs as a complication o f  bacteraemia in some cases, but not 
others.
1.2.2 The changing face of infective endocarditis
Recent articles have alluded to the ‘changing face’ o f infective endocarditis in 
reference to the shifting epidemiology o f this condition (Mouly et al., 2002, 
Prendergast, 2006). Although viridans streptococci including Streptococcus
sanguinis, Streptococcus oralis and Streptococcus mitis have traditionally been the 
most common cause o f infective endocarditis, S. aureus now accounts for up to 49% 
o f cases in non-intravenous drug abusers, in comparison to 14% to 21% for viridans 
streptococci (Table 1.1) (Moreillon & Que, 2004, Murdoch et al., 2009, 
Watanakunakorn & Burkert, 1993).
16
Table 1.1. Causes of infective endocarditis classified by patient sub­
group. Data adapted from (Moreillon & Que, 2004).









Staphylococci 44% 69% 49%
S. aureus 38% 69% 21%
Coagulase-negative 6% 0% 28%
staphylococci
Streptococci 31% 8% 29%
Oral streptococci 21% 3% 22%
Others 10% 5% 7%
Enterococci 8% 2% 7%
HACEK group 4% 0% 1%
Other bacteria 4% 5% 2%
Fungi 1% 2% 0%
Polymicrobial 2% 9% 1%
Negative blood cultures 6% 5% 10%
IVDA, intravenous drug abusers; HACEK, Haemophilus  spp, Aggregatibacter 
actinomycetem com itans , Cardiobacterium hominis, Eikenella corrodens and 
King el I a kingae.
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The emergence o f S. aureus as the main cause o f infective endocarditis is largely 
through iatrogenic means (Fowler et al., 2005b). Long-term intravenous or intra- 
arterial access routes, intra-cardiac devices and prostheses act as portals o f entry for 
bacteria (Fowler et al., 2005b, M oreillon et al., 2002). Commensal bacteria such as 
S. aureus that normally colonise human skin with no adverse effects are able to gain 
access to the bloodstream and persist on cardiac valves. Furthermore, there has been 
an increase in the incidence o f  community-acquired S. aureus infective endocarditis 
due to the increased prevalence o f haemodialysis catheters, pacemakers and 
prosthetic heart valves in the community (M illar et al., 2008). Intravenous drug 
abuse, an ageing population and improved diagnostic procedures have also 
contributed to the increased prevalence o f S. aureus infective endocarditis (Moreillon 
et al., 2002, Nadji et al., 2005).
S. aureus has been associated with a more aggressive course o f  infective endocarditis 
as compared to other organisms such as streptococci, manifested by increased rates 
o f emboli and death (Fowler et al., 2005b, Nadji et al., 2005). This may be due in 
part to its ability to colonise undamaged human heart valves (M oreillon et al., 2002). 
Despite advances in diagnostics and therapeutics, the mortality rate o f  S. aureus 
infective endocarditis approaches 65%, which is higher than that observed for most 
other organisms (Cabell et al., 2002, Fowler et al., 2005b, Nadji et al., 2005).
1.2.3 Diagnosis of infective endocarditis
The diagnosis o f infective endocarditis is largely based upon the modified Duke 
criteria, where positive serial blood cultures for typical microorganisms and 
echocardiographic features form the main criteria (Table 1.2) (Li et al., 2000b). 
Infective endocarditis is considered to be definite in the presence o f  1 pathological 
Duke criterion, 2 major clinical criteria, 1 major and 3 minor clinical criteria or all 5 
minor criteria, and is thought to be possible when 1 major and 1 minor clinical 
criterion or 3 minor clinical criteria are fulfilled (Li et al., 2000b). The diagnosis o f 
infective endocarditis is rejected if the criteria are not met, if there is a firm
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alternative diagnosis, or if  the patient’s symptoms resolve within 4 d o f  antibiotic 
therapy (Li et al., 2000b). Clinical judgem ent is often used to aid diagnosis.
There have been conflicting results from clinical studies regarding the type o f 
echocardiogram that should be performed to safely exclude infective endocarditis. 
Fowler et al identified increased sensitivity and specificity with transoesophageal 
echocardiography in the detection o f vegetations, particularly in patients with S. 
aureus bacteraemia, prosthetic valves, abscesses or right-sided involvement, and 
advocate its use in all patients (Fowler et al., 1997). However, other studies have 
suggested that only those with a high pre-test probability o f  infective endocarditis, as 
evidenced by embolic phenom ena or significant valvular regurgitation on 
transthoracic echocardiography, should have a transoesophageal echocardiogram 
(Thangaroopan & Choy, 2005, Van Hal et al., 2005). Although transoesophageal 
echocardiography is more invasive than transthoracic echocardiography, it appears to 
be better overall at excluding infective endocarditis.
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Table 1.2. Modified Duke criteria for the diagnosis of infective




Pathological 1 M icroorganisms demonstrated by culture or histological 
Criteria examination o f  a vegetation, a vegetation that has embolised, or
an intracardiac abscess specimen, or
2 Pathological lesions - vegetation or intracardiac abscess 
confirmed by histological examination showing active 
endocarditis
Major Clinical 1. Blood culture positive for infective endocarditis 
Criteria
a) Typical microorganisms consistent with infective 
endocarditis from 2 separate blood cultures:
i. Viridans streptococci, Streptococcus bovis, HACEK 
group, Staphylococcus aureus, or
ii. Community-acquired enterococci, in the absence o f a 
primary focus, or
b) M icroorganisms consistent with infective endocarditis from 
persistently positive blood cultures, defined as follows:
i. At least 2 positive cultures o f blood samples drawn 
>12 h apart, or
ii. All o f 3 or a majority o f  4 separate cultures o f  blood 







c) Single positive blood culture for Coxiella burnetii or 
antiphase I IgG antibody titre > 1:800
. Evidence o f endocardial involvement
. Echocardiogram positive for infective endocarditis
a) Oscillating intracardiac mass on valve or supporting 
structures, in the path o f regurgitant jets, or on implanted 
material in the absence o f  an alternative anatomic 
explanation, or
b) Abscess, or
c) New partial dehiscence o f prosthetic valve
4. New valvular regurgitation (worsening or changing o f pre­
existing murmur not sufficient)
1. Predisposition, predisposing heart condition or injection drug 
use
2. Fever, temperature >38°C
3. Vascular phenomena: major arterial emboli, septic pulmonary 
infarcts, mycotic aneurysms, intracranial haemorrhage, 
conjunctival haemorrhages, and Janew ay’s lesions
Immunologic phenomena: glomerulonephritis, O sier’s nodes, 
Roth’s spots, and rheumatoid factor
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Type o f 
c r ite r ia
Features
5. Microbiological evidence: positive blood culture but does not 
meet a major criterion as noted above or serological evidence o f 
active infection with organism consistent with infective 
endocarditis
HACEK, Haemophilus spp, Aggregatibacter actinom ycetem com itans ,
Cardiobacterium hominis, Eikenella corrodens and Kingella kingae.
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1.2.4 Management and prevention of infective endocarditis
Current treatment o f infective endocarditis follows national and international 
guidelines, such as those issued by the European Society o f Cardiology, and includes 
the use o f appropriate antibiotics according to microbiological culture and sensitivity 
results (Habib et al., 2009). However, approximately 40% o f cases fail to respond to 
medical therapy alone and require valve replacement or repair (Cabell et al., 2005).
Surgical treatment o f infective endocarditis is often delayed until the acute phase o f 
infection has resolved, in order to minimise the risk o f peri- and early post-operative 
infective endocarditis (Habib et al., 2009). However, early surgery is indicated for 
patients at high risk o f developing intractable cardiac failure, those with large 
vegetations with potential for embolism, abscesses, fistulae, valve obstruction, 
destruction or dehiscence and infection with organisms that are refractory to 
antibiotic treatment (Bashore et al., 2006, Habib et al., 2009).
Surgical treatment is associated with a significant improvement in prognosis, 
especially in patients with aortic valve or S. aureus infective endocarditis (Bishara et 
al., 2001, Cabell et al., 2005, Croft et al., 1983), but these trials are predominantly 
retrospective, single-centre observational studies (Bishara et al., 2001, Croft et al., 
1983, Habib et al., 2009). Furthermore, the potential benefits o f surgery in the most 
seriously ill patients are unknown, as they are often deemed to have unacceptably 
high risks o f peri-operative complications, including death (Habib et al., 2009).
Antibiotic prophylaxis has traditionally been recommended for patients considered to 
be at risk o f infective endocarditis, including those with acquired or congenital 
structural heart disease, prosthetic heart valves and previous infective endocarditis, 
undergoing invasive dental, genitourinary and gastrointestinal procedures (Habib el 
al., 2009). However, no randomised controlled trials have analysed the potential 
benefits o f oral antibiotic prophylaxis, whereas it is widely known that antimicrobials 
such as penicillins are associated with a risk o f anaphylaxis (Habib et al., 2009). 
Recent guidelines issued by the National Institute for Clinical Excellence and the
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European Society o f Cardiology have revised recommendations for antibiotic 
prophylaxis, such that only high-risk patients undergoing high-risk procedures are 
advised to receive preventative treatment (Habib et al., 2009, National Institute for 
Health and Clinical Excellence, 2008). It is clear that more robust evidence is 
required to determine the benefits o f existing and novel therapeutics and 
prophylactics in infective endocarditis.
1.3 Staphylococcus aureus, the major infective endocarditis 
pathogen
1.3.1 Diseases caused by S. aureus
S. aureus is a coagulase-positive, Gram-positive coccus (Lowy, 1998). First 
identified by Sir Alexander Ogston in Aberdeen, Scotland, 1880, S. aureus is the 
most pathogenic human staphylococcal species, responsible for a wide array o f 
invasive and non-invasive diseases (Table 1.3) (van Belkum et al., 2009). 
Endocarditis currently accounts for 18% to 35% o f S. aureus bacteraemia cases 
(Fowler et al., 1997, Lowy, 1998, Van Hal et al., 2005), increasing to 51% in 
patients with a prosthetic heart valve (El-Ahdab et al., 2005). S. aureus has also 
been implicated in a variety o f  infectious diseases in animals, ranging from mastitis 
in ruminants and skeletal infections in chickens, to skin and bloodstream infections 
in rabbits (Ben Zakour et al., 2008).
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Table 1.3. The wide range of human diseases caused by S. aureus
(Lowy, 1998, G reene et a i,  1995, Sinha & Herrm ann, 2005 , van Belkum et 
a/., 2009).
Human (non-invasive) Human (invasive)
Boils Cystitis
Carbuncles Gastroenteritis





Staphylococcal scalded skin syndrome Septic arthritis
Stye Septicaemia
Superficial abscesses Toxic shock syndrome 
Urinary tract infections 
Wound infections/deep abscesses
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S. aureus colonises the human nares, axillae, pharynx, vagina and skin, with a 
combination o f host, bacterial and environmental factors contributing to host 
colonisation (van Belkum et ah, 2009, W ertheim et al., 2005a). The anterior nares 
are the most common site o f colonisation in humans, with approximately 20% of 
healthy adults permanently colonised and 30% intermittently colonised by S. aureus 
(Lowy, 1998, Wertheim et ah, 2005a). Permanent carriers are thought to constantly 
harbour the same strain, while intermittent carriers tend to be colonised by different 
strains (Wertheim et ah, 2005a). In the presence o f favourable conditions, 
commensal isolates have the potential to cause invasive infection, but the underlying 
virulence and host factors contributing to this are not fully understood (Feil et al., 
2.003, Lindsay et al., 2006, Wertheim et ah, 2005a).
1.3.2 Antibiotic resistance in S. aureus
With the increased number o f infections attributable to S. aureus, there has been an 
associated increase in antimicrobial use, leading to antibiotic resistance (Lowy, 
2003). Prior to the advent o f the (3-lactam antibiotic penicillin, 70% o f S. aureus 
infections were complicated by haematogenous dissemination with an associated 
80% mortality rate (Deurenberg et al., 2007, Lowy, 2003). The introduction o f 
penicillin in clinical practice in 1940 substantially reduced S. tfwrews-associated 
morbidity and mortality, but was followed 2 years later by the first case o f  penicillin- 
resi stance due to the acquisition o f (3-lactamases by S. aureus (Deurenberg & 
Stobberingh, 2008, Lowy, 2003). Within 10 years, approximately 90% o f S. aureus 
strains had developed penicillin-resistance (Boyle-Vavra & Daum, 2007, Lowy, 
2003).
The (3-lactamase-resistant antibiotic methicillin, was introduced in 1959, but was 
swiftly followed by the first case o f  methicillin-resistant S. aureus (MRSA), 
identified in the United Kingdom in 1961 (Deurenberg & Stobberingh, 2008). Since 
then, the number o f cases o f MRSA has escalated worldwide, particularly in the 
context o f nosocomial infection, with associated high mortality rates (Boyle-Vavra &
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Daum, 2007, Fowler et al., 2005b, Lowy, 2003). Approximately 27% o f cases o f  S. 
aureus bacteraemia or infective endocarditis in developed countries are due to 
MRS A (Fowler et a l ,  2005b).
Methicillin resistance is conferred by the acquisition o f penicillin-binding protein 2a 
(PBP2a) encoded by the mecA gene on staphylococcal cassette chromosome 
(SCCmec) (Boyle-Vavra & Daum, 2007). PBP2a prevents binding o f (3-lactams to S. 
aureus, enabling S. aureus cell wall synthesis to continue and facilitating pathogen 
survival (Boyle-Vavra & Daum, 2007). Seven different types o f  SCC mec have been 
identified to date and are classified according to the type o f recombinase they encode 
(Deurenberg & Stobberingh, 2008).
MRSA has traditionally been associated with hospital stay, but community-acquired 
MRS A (CA-MRSA) is increasing in prevalence (Deurenberg et al., 2007). CA- 
MRSA first emerged in the 1990s and is now a global phenom enon (Diep & Otto,
2008). As o f 2007, there were 23 published cases o f  CA-M RSA infective 
endocarditis (Millar et al., 2008).
CA-MRSA differs from hospital-acquired MRSA (F1A-MRSA) in that younger 
individuals with a history o f skin lesions, intravenous drug abuse or diabetes mellitus 
are more likely to be affected (Millar et al., 2008). Furthermore, CA-MRSA is more 
likely to harbour SCC mec types IV or V, while HA-MRSA possesses SCC mec types 
I to III (Deurenberg et al., 2007). Notably, SCC mec IV is smaller, more likely to be 
horizontally transferred and contains fewer antibiotic resistance genes than SCC mec 
types I to III (Deurenberg et al., 2007). CA- and FIA-MRSA strains also have 
different genetic backgrounds (see Section 1.3.3), leading to the belief that CA- 
MRSA originated from CA-methicillin sensitive S. aureus (MSSA) rather than HA- 
MRSA strains (Boyle-Vavra & Daum, 2007).
CA-MRSA strains, particularly those o f the USA300 lineage, have been associated 
with increased virulence as compared to HA-M RSA strains (Li et al., 2009). The 
increased virulence o f CA-MRSA was initially attributed to Panton-Valentine 
leucocidin (PVL), a bi-component pore-forming leucotoxin present in a large
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proportion o f CA-MRSA isolates (Boyle-Vavra & Daum, 2007, Labandeira-Rey et 
al., 2007). Although an early study identified an association between the presence of 
PVL and the development o f necrotising pneumonia in a murine model o f infection 
(Labandeira-Rey et al., 2007), recent evidence suggests that the creation o f an 
isogenic PVL-negative mutant in this study was complicated by an unintentional 
point mutation in the P2 promoter o f the accessory gene regulator (agr) (see Section
1.3.6) (Villaruz et al., 2009). Subsequent repair o f the agr mutation resulted in PVL 
having no significant effect on the pathogenesis o f severe pneumonia (Villaruz et al.,
2009). Recently, the pathogenicity o f CA-MRSA has been attributed to increased 
production o f core genome-encoded virulence factors such as a-toxin  and phenol- 
soluble modulins (Li et al., 2009).
Some MRSA strains have now acquired reduced susceptibility to the ‘antibiotic o f 
last resort’ vancomycin, resulting in the emergence o f vancomycin intermediate- 
resistant S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA) (Lowy,
2003). VISA, which first emerged in Japan in 1997, develops following changes in 
S. aureus peptidoglycan synthesis and cross-linking, leading to thickened, irregular 
cell walls that trap vancomycin (Lowy, 2003). Conversely, complete resistance to 
vancomycin first occurred in 2002 following transfer o f the vanA operon from 
vancomycin-resistant enterococci, resulting in alteration o f  the terminal peptide o f 
peptidoglycan, leading to reduced affinity for vancomycin (Lowy, 2003). A t present 
29% o f cases o f MRSA infective endocarditis are due to strains that are also VISA, 
and such cases are associated with increased rates o f persistent bacteraemia and 
cardiac failure (Bae et al., 2009).
Daptomycin has recently emerged as an effective antibiotic for the treatment o f 
MRSA, VISA and VRSA infections (Fowler et al., 2006). However, cases o f 
reduced susceptibility to daptomycin, often linked with vancomycin resistance, have 
arisen (Kirby et al., 2009, Sakoulas et al., 2008). It is clear that new therapeutics are 
required in the management o f S. aureus bacteraemia and infective endocarditis.
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1.3.3 Population genetics and evolution of S. aureus
The S. aureus genome varies in size from a 2.5 to 2.9 Mbp circular chromosome that 
codes for numerous virulence factors and may also contain antibiotic resistance 
genes (Lowy, 1998, Sinha & Herrmann, 2005). Since the S. aureus genome was first 
sequenced in 2001, 15 S. aureus strain sequences have been published, with over 100 
strains currently being sequenced (National Centre for Biotechnology Information, 
National Centre for Biotechnology Information, UniProt Consortium). The S. aureus 
genome is considered to consist o f the core, core variable and accessory genomes 
(Lindsay et al., 2006). Three-quarters o f genes are present in the core genome, 
which is largely invariable as the genes present are involved in so-called 
‘housekeeping’ functions, which facilitate S. aureus growth and survival (Ben 
Zakour et al., 2008). Approximately 10% to 12% o f genes are in the core variable 
genome, including many virulence factors (Ben Zakour et al., 2008, Lindsay et al., 
2006). The accessory genome predominantly contains horizontally-acquired genes 
encoding antibiotic resistance and virulence factors (Ben Zakour et al., 2008). 
Mobile genetic elements such as genomic islands, staphylococcal pathogenicity 
islands, prophages, integrated plasmids and transposons make up the accessory 
genome and confer marked plasticity to the S. aureus genome (Lindsay et al., 2006, 
Peacock et al., 2002).
The clonal diversity o f S. aureus has been examined by multi-locus sequence typing 
(MLST) (Feil et al., 2003). A study by Feil et al demonstrated that 78% o f S. aureus 
strains could be grouped into 1 o f 11 clonal complexes (CC), consisting o f S. aureus 
sequence type (ST) strains and single locus variants (SLVs), the latter only differing 
from STs at 1 o f the 7 alleles used to determine sequence type (Feil et al., 2003). 
Although S. aureus strain lineage and gene prevalence does not correlate with 
disease causation in humans (Feil et al., 2003, Lindsay et al., 2006), S. aureus strains 
of clonal lineages CC5 and CC30 have been associated with the development o f 
haematogenous complications o f S. aureus bacteraemia, including infective 
endocarditis (Fowler et al., 2007).
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1.3.4 S. aureus virulence factors implicated in the pathogenesis of 
infective endocarditis
Virulence factors are components o f an organism that contribute to disease 
pathogenesis, and are often identified in animal models o f infection (Foster, 2005). S. 
aureus produces a great array o f virulence factors, including secreted toxins, 
enzymes and proteins, and anchorless and cell wall-anchored proteins, as outlined in 
Table S l . l .  A selection o f S. aureus virulence factors, including those implicated in 
the pathogenesis o f infective endocarditis, are discussed below in further detail.
1.3.4.1 S. aureus toxins
Toxins produced by S. aureus include a - , (3-, 5- and y-toxins, which induce lysis o f 
host cells as described in Table S l . l  (Dinges et al., 2000, Lowy, 1998). a-tox in  has 
been implicated in the destruction o f valvular tissue following S. aureus 
phagocytosis by endothelial cells (see Section 1.4.3.2) (Chorianopoulos et al., 2009, 
Sinha & Herrmann, 2005). Although a-toxin  has been reported to induce aggregation 
o f human platelets in vitro (Bhakdi et al., 1988), a strain expressing increased levels 
o f a-toxin had paradoxically reduced virulence in a rabbit model o f infective 
endocarditis, possibly due to a-toxin-m ediated platelet lysis and release o f platelet 
microbicidal proteins (PMPs) (Bayer et al., 1997) (see Section 1.5.2). a-tox in  has 
also been demonstrated to repress regional cardiac perfusion and myocardial 
contractility in rats via increased generation o f thromboxane and eicosanoid release 
(Grandel et al., 2009).
Other toxins include S. aureus superantigens, o f which at least 18 have been 
identified to date, and consist o f enterotoxins and toxic shock syndrome toxin-1 
(TSST-1), responsible for staphylococcal food poisoning and toxic shock syndrome, 
respectively, as outlined in Table Sl . l  (Fraser & Proft, 2008). Superantigens are so 
named because they are able to induce T-cell proliferation and cytokine release by 
binding to major histocompatibility class (MHC) II complexes on T-cells (Fraser &
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Proft, 2008). Exfoliative toxins such as epidermolytic toxins A and B are 
responsible for desquamating skin conditions such as staphylococcal scalded skin 
syndrome (Dinges et al., 2000). In addition, the leucocytolytic toxin PVL has been 
implicated in severe cutaneous infection as detailed in Table S l . l  (Foster, 2005).
1.3.4.2 S. aureus enzymes
S. aureus also produces enzymes, including proteases, lipases, hydrolases and 
collagenase, which contribute to nutrient acquisition and host tissue destruction, 
facilitating survival in the host (Table S l . l )  (Dinges et al., 2000, Lowy, 1998, 
Novick, 2003). (3-lactamase mediates S. aureus resistance to (3-lactam antibiotics 
(Lowy, 1998). Coagulase and staphylokinase have been implicated in clot formation 
and dissolution respectively, however neither influences the development o f  infective 
endocarditis (Table S l . l )  (Baddour et al., 1992, Bokarewa et al., 2006, Lowy, 1998, 
Moreillon et al., 1995). Specifically, Ruotsalainen et al did not identify any 
difference in the prevalence o f genes encoding staphylokinase between S. aureus 
strains isolated from cases o f bacteraemia and infective endocarditis (Ruotsalainen et 
al., 2008). However, staphylokinase may facilitate dissolution and fragmentation o f 
vegetations in infective endocarditis resulting in embolism, although this has not 
been examined to date (Bokarewa et al., 2006). In addition, the presence o f 
coagulase did not alter early vegetation formation in a rat model o f  infective 
endocarditis, but its role in the later stages o f infective endocarditis or in the disease 
process in humans is unknown (Moreillon et al., 1995).
1.3.4.3 Other S. aureus secreted proteins, cell wall and capsule
S. aureus secretes a number o f proteins, including chemotaxis inhibitory protein o f 
staphylococci (CHIPS), staphylococcal complement inhibitor (SCIN), extracellular 
adhesion protein (Eap) and staphylococcal superantigen-like proteins (SSLs), with 
roles o f these virulence factors outlined in Table Sl . l  (Foster, 2005, Fraser & Proft,
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2008, Sinha & Herrmann, 2005). SSLs are so named because they share sequence 
similarity to superantigens such as TSST-1 (Fraser & Proft, 2008). Fourteen SSLs 
have been identified to date but rather than bind MHC II complexes, they bind IgA, 
complement components and inhibit neutrophil binding to endothelium, inhibiting 
host immune activity (Fraser & Proft, 2008). SSL-5 is also able to induce platelet 
aggregation via a platelet glycoprotein (GP)Ib receptor-dependent mechanism, but its 
role in the induction o f infective endocarditis in animal models has not been 
examined to date (de Haas et al., 2009).
The S. aureus cell wall, mainly consisting o f  peptidoglycan, mediates platelet 
aggregation at the stationary phase o f growth (Kessler et al., 1991), while 
lipoteichoic acid, which forms part o f the cell wall, independently inhibits platelet 
aggregation induced by pharmacological agonists (Sheu et al., 2000). The role o f the 
S. aureus cell wall in the induction o f infective endocarditis is unknown. The outer 
S. aureus capsule inhibits bacterium-platelet interactions (see Section 1.3.5.2) and 
prevents complement recognition by leucocytes, thus reducing phagocytosis (Foster, 
2005, Risley et al., 2007).
1.3.4.4 Cell wall-associated proteins of S. aureus
A number o f anchorless and cell wall-anchored adhesins are expressed on the surface 
o f S. aureus, and described in Table S l . l .  Anchorless proteins, also termed 
secretable expanded repertoire adhesive molecules (SERAMs), are bound non- 
covalently to the cell wall upon secretion, and include the extracellular matrix 
(ECM)-binding protein homologue and the ECM protein-binding protein (Emp) that 
mediate adherence to plasma proteins and endothelial cells, as well as contributing to 
biofilm formation (Johnson et al., 2008, Sinha & Herrmann, 2005). Extracellular 
fibrinogen-binding protein (Efb) is multifunctional as it interferes with immune 
defence, wound healing and platelet aggregation (Shannon & Flock, 2004). Other 
anchorless proteins include autolysins, while PBPs are attached to the cytoplasmic 
membrane, and elastin-binding protein is transmembranous and enables S. aureus to
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bind elastin (Clarke & Foster, 2006, Downer et al., 2002, Lowy, 1998). The 
contribution o f S. aureus anchorless proteins to the pathogenesis o f infective 
endocarditis is not known.
A large number o f cell wall-anchored proteins such as plasmin-sensitive protein 
(Pis), serine-rich adhesin for platelets (SraP) and Microbial Surface Components 
Recognising Adhesive Matrix Molecules (MSCRAM Ms) are expressed by S. aureus 
(Table S l . l )  (Foster & Hook, 1998, Juuti et a l ,  2004, Siboo et al., 2005). The gene 
encoding Pis is only present in type I SCCmec found in MRSA strains (Juuti et al.,
2004). Pis may contribute to nasal colonisation by binding nasal epithelium, but is 
associated with inhibition o f platelet aggregation, reduced fibronectin binding and 
cellular invasion, possibly via decreased expression o f  clumping factor A (ClfA) and 
steric hindrance o f  fibronectin-binding proteins (FnBPs), respectively (Hussain et al., 
2009, Juuti et al., 2004). Conversely, SraP binds platelets and is associated with 
increased virulence in a rabbit model o f infective endocarditis (Siboo et al., 2005).
1.3.4.4.1 S. aureus MSCRAMMs
The term MSCRAMM has been coined to describe the cell wall-anchored proteins 
present on S. aureus that bind ECM proteins (Foster & Hook, 1998). Twenty-one 
MSCRAMMs have been identified to date and include fibronectin-binding proteins 
A and B (FnBPA, FnBPB), clumping factors A and B (ClfA, ClfB), serine-aspartate 
repeat (Sdr) proteins, staphylococcal protein A (SpA), collagen adhesin (Cna), S. 
aureus surface (Sas) proteins and iron-regulated surface determinants A and B (IsdA, 
IsdB) (Table S l . l )  (Clarke & Foster, 2006, Roche et al., 2003).
The main roles o f MSCRAMMs are to facilitate bacterial adhesion to ECM, evasion 
o f host immune defences and internalisation by host cells, culminating in disease 
pathogenesis (Clarke & Foster, 2006). FnBPs, SpA, C lf and Isd proteins are 
discussed in further detail (see Section 1.3.5). Cna contributes to S. aureus adherence 
to valvular sub-endothelium (see Section 1.4.3.2), but is predominantly involved in
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the development o f bone and joint infections (Clarke & Foster, 2006). SdrC and 
SdrD have been implicated in nasal colonisation, while SdrE weakly induces platelet 
aggregation (Corrigan et al., 2009, O'Brien et al. , 2002a). SasC facilitates biofilm 
formation, SasG has been implicated in biofilm  formation, nasal colonisation and 
inhibition o f the ligand-binding activities o f other M SCRAMM s, and SasH has been 
associated with the development o f invasive S. aureus infection (Clarke & Foster, 
2006, Roche et a l ,  2003). However, the role o f S. aureus Sas and Sdr proteins in the 
pathogenesis o f infective endocarditis is unknown.
Many MSCRAMMs bind multiple ligands, yet there is also redundancy as a number 
o f MSCRAMMs are capable o f binding the same ligand (Clarke & Foster, 2006). 
For example, FnBPA adheres to both fibrinogen and fibronectin at the mid­
exponential phase o f growth, while ClfA adheres to fibrinogen, predominantly at the 
stationary phase o f growth, and both have been implicated in the pathogenesis o f 
infective endocarditis (see Section 1.3.5) (Clarke & Foster, 2006). This plasticity in 
ligand-binding ability appears to be beneficial for S. aureus, as it facilitates host 
colonisation and disease causation under varying environmental conditions and 
during different growth phases, accounting for the capacity o f this pathogen to infect 
a range o f hosts and cause invasive and non-invasive diseases (Table 1.3) (Clarke & 
Foster, 2006).
1.3.4.4.2 Structure of S. aureus MSCRAMMs
The structure o f selected MSCRAMMs, outlining binding regions and ligands are 
depicted in Figure 1.1. The N-terminus contains the approximately 40 amino acid 
long signal sequence (S), which facilitates secretion o f the M SCRAM M through the 
cell membrane. Adjacent to this are the A to E or N-terminal NEAr Transporter 
(NEAT) ligand-binding domains, binding fibrinogen, fibronectin, von Willebrand 
factor (vWF), complement, IgG, elastin, cytokeratin, haem and transferrin as 
outlined (Clarke & Foster, 2006, Clarke et al., 2004, M azmanian et al., 2003). The 
serine-aspartate dipeptide repeats (R) facilitate extension o f the ligand-binding 
regions (Hartford et al., 1997). The wall-spanning region (W) is composed o f
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proline and glycine residues and includes octapeptide (Wr) and non-repeat (Wc) 
regions, while the hydrophobic membrane-spanning region (M) at the C-terminus 
contains positively-charged residues (Clarke & Foster, 2006).
The LPXTG amino acid m otif is located between regions W and M and plays a 
crucial role in the attachment o f M SCRAMM s to the cell wall peptidoglycan (Clarke 
& Foster, 2006). Cleavage o f LPXTG between the threonine and glycine residues by 
the membrane bound transpeptidase Sortase A, establishes an amide bond between 
the carboxyl group o f threonine and the amino group o f the cell wall, anchoring the 
MSCRAMM (Clarke & Foster, 2006).
MSCRAMMs can either have a circumferential or punctate distribution on the S. 
aureus cell surface, with a circumferential distribution conferred by the presence o f a 
YSIRK/GS amino acid m otif 18 to 20 residues upstream o f the peptide cleavage site 
in MSCRAMMs such as ClfA, FnBPB and SpA (DeDent et al., 2008).
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Figure 1.1. The structural organisation of S. aureus Microbial Surface 
Components Recognising Adhesive Matrix Molecules (MSCRAMMs). Regions 
in purple bind fibrinogen, in grey bind fibronectin and in blue bind von Willebrand 
factor, complement and IgG-Fc fragments. Additionally, the A domain of FnBPA 
binds elastin and the A domain of ClfB binds cytokeratin. N-terminal NEAr 
Transporter (NEAT) domains are able to bind haem and transferrin and in the case 
of IsdA, also bind fibrinogen, fibronectin and cytokeratin. Regions are not drawn to 
scale. FnBPA, fibronectin-binding protein A; FnBPB, fibronectin-binding protein B; 
ClfA, clumping factor A; ClfB, clumping factor B; SpA, staphylococcal protein A; 
IsdA, iron-regulated surface determinant A; IsdB, iron-regulated surface determinant
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B. S, signal sequence; letters A-E, ligand-binding domains; R, serine-aspartate 
dipeptide repeats; W, wall-spanning region; Wr, octapeptide repeat; Wc, non-repeat 
region; M, membrane-spanning region; LPXTG, the amino acid motif that is cleaved 
by Sortase A. Adapted from references (Clarke & Foster, 2006, Foster & Hook, 
1998).
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1.3.5 The role of MSCRAMMs in the pathogenesis of S. aureus 
infective endocarditis
1.3.5.1 Fibronectin-binding proteins (FnBPs)
FnBPA and FnBPB are encoded by genes fnbA  and fnbB , respectively (Greene et al.,
1995). Strain-dependent variation in the distribution o ffn b  genes has been observed, 
with 77% of S. aureus clinical isolates possessing both genes and 23% carrying one 
gene (Peacock et al., 2000). Although isolates associated with invasive disease are 
more likely to contain both fn b  genes, this does not correlate with the ability o f these 
strains to bind immobilised fibronectin in vitro (Peacock et al., 2000). Maximal 
expression o f both FnBPs occurs during the mid-exponential phase o f growth, with 
positive regulation by staphylococcal accessory regulator A (SarA), sigma B ( a B) 
and S. aureus exoprotein expression (sae) and negative control by agr (See Section
1.3.6) (Cheung et al., 2009, Entenza et al., 2005, Wolz et al., 2000).
The FnBPA A region binds elastin and the y chain o f fibrinogen (Figure 1.1), 
whereas the BCD regions o f both FnBPs bind the FI region o f the N-terminal 
domain o f fibronectin using a (3-zipper mechanism (Clarke & Foster, 2006, Keane et 
al., 2007). Eleven fibronectin-binding repeat regions have been identified within the 
BCD domains o f both FnBPA and FnBPB, with six repeats exhibiting evidence o f 
multivalent binding in each M SCRAM M (Meenan et al., 2007).
Using a genetically diverse collection o f S. aureus strains, Loughman et al detected 
24% to 34% amino acid sequence diversity in the A region o f  FnBPs with 7 different 
alleles identified for FnBPA and 3 different isotypes for FnBPB (Loughman et al., 
2008). Variation in the amino acid sequence o f the A domain was confined to the 
N2N3 regions with minimal involvement o f the ligand-binding and latch-forming 
regions, thus conferring antigenic variation with preserved fibrinogen- and elastin- 
binding affinity and ability to cause disease (Loughman et al., 2008). Sequence 
diversity o f the A domain o f FnBPs does not correlate with S. aureus clonal origin
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(ST), suggesting that this allelic variation developed via horizontal gene transfer or 
recombination (Loughman et al., 2008).
FnBPA and FnBPB share 95% amino acid identity in the D, W and M regions, 
suggesting that they arose as a result o f gene duplication (Sinha and Herrmann,
2005). However, the A regions o f FnBPA and FnBPB have only 45% amino acid 
identity, and this is reflected in their varying ability to bind plasma proteins as the A 
domain o f FnBPA binds fibrinogen and elastin, while the FnBPB A domain does not 
exhibit any ligand-binding ability (Clarke & Foster, 2006, Keane et al., 2007). In 
spite o f the fact that both the ClfA and FnBPA A domains bind fibrinogen at its y 
chain, they only share 25% to 29% amino acid identity (Clarke and Foster, 2006).
Early animal experiments provided conflicting evidence as to the role o f  FnBPA in 
the pathogenesis o f infective endocarditis. Kuypers et al discovered that vegetations 
infected with low fibronectin-binding mutants o f S. aureus had 100-fold reduced 
bacterial densities (Kuypers & Proctor, 1989), while S. aureus mutants deficient in 
sar alone or both sar and agr exhibited reduced attachment to vegetations, attributed 
to the loss o f fibronectin-binding capacity (Cheung et al., 1994). Furthermore, the 
double sar/agr mutant was reported to have an attenuated ability to persist and 
multiply within vegetations (Cheung et al., 1994). However, other studies have not 
identified differences in vegetation bacterial counts with sar and agr single and 
double mutants or with strains deficient in FnBPs, despite variation in fibronectin 
binding in vitro (Flock et al., 1996, Xiong et al., 2004).
MSCRAMM redundancy may have been responsible for these inconclusive results. 
FnBPA, FnBPB and ClfB are all expressed during the mid-exponential phase o f 
growth, and FnBPA-deficient mutants may therefore retain ligand-binding activity 
and exhibit no difference in their ability to induce experimental infective 
endocarditis (Que et al., 2001). In order to address this issue, M SCRAM M s were 
expressed in a heterologous host, Lactococcus lactis (Que et al., 2001). Significantly 
smaller inocula o f FnBPA- or ClfA-expressing L. lactis strains, were required to
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induce endocarditis as compared to the parent L. lactis strain, suggesting a role for 
these MSCRAMMs in the pathogenesis o f infective endocarditis (Que et al., 2001).
Further studies were performed by the same group to determine the precise role and 
interplay o f FnBPA and ClfA in the pathogenesis o f infective endocarditis. In 
catheter-induced models o f infective endocarditis, both ClfA- and FnBPA-expressing 
L. lactis were present within cardiac vegetations, but ClfA-positive strains were 
confined to vegetations and eradicated within 10 d, while FnBPA-positive strains 
persisted with evidence o f invasion o f adjacent endothelium (Piroth et al., 2008, Que 
et al., 2005). Loss o f fibrinogen-binding capacity completely abrogated colonisation 
and reduced fibronectin-mediated cell internalisation in these studies, suggesting a 
synergistic role for these MSCRAMM s in the pathogenesis o f infective endocarditis 
(Piroth et al., 2008, Que et al., 2005).
Piroth et al have recently demonstrated that the A4+i6 domain o f FnBPA is crucial 
for both fibrinogen and fibronectin binding, and when expressed on L. lactis, 
independently mediates development o f infective endocarditis in an experimental rat 
model (Piroth et al., 2008). Pathogenesis o f infective endocarditis correlated with 
fibrinogen-binding capacity, while disease severity correlated with both fibrinogen 
and fibronectin binding, suggesting synergistic roles for these ligand-binding 
activities in infective endocarditis (Piroth et al., 2008).
In a study analysing the capacity o f both FnBPA and FnBPB to induce platelet 
aggregation following expression in Staphylococcus carnosus, FnBPA, but not 
FnBPB, was able to induce fibrinogen- and fibronectin-mediated platelet aggregation 
in vitro (Heilmann et al., 2004). However, a more recent study has demonstrated that 
both FnBPs are capable o f inducing platelet aggregation in vitro (Fitzgerald et al., 
2006b). The role o f FnBPB in the induction o f infective endocarditis in experimental 
animal models has not been investigated.
FnBPs also facilitate S. aureus invasion o f a wide variety o f host cells, including 
endothelial cells, epithelial cells, keratinocytes, osteoblasts and alveolar cells, and
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FnBP-mediated endothelial invasion contributes to the pathogenesis o f infective 
endocarditis (see Section 1.4.3.2) (Clarke & Foster, 2006, McElroy et a t ,  2002). 
FnBPs facilitate biofilm development by MRS A strains (O'Neill et al., 2008, 
Vergara-Irigaray et al., 2009), but are paradoxically associated with reduced 
virulence in animal models o f pneumonia, possibly via FnBPA-mediated 
phagocytosis and elimination o f S. aureus from murine lungs (McElroy et al., 2002).
1.3.5.2 Clumping factor A (ClfA)
ClfA and ClfB are members o f the Sdr family o f  MSCRAM M s, characterised by 
serine-aspartate dipeptide repeats within the R region (Figure 1.1) (Clarke & Foster, 
2006). The A domain o f C lf proteins is approximately 520 amino acids long in most 
strain, and at the N2 and N3 domains binds the C-terminal o f the fibrinogen y chain 
at residues H6, H7, G10, Q13, A14 and G15 (Ganesh et al., 2008, M cDevitt et al., 
1997). Clumping factor-mediated fibrinogen binding occurs via a ‘latch and dock 
m echanism ’ by the formation o f an IgG-like fold between the N2 and N3 domains, 
similar to the mode o f fibrinogen binding employed by Staphylococcus epidermidis 
SdrG (Foster & Hook, 1998, Ganesh et al., 2008). ClfA binds fibrinogen at the 
same region as the platelet glycoprotein (GP)IIb/IIIa receptor, and this interaction is 
inhibited by calcium binding to the EF-hand m otif o f  the A region (Ganesh et al., 
2008, McDevitt et al., 1997).
The R region o f ClfA, which is 308 amino acids long in S. aureus Newman, does 
not possess any intrinsic ligand-binding activity, but facilitates extension o f  the 
ligand-binding A region (Hartford et al., 1997). Unlike the A domain, region R has 
been reported to vary in size from 193 to 440 amino acids between different strains, 
but this does not influence fibrinogen binding (M cDevitt & Foster, 1995). ClfA is 
encoded by the clfA gene found in all strains o f S. aureus (Tristan et al., 2003), and 
is predominantly expressed during the stationary phase o f growth in vitro and in 
vivo under the control o f a B but independent o f agr (see Section 1.3.6) (Entenza et 
al., 2005, Goerke et al., 2005, Wolz et al., 1996).
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Studies have demonstrated that ClfA contributes to the early stages o f development 
o f experimental infective endocarditis through its ability to bind fibrinogen 
(Entenza et al., 2005, M oreillon et al., 1995, Sullam et al., 1996). To avoid the 
possibility o f MSCRAMM functional overlap, Stutzmann M eier et al used 
Streptococcus gordonii as a heterologous host for ClfA expression in a rat model o f 
infective endocarditis (Stutzmann Meier et al., 2001). ClfA-positive strains were 
associated with significantly increased vegetation adherence with no effect on 
vegetation bacterial densities (Stutzmann Meier et al., 2001), confirming the 
primary role o f ClfA in vegetation colonisation (Que et al., 2005). However, the 
importance o f ClfA in the pathogenesis o f infective endocarditis has recently been 
questioned as ClfA-induced fibrinogen binding and induction o f infective 
endocarditis in animal models is inhibited by S. aureus capsule, which is present in 
vivo, but often absent when cells are processed for the above experiments (Baddour 
et al., 1992, Risley et al., 2007).
It has also been postulated that ClfA promotes the development o f  arthritis and 
inhibits phagocytosis by fibrinogen-dependent and -independent mechanisms, the 
latter involving enhanced inactivation o f complement C3b by the ClfA A domain 
binding serum factor I (Clarke & Foster, 2006, Hair et al., 2008, Higgins et al.,
2006).
1.3.5.3 Clumping factor B (ClfB)
In contrast to the FnBPs which contain almost identical D regions, there is only 
27% amino acid identity between ClfA and ClfB, suggesting that they arose 
independently o f each other (Clarke & Foster, 2006). This is manifest in variation 
in their ligand-binding ability, as instead o f binding the y chain o f fibrinogen, the A 
domain o f ClfB binds repeat region 5 within the C-terminal end o f the A a  chain o f 
fibrinogen (Ni Eidhin et al., 1998, Walsh et al., 2008). Furthermore, ClfB binds 
fibrinogen less efficiently than ClfA, as each molecule o f fibrinogen adheres to two 
ClfA molecules or one ClfB protein (Clarke & Foster, 2006, Miajlovic et al., 2007).
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ClfB binds avidly to cytokeratin-10 on the surface o f squamous epithelial cells, 
facilitating persistent nasal colonisation in both animals and humans (O'Brien et al., 
2002b, Walsh et al., 2008, Wertheim et al., 2008). In nutrient-rich media, ClfB is 
only expressed during the exponential phase o f growth, as it is later cleaved 
between the N1 and N2 domains by S. aureus aureolysin (Ni Eidhin et al., 1998, 
Walsh et al., 2008). However, intact ClfB is present late into the stationary phase 
o f growth when cultured in nutrient-deplete media (W ertheim et al., 2008).
As ClfA and ClfB are maximally expressed at different growth phases, it has been 
postulated that they work synergistically in the development o f  infective 
endocarditis. The single and double ClfA- and ClfB-negative derivatives o f  S. 
aureus strain Newman, which lacks functional FnBPs (Grundmeier et al., 2004), 
had longer times to platelet aggregation than the wild type in vitro (Loughman et 
al., 2005, Miajlovic et al., 2007, O'Brien et al., 2002a). In addition, L. lactis 
expressing ClfA had a shorter lag time to platelet aggregation than ClfB-expressing 
strains, suggesting that ClfA is more potent than ClfB in inducing platelet 
aggregation (O'Brien et al., 2002a). Conversely, neither single nor double ClfA- 
and ClfB-mutants affected the ability o f S. aureus to infect cardiac vegetations in a 
catheter-induced rat model o f infective endocarditis (Entenza et al., 2000).
1.3.5.4 Staphylococcal protein A (SpA)
SpA is a 42 kDa protein that comprises 7% o f the S. aureus cell wall and is 
expressed in most isolates (Gao & Stewart, 2004, Nguyen et al., 2000). It was the 
first cell wall-associated protein to be identified, yet its structure is different from 
most other M SCRAM Ms (Fig. 1.1) (Clarke & Foster, 2006). SpA contains four or 
five 60 amino acid long ligand-binding domains (D, E, A, B and C), forming three 
a  helices at its N-terminus (Sjodahl, 1977). Expression is positively regulated by 
SarS, SarT and repressor o f toxins {rot) and negatively regulated by SarA either 
alone or in combination with agr (see Section 1.3.6) (Cheung et al., 1997, Gao & 
Stewart, 2004). Maximal expression o f SpA occurs during the exponential phase o f
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growth in most strains (Gao & Stewart, 2004).
SpA confers a survival advantage to S. aureus by phagocytosis avoidance, as it 
binds the Fc portion o f IgG, altering its orientation and preventing the antibody 
from binding leucocytes (Clarke & Foster, 2006). SpA also binds the F(ab ’ )2 
region o f certain antibodies, IgM, vWF, complement and tum our necrosis factor 
receptor-1 (Clarke & Foster, 2006, Nguyen et al., 2000), and contributes to the 
development o f abscesses in murine infection models (Cheng et al., 2009).
Although early research suggested that cell wall SpA bound to IgG-Fc was required 
for platelet aggregation (Hawiger et al., 1979), a more recent study has 
demonstrated that SpA is not capable o f independent platelet aggregation and 
instead contributes to ClfA-mediated thrombus formation (O'Brien et al., 2002a). 
SpA-mediated S. aureus-platelet binding is thought to be particularly important 
under the high shear conditions present in vivo (see Section 1.4.4.3).
1.3.5.5 Iron-reguiated surface determinants (Isd proteins)
Although the above studies have identified putative M SCRAM M s implicated in the
pathogenesis o f infective endocarditis, the employed growth conditions do not
accurately reflect the in vivo milieu, particularly as the artificial growth media
utilised for bacterial culturing are nutrient-rich. In contrast, human blood only 
18contains 10’ M free iron as iron is insoluble in the presence o f oxygen (Pluym et 
al., 2008). M ost iron within the bloodstream is stored within binding proteins such 
as haemoglobin, transferrin and lactoferrin (Ahn et al., 2004, Ward et al., 1996). 
This iron-deplete environment appears to form part o f  the immune response to 
microbial infection as bacteria, like other organisms, require iron for oxidative and 
metabolic processes and hence survival (Ahn et al., 2004, Skaar el al., 2004). In 
addition, iron deficiency is thought to mediate the bacteriocidal and bacteriostatic 
effects o f plasma proteins by inhibition o f bacterial RNA synthesis (Ward et al.,
1996).
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Consequently, organisms such as S. aureus have adapted to the hostile in vivo 
environment by the production o f iron-uptake systems such as siderophores to 
remove transferrin-bound iron, and specific receptors to remove iron from the 
tetrapyiTole haem (Skaar et al., 2004). Haem iron, present in haemoglobin and 
myoglobin, is the favoured iron source for S. aureus, particularly during the mid­
exponential phase o f growth, with increased uptake o f  iron from transferrin in later 
growth phases (Skaar et al., 2004, Torres et al., 2006).
Haem iron acquisition by S. aureus is facilitated by the Isd pathway, consisting o f 
IsdA to Isdl (Mazmanian et al., 2003). A model for the Isd system involves the 
actions o f a-toxin  on erythrocytes, liberating haemoglobin, which binds IsdB, and 
to a lesser degree IsdH, and is converted to haem (Pishchany et al., 2009, Torres et 
al., 2006). Haem is then transferred to IsdA, transported to cell wall IsdC and taken 
up by adenosine triphosphate (ATP)-binding cassette transporters IsdD to IsdF (Liu 
et al., 2008, Mazmanian et al., 2003). Iron is removed from haem by haem 
oxygenases IsdG and Isdl within the cytoplasm and utilised for metabolic processes 
(Mazmanian et al., 2003).
The isd locus is present in all S. aureus genomes, with 8 genes encoding 3 iron- 
regulated transcriptional units (Vermeiren et al., 2006). Transcription o f Isd 
proteins is increased in low environmental iron conditions, maintained by negative 
feedback from the ferric uptake repressor (fur) (Clarke et al., 2004). IsdA and IsdB 
are expressed on the cell wall and along with IsdH contain LPXTG motifs, while 
IsdC contains an NPQTN sorting signal and is attached to the cell wall envelope by 
Sortase B (Mazmanian et al., 2002). Each Isd protein contains at least one copy o f 
the 150 amino acid long NEAT domain, which is required for haem binding (Figure 
1.1) (Andrade et al., 2002).
1.3.5.5.1 Iron-regulated surface determinant A (IsdA)
Whereas expression o f other MSCRAMMs is downregulated during growth in body
45
fluids, IsdA is preferentially expressed during growth in human serum, dialysate 
and other low iron conditions (Clarke et al., 2004, Morrissey et al., 2002, Wiltshire 
& Foster, 2001). IsdA binds fibronectin as well as both the B|3 and y chains o f 
fibrinogen at its NEAT domain, with twenty times the affinity o f  ClfA for 
fibrinogen (Clarke et al., 2004). IsdA, particularly in combination with ClfB or 
SdrCDE, binds cytokeratin-10 and locirin in desquamated human nasal epithelial 
cells at its NEAT domain, mediating nasal colonisation (Clarke et al., 2009, 
Corrigan et al., 2009). It is also able to bind asialofetuin, fetuin, haem, 
haemoglobin and transferrin (Clarke et al., 2004, Vermeiren et al., 2006). 
Expression o f IsdA is maximal at the early stationary phase o f growth (Clarke et al., 
2004, Corrigan et al., 2009).
The C domain o f IsdA plays a role in mediating resistance to host defences such as 
sebum, C-6-H, lactoferrin and antibiotics and facilitates survival on human skin 
(Clarke & Foster, 2008, Clarke et al., 2007). IsdA is associated with reduced 
biofilm formation in some strain backgrounds, but not others (Clarke et al., 2007). 
The role o f IsdA in platelet adhesion, aggregation and the pathogenesis o f infective 
endocarditis has not been investigated to date.
1.3.5.5.2 Iron-regulated surface determinant B (IsdB)
IsdB is a cell wall-anchored MSCRAMM which contains two NEAT domains 
(Figure 1.1) and has a 19-fold greater expression in low, as opposed to high, iron 
conditions (Mazmanian et al., 2002, Torres et al., 2006, Pishchany et al., 2009). It 
co-localises with IsdA on the S. aureus cell surface, forming a complex at the site 
o f cell division (Pishchany et al., 2009). With decreasing iron concentrations, IsdA 
and IsdB display a circumferential distribution on the cell wall, while a more 
punctate and discrete distribution is observed at high iron concentrations (Pishchany 
et al., 2009).
Both IsdA and IsdB are expressed on the S. aureus cell surface in murine infection
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models, and have been detected with increased expression in the heart (Pishchany et 
al., 2009, Torres et al., 2006). Furthermore, S. aureus strains lacking IsdB are 
associated with reduced virulence in mouse models o f abscess formation and 
bacteraemia (Cheng et al., 2009, Pishchany et al., 2009, Torres et al., 2006). 
However it is not known whether IsdB can bind plasma proteins, induce platelet 
aggregation or contribute to the pathogenesis o f infective endocarditis.
1.3.6 The genetic regulation of S. aureus MSCRAMM expression
Expression o f MSCRAMMs is under tight genetic regulation. There are a 
multitude o f regulatory systems, including agr, sae, staphylococcal respiratory 
response (srr), autolysis-related locus (arl), sar, rot, a B and fu r , that control the 
expression o f S. aureus virulence factors (Fournier & Hooper, 2000, Harraghy et 
al., 2005, Novick, 2003, Yarwood et al., 2001).
Agr plays an important role in the regulation o f S. aureus virulence (Novick, 2003). 
It is one o f many two-component systems, so named because they consist o f a sensor 
histidine kinase and a response regulator, which enable gene expression to be 
modulated by environmental stimuli (Blevins et al., 2002, Novick, 2003). The main 
effects o f agr are to upregulate exoprotein and downregulate surface protein 
expression during the post-exponential phase o f growth (Blevins et al., 2002, 
Novick, 2003, Wolz et al., 1996, Xiong et al., 2004). Agr has also been reported to 
have important metabolic effects (Dunman et al., 2001).
Agr is stimulated by an extracellular ligand known as the auto-inducing peptide, 
derived from AgrD (Figure 1.2) (Novick, 2003). This binds to the signal receptor 
AgrC, leading to activation o f the two-component system and upregulation o f 
promoters P2 and P3 through AgrA (Novick, 2003). The resultant expression o f 
RNAIII leads to reduced synthesis o f some MSCRAMMs, increased production o f 
exoproteins and overall increased bacterial virulence (Blevins et al., 2002, Cheung et 
al., 1994).
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The S. aureus genome encodes at least 15 other two-component systems (Cheung et 
al., 2004). One example is sae, which is transcribed at the early exponential phase o f 
growth, and in the presence o f agr, is expressed during the post-exponential growth 
phase. Sae controls nuclease and coagulase production and also upregulates FnBP 
expression (Cheung et al., 2009, Novick, 2003). ArlRS  is another two-component 
system that appears to be upregulated by agr, but is itself able to downregulate agr, 
leading to a reduction in exoprotein synthesis (Novick, 2003). SrrAB  facilitates S. 
aureus growth in anaerobic conditions and is mutually downregulatory with agr 
(Novick, 2003).
Sar encodes three overlapping transcripts -  SarA, SarB and SarC, transcribed from 
promoters P I, P2 and P3 respectively (Cheung et al., 1992, Wolz et al., 2000). SarA 
and SarB are upregulated during the exponential phase o f  growth, whilst SarC 
expression is upregulated in the post-exponential growth phase by the a B-dependent 
P3 promoter (Blevins et al., 2002, Novick, 2003, W olz et al., 2000). SarA is the 
most studied component and is known to bind AT-rich sequences within numerous 
genes, including those between the agr promoters P2 and P3, facilitating RNAIII 
production (Figure 1.2) (Novick, 2003). Sar has therefore been described as a 
transcription factor (Novick, 2003). SarA upregulates M SCRAM M expression and 
downregulates exoprotein and SpA synthesis during the exponential phase o f growth 
(Blevins et al., 2002, Novick, 2003). There is ongoing debate as to whether sar or 
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Figure 1.2. The accessory gene regulator (agr) system. The auto-inducing pro­
peptide (pro-AIP), derived from AgrD, is processed and secreted by AgrB, binds to 
an extracellular histidine protein kinase (HPK) loop in the AgrC receptor, leading to 
auto- or dephosphorylation in AgrC and AgrA. AgrA, in conjunction with 
staphylococcal accessory regulator A (SarA,) activates the two agr promoters P2 
and P3, resulting in the production of RNAIII, which via other two-component 
systems such as S. aureus exoprotein expression (sae)RS, controls transcription of 
target genes. Adapted from (Novick, 2003).
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a B and rot have been described as virulence modulators (Entenza et al., 2005, Gao & 
Stewart, 2004, Novick, 2003). Rot is part o f the sar family and has been reported to 
positively regulate SarS and thus SpA expression indirectly (Said-Salim et al., 2003). 
crB is an alternative sigma factor which, rather than being activated through two- 
component systems, is directly activated within the cell by environmental stimuli 
(Novick, 2003). It upregulates MSCRAMM  expression, but unlike SarA, mainly has 
its effects during the post-exponential phase o f growth (Entenza et al., 2005, Novick, 
2003). It is feasible that there are S. aureus gene regulators that are still to be 
identified (van Belkum et al., 2009).
1.4 Cardiac vegetations
1.4.1 The role of cardiac vegetations in infective endocarditis
Vegetations are bacterial-platelet-fibrin complexes which form on native and 
prosthetic cardiac valves and implanted pacemaker leads in infective endocarditis 
(Durack, 1975). They are identified in 50% to 80% o f patients with infective 
endocarditis using transthoracic echocardiography and 75% to 95% o f patients using 
transoesophageal echocardiography (De Castro et al., 1997, Di Salvo et al., 2001, 
Thuny et al., 2005, Vilacosta et al., 2002). Vegetations contribute to bacterial 
persistence by facilitating evasion o f the host immune system, antibiotic therapies 
and the shear forces o f arterial blood, while enabling bacterial growth and systemic 
dissemination via embolism (Carrizosa et al., 1978, Durack, 1975, Ferguson et al., 
1986a, Moreillon & Que, 2004).
Early studies failed to identify correlations between vegetation characteristics on 
echocardiograms and morbidity and mortality in infective endocarditis (De Castro et 
al., 1997, Roder et al., 1997, Steckelberg et al., 1991). However, more recent studies 
have identified relationships between the presence o f  vegetations, vegetation size and 
vegetation mobility and the risk o f emboli, valvular regurgitation and death (Cabell 
et al., 2001, Di Salvo et al., 2001, Fabri et al., 2006, M artin-Davila et al., 2005,
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Wallace et al., 2002). On meta-analysis, vegetation size greater than 10 mm was 
associated with embolism and need for surgery in infective endocarditis (Tischler & 
Vaitkus, 1997). Notably, S. aureus infective endocarditis is associated with large 
vegetations, possibly accounting for its association with high embolism and mortality 
rates (Fowler et al., 2005b, Nadji et al., 2005, Vilacosta et al., 2002). Vegetations 
may therefore represent important therapeutic targets in infective endocarditis.
1.4.2 Vegetation composition
Light and electron microscopy o f sterile vegetations from rabbit models o f  infective 
endocarditis demonstrate that they are predominantly composed o f  platelets in 
association with fibrin, leucocytes and erythrocytes (Carrizosa et al., 1978, Durack, 
1975, Ferguson et al., 1986b). Bacteria are able to colonise sterile vegetations within 
30 min o f inoculation, with streptococci phagocytosed within monocytes and 
macrophages, and staphylococci mainly adherent to the irregular vegetation surface 
(Durack, 1975).
Approximately 3-6 h post-inoculation, bacteria replicate within vegetations in areas 
devoid o f leucocytes (Durack, 1975, Ferguson et al., 1986a, Ferguson et al., 1986b). 
They aggregate in round colonies that are uniformly enclosed by protective fibrin 
layers and are dispersed amongst the reticular platelet-fibrin matrix (Carrizosa et al., 
1978, Durack, 1975, Ferguson et al., 1986a). Activated platelets have been 
identified within infected vegetations, mainly at the interface o f the vegetation 
surface and circulating blood (Rouzet et al., 2008). Accumulation o f successive 
layers o f platelets, fibrin and bacteria leads to progressive enlargement o f the 
vegetation. Healing eventually occurs by vegetation endothelialisation, 
phagocytosis, calcification and fibrous organisation, which are all enhanced by 
antimicrobial therapy (Durack, 1975).
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1.4.3 Vegetation formation
The exact mechanism o f vegetation formation in infective endocarditis is complex 
and still not fully understood. However, it is commonly thought that vegetations 
develop following bacterial, viral or fungal infection o f sterile thrombi (Figure 1,3A) 
(Bashore et al., 2006). Following microbial adherence to and incorporation within 
vegetations, monocytes are recruited by inter-cellular adhesion m olecule-1 (ICAM- 
1) and vascular cell adhesion m olecule-1 (VCAM-1), and secrete chemokines and 
proinflammatory cytokines, leading to tissue destruction (Chorianopoulos et al., 
2009, Heying et al., 2007). M onocytes and endothelial cells also liberate tissue 
factor, resulting in platelet activation, increased fibrin generation and vegetation 
propagation (Moreillon et al., 2002, Veltrop et al., 2000).
Vegetation formation may also be initiated by bacterial attachment to plasma 
proteins coating native or prosthetic valvular tissue, followed by leucocyte and 
platelet recruitment (Figure 1.3B) (Bryers, 2008). Alternatively, preformed 
bacterium-platelet aggregates can adhere to cardiac valves (Figure 1.3C). It is not 
known at present whether platelets or bacteria are recruited to the valvular 
endothelium first (Chorianopoulos et al., 2009). Either way, it is clear that platelet- 
bacterial-(sub)endothelial interactions contribute to vegetation formation.
A B C
Endothelium or sub-endothelium
Figure 1.3. Possible mechanisms for bacterium and platelet attachment to 
cardiac valves. Bacteria are depicted in yellow, platelets in maroon. Platelets can 
adhere to (sub)-endothelium first and then recruit bacteria (A). Alternatively, 
bacteria can initially attach to cardiac valves and then recruit platelets (B). It is also 
feasible that bacterium-platelet aggregates form in the bloodstream and 
subsequently adhere to the valvular (sub)-endothelium (C).
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1.4.3.1 Platelet-(sub)endothelium interactions
Platelets can translocate and roll on the endothelial surface, but platelet-endothelial 
interactions are usually prevented by the natural anticoagulant state o f  the vascular 
endothelium conferred by mediators such as nitric oxide, prostacyclin, heparan 
sulphate, thrombomodulin, glycocalyx, protein C and the ecto-ADPase CD39 (Chen 
& Lopez, 2005, Gawaz et al., 2005). However, endothelial inflammation, as occurs 
in congenital and degenerative valvular heart disease, disables these inhibitory 
mechanisms (Chen & Lopez, 2005, M oreillon et al., 2002). Platelets can then bind 
inflamed endothelium via GPIb or P-selectin glycoprotein ligand-1 (PSGL-1) 
binding to P-selectin, GPIb binding to vWF or GPIIb/IIIa adhering to vWF, 
fibrinogen or fibronectin (Figure 1,4A) (Chen & Lopez, 2005, Gawaz et al., 2005).
Turbulent blood flow and inflammation from regurgitant or stenotic valves lead to 
endothelial denudation, exposing the subendothelial matrix proteins collagen and 
vWF (Moreillon et al., 2002). Under the high shear conditions present in vivo, 
platelets form reversible bonds to these ligands via glycoprotein (GP)VI and GPIb 
receptors, respectively (Figure 1.4B) (Chen & Lopez, 2005, Gawaz et al., 2005). 
Firm platelet binding to the subendothelium requires the formation o f stronger low 
shear bonds between platelet receptors a 5(3i, a 2|3i, GPIIb/IIIa and their respective 
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Figure 1.4. Platelet interactions with inflamed vascular endothelium and 
subendothelium resulting in the formation of thrombi on the valvular surface.
Platelet receptors P-selectin glycoprotein ligand 1 (PSGL 1) (green), GPIb (grey) 
and GPIIb/llla (blue) are able to bind inflamed endothelium via their respective 
ligands (A). Platelet-subendothelium interactions under high shear involve GPVI 
(black) binding collagen (brown) and GPIb binding von Willebrand factor (vWF) 
(green) (B). At low shear, GPIIb/llla, a 5p-, (brown) and a 2Pi (red) bind the sub­
endothelium via vWF, fibrinogen (grey) and collagen. Other extracellular matrix 








The ability o f bacteria to adhere directly to valvular tissue, in particular undamaged 
endothelium, increases virulence and their ability to cause infective endocarditis 
(Chorianopoulos et al., 2009, Vriesema et al., 2000). S. aureus binds vascular 
subendothelium via a SpA-vWF interaction under low shear, or through Cna binding 
collagen under high shear (Figure 1.5A) (Chavakis et al., 2005). S. aureus is also 
capable o f adhering directly to undamaged endothelium, mainly via fibronectin 
bridges between the A4+l6 and BCD domains o f  FnBPA, and to a lesser extent 
FnBPB, and the endothelial integrin receptor a s^ i under low shear (Figure 1.5B) 
(Chavakis et al., 2005, Heying et al., 2007, Piroth et al., 2008). Cell wall teichoic 
acid has also been implicated in endothelial binding and virulence in animal models 
o f infective endocarditis (Chorianopoulos et al., 2009).
Once bound to the endothelium, S. aureus is phagocytosed by endothelial cells and 
releases a-toxin , resulting in valve destruction, abscess and fistula formation 
(Chorianopoulos et al., 2009, Sinha & Herrmann, 2005). Valve destruction leads to 
the exposure o f the subendothelial matrix, facilitating further bacterial and platelet 








Figure 1.5. Staphylococcus aureus interactions with the sub-endothelium and 
endothelium contributing to valve colonisation in infective endocarditis.
Collagen (brown) and von Willebrand factor (vWF) (green) exposed on denuded 
sub-endothelium can bind S. aureus via collagen adhesion (Cna) and 
Staphylococcal protein A (SpA), respectively (A). S. aureus is also able to bind 
integrins expressed on intact endothelium via fibronectin (black) bridges from the 
A4+16 or BCD domains of fibronectin-binding proteins A or B (FnBPA/FnBPB) and 
the asPi receptor (olive green) (B).
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1.4.3.3 Bacterium-platelet interactions
It is widely considered that the interaction between bacteria and platelets is central to 
the pathogenesis o f infective endocarditis (Pawar et al., 2004, Sullam et al., 1996). 
However, it was only recently that the first steps were taken in determining the 
molecular basis for this interaction. Bacterium-induced platelet aggregation is a two- 
step process, where the initial reversible bacterium-platelet adhesion is followed by a 
more stable irreversible interaction (Bayer et al., 1995, Yeaman et al., 1992c).
Bacterium-induced platelet activation and aggregation are mediated by the formation 
o f IgG and plasma protein bridges between MSCRAM Ms and platelet Fc and 
glycoprotein receptors (Fitzgerald et al., 2006a). Such interactions result in ‘inside- 
out’ platelet activation via tyrosine kinase-dependent pathways, mediating the 
change in platelet shape from discoid to spherical, the release o f  platelet granule 
contents, and a conformational change and increase in the number o f  GPIIb/IIIa 
receptors, enabling fibrinogen binding and ‘outside-in’ platelet activation and 
recruitment (Figure 1.6) (Davi & Patrono, 2007, Fitzgerald et al., 2006a). Thrombus 
formation is then mediated by cross-linking o f GPIIb/IIIa on adjacent platelets via 
the dimeric fibrinogen molecule, leading to vegetation development (Figure 1.6) 






Figure 1.6. The mechanism of bacterium-induced platelet aggregation.
Following bacterial adhesion to platelets via fibronectin or fibrinogen bridges 
between microbial surface components recognising adhesive matrix molecules 
(MSCRAMMs) and the platelet GPIIb/llla receptor (A), platelet activation occurs, 
resulting in a change of platelet shape from discoid to spherical and increased 
expression of GPIIb/llla (B). The activated GPIIb/llla receptors are able to bind 
soluble fibrinogen in plasma which cross-links, leading to platelet aggregation and 
thrombus formation (C). Adapted from (Fitzgerald et a!., 2006a).
59
1.4.3.3.1 The mechanisms of Streptococcus-p\ate\et interactions
A number o f organisms have the capacity to induce platelet aggregation and this has 
been extensively reviewed (Fitzgerald et al., 2006a). The mechanisms o f platelet 
aggregation induced by viridans streptococci were the first to be partially 
characterised. Early studies implicated S. sanguinis serine-rich protein A (SrpA) and
S. gordonii Hsa and GspB interacting with the platelet GPIb receptor, independently 
o f vWF (Kerrigan et al., 2002, Plummer et al., 2005, Takamatsu et al., 2005). 
However, McNicol et al recently identified a role for vWF in S. sanguinis-induced  
platelet aggregation, as platelet aggregation did not occur when platelets were 
suspended in cryosupematant depleted o f  vWF (McNicol et al., 2007). Other 
postulated mechanisms o f streptococcus-induced platelet aggregation include 
binding via complement, by a fibrinogen bridge to the GPIIb/IIIa platelet receptor, 
via platelet-aggregation-associated protein (PAAP) binding to collagen and by an 
IgG-FcyRIIa interaction (Ford et al., 1997, Ford et al., 1996, Herzberg et al., 1992, 
Pampolina & McNicol, 2005, Sullam et al., 1988).
1.4.3.3.2 The mechanisms of S. aureus-platelet interactions
Early research into streptococcus-induced platelet aggregation served as a model for 
elucidation o f the mechanisms o f S. aureus-platelet interactions. The initial binding 
o f S. aureus to platelets can either occur directly via M SCRAMM s, or indirectly via 
bridging plasma proteins such as fibrinogen or fibronectin binding to the platelet 
GPIIb/IIIa receptor (Figures 1.7A and 1.7B) (Fitzgerald et al., 2006b, O'Brien et al., 
2002a). An alternative slower fibrinogen-independent mechanism utilising 
complement has also been identified (Figure 1.7C) (Loughman et al., 2005, 
Miajlovic et al., 2007, O 'Brien et al., 2002a). Furthermore, SpA is capable o f 
inducing platelet activation via methods similar to those observed for streptococci, 
including the use o f complement bound to the gClqR/p33 complement receptor, 
vWF to the GPIb receptor or the Fc portion o f  IgG to the FcyRIIa platelet receptor 
(Figure 1,7D) (Hartleib et al., 2000, Nguyen et al., 2000, O'Brien et al., 2002a).
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Figure 1.7. The mechanisms of S. aweus-induced platelet aggregation. Initial 
rapid bacterium-platelet adhesion is mediated by linkage of microbial surface 
components recognising adhesive matrix molecules (MSCRAMMs) to GPIIb/llla via 
either fibronectin (A) or fibrinogen (B) bridges. Platelet activation and aggregation 
occur when IgG specific for MSCRAMMs binds irreversibly to the platelet FcyRlla 
receptor (A and B). Alternatively, slower activation can be facilitated through 
complement (C). Staphylococcal protein A (SpA) is capable of mediating platelet 
aggregation by various methods, including the use of complement, by binding to the 
Fc portion of IgG or via a von Willebrand factor (vWF) bridge to the GPIb receptor 
(D). FnBPA, fibronectin-binding protein A; ClfA, clumping factor A. Adapted from 
(Fitzgerald etal., 2006a, Fitzgerald etal., 2006b, O'Brien eta!., 2002a).
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MSCRAMM binding to GPIIb/IIIa or GPIb is rapid, saturable and reversible, but 
insufficient to independently cause platelet activation and thrombus formation 
(Bayer et al., 1995). Cross-linking o f the Fc portion o f antibody specific for the 
MSCRAMM mediating platelet adherence to the platelet FcyRIIa receptor, facilitates 
platelet activation and aggregation (Fitzgerald et al., 2006a, Sjobring et al., 2002) 
(Figures 1.7A and 1.7B). Indeed, inhibition o f the FcyRIIa receptor completely 
abrogates S. aureus-induced platelet activation in vitro (Fitzgerald et al., 2006b, 
Sjobring et al., 2002).
1.4.3.3.3 The mechanisms of S. aureus-platelet interactions under
high shear
Blood flow in vivo is pulsatile and not uniform as it is highest at the centre o f a 
vessel with minimum flow adjacent to the vessel wall (Kroll et al., 1996). This leads 
to shearing effects between layers o f fluid that are moving against each other at 
different speeds, with the greatest shearing effects seen at the vessel wall (Kroll et 
al., 1996). Under high shear, erythrocytes and leucocytes flow in the middle o f the 
vessel, while platelets are at the periphery and in a better position to rapidly adhere to 
cardiac valves (Kerrigan et al., 2007). Coronary vessels are under high shear, while 
the valve surface is more complex due to the additional presence o f turbulent blood 
flow (Kerrigan et al., 2007).
Studies analysing S. aureus-platelet interactions under varying shear have reported 
that fewer and smaller S. aureus-platelet thrombi are formed under high shear as 
compared to low shear conditions (Johnson & Ross, 2008). Furthermore, S. aureus- 
platelet binding varies with both shear and bacterial growth phase in vitro (George et 
al., 2007, Pawar et al., 2004). Binding is greatest at low shear for exponential phase 
strains and at high shear for stationary phase cultures, reflecting the maximal 
expression o f FnBPs at the exponential phase o f growth and increased expression o f 
ClfA during the stationary phase o f growth (George et al., 2007). High shear S. 
aureus-platelet interactions at both stationary and exponential phases o f growth
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involve a two-step process, where the initial adhesion is mediated by SpA binding to 
GPIb via vWF (Fig. 1.7D), increasing contact time to enable the slower yet stronger 
bond between ClfA and the platelet surface to form (George et a l., 2007, George et 
al., 2006, Kerrigan et al., 2007, Pawar et al., 2004). Recently however, high shear S. 
awrew.v-platelet interactions mediated by FnBPs binding fibrinogen or fibronectin 
during the early exponential phase o f growth have been described (George et al.,
2007).
1.5 The role of platelets in sepsis and infective endocarditis
1.5.1 Platelet function in sepsis
Even in the absence o f infective endocarditis, sepsis is a pro-thrombotic state with 
upregulation o f pro-coagulant and reduced anti-coagulant activity (Schouten et al.,
2008). Platelet activation is increased in sepsis, as measured by GPIIb/IIIa receptor 
activity, thrombospondin, platelet P-selectin expression and platelet monocyte 
aggregate (PMA) formation (Gawaz et al., 1995, Ogura et al., 2001, Russwurm et 
al., 2 0 0 2 ).
Bacteria induce platelet activation by stimulating the production o f pro-inflammatory 
cytokines such as interleukin-1, tumour necrosis factor-a, C-reactive protein (CRP) 
and the release o f endotoxin by Gram-negative organisms (Levi et al., 2003). In 
addition, they activate the coagulation cascade by stimulating the release o f  tissue 
factor, impairing the action o f physiological anticoagulants (e.g. anti-thrombin, 
protein C) and by inducing fibrinolysis via plasminogen activation (Levi et al., 2003, 
Schouten et al., 2008). Although activation o f the host coagulation system forms 
part o f the innate immune defence, an exaggerated response can lead to disease 
pathogenesis (Schouten et al., 2008, Sjobring et al., 2002). Specifically, an 
uncontrolled coagulation cascade can lead to a generalised consumption 
coagulopathy, which contributes to the development o f thrombocytopaenia,
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hypovolaemic shock, disseminated intravascular coagulation (DIC) and multi-organ 
failure in sepsis (Gawaz et al., 1997, Schouten et al., 2008).
The initial recruitment o f platelets to the site o f infection appears to be protective and 
forms part o f the immune response (Sjobring et al., 2002). Platelets exhibit pro- 
inflammatory effects via the expression o f IgG-Fc and complement receptors for 
opsonisation, release o f interleukin-1(3, generation o f toxic oxygen free radicals and 
enhancement o f leucocyte recruitment to the site o f sepsis (Yeaman, 1997). Platelets 
increase neutrophil respiratory burst in response to opsonised and non-opsonised 
organisms including S. aureus (Miedzobrodzki et al., 2008), and can engulf 
microorganisms, although there is no evidence o f bacterial killing (White, 2006, 
Youssefian et al., 2002). In addition, platelets exert antimicrobial effects via the 
release o f  PMPs (Yeaman, 1997).
1.5.2 Platelet microbicidal proteins (PMPs)
PMPs are small cationic proteins released from platelet a-granules at sites o f 
endovascular damage or microbial colonisation (Fowler et al., 2004). Their release 
is stimulated by thrombin or bacteria activating platelet receptors P2Xi and P2 Yi2 
(Trier et al., 2008). PMPs disrupt bacterial membranes and intracellular 
macromolecular synthesis, while enhancing the lymphocyte response to infection 
(Kupferwasser et al., 2002, Tang et al., 2002). They exert microbicidal activity 
against a wide range o f organisms including staphylococci, viridans streptococci, 
Escherichia coli, and Candida spp  (Tang et al., 2002, Yeaman et al., 1994). To date, 
at least 7 PMPs have been identified from resting and activated human platelets, the 
most prevalent being connective tissue-activating peptide 3 and platelet factor-4 
(Tang et al., 2002).
PMPs reduce S. aureus adherence to platelets and sterile thrombi and reduce 
bacterial proliferation within established vegetations (Mercier el al., 2004, Yeaman 
et al., 1994). Furthermore, PMPs and antibiotics act synergistically; PMPs potentiate
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et al., 1994). Furthermore, PMPs and antibiotics act synergistically; PMPs potentiate 
the microbicidal activity o f vancomycin and penicillin, while antibiotics increase the 
ability o f PMPs to reduce bacterium-platelet binding in vitro (M ercier et al., 2004, 
Yeaman et al., 1994, Yeaman et al., 1992a).
Staphylococci and viridans streptococci can acquire PMP-resistance which confers a 
survival advantage, increases microbial virulence and increases the propensity to 
cause infective endocarditis, particularly in patients with intravascular device 
infection (Fowler et al., 2000, Kupferwasser et al., 2002, Wu et al., 1994). In a 
study analysing 60 S. aureus clinical isolates, 83% o f strains isolated from cases o f 
infective endocarditis were PMP-resistant, in comparison to one-third o f strains 
implicated in soft tissue sepsis (Bayer et al., 1998). Notably, Yeaman et al could not 
identify a correlation between the ability o f S. aureus strains to induce platelet 
aggregation and exhibit PMP resistance in vitro, suggesting these phenom ena are 
independent o f one another (Yeaman et al., 1992b).
1.5.3 The role of platelets in the development of infective endocarditis
In theory, platelets could have a conflicting role in the pathogenesis o f infective 
endocarditis. They form part o f the immune response, but can also interact with 
bacteria to form thrombi and vegetations (see Section 1.4.3). Trier et al provided 
evidence that the outcome o f bacterium-platelet interactions may depend on the ratio 
o f platelets to bacteria, as platelet:,?. aureus ratios o f 1 0 :1  or greater were associated 
with reduced bacterial viability (Trier et al., 2008).
Thrombocytopenia, often in association with DIC, is present in 14% to 18% of 
patients with infective endocarditis, and has been attributed to the development o f 
antibodies against the platelet GPIIb/IIIa receptor (Bouza et al., 2001, Mouly et al.,
2002). Flowever, Hogevik et al could not identify a correlation between platelet 
count and a diagnosis o f infective endocarditis (Hogevik et al., 1997). 
Thrombocytopenia has been associated with increased intra-vegetation bacterial
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proliferation in an experimental rabbit model (Sullam et al., 1993), and a non­
significant trend towards increased mortality in a study o f 89 patients with infective 
endocarditis (Mouly et al., 2002). Both o f these studies suggest that platelets play a 
predominant role in immune defence rather than the development o f infective 
endocarditis, although it is not clear whether these are causal relationships.
A number o f  factors may affect platelet function in infective endocarditis and should 
be taken into consideration in platelet activation studies. For example, 
anticoagulants increase platelet activation (Harding et al., 2006a, M ieszczak & 
Winther, 1996) and multi-organ failure is associated with reduced platelet activation 
(Gawaz et al., 1995, Russwurm et al., 2002). Furthermore, increased platelet 
activation has been observed in patients with mitral stenosis and mitral regurgitation 
(Chen et al., 2004, Tse et al., 1997), while either increased (Chirkov et al., 2002, 
Goldsmith et al., 2000) or reduced (O'Brien et al., 1995, Pareti et al., 2000) platelet 
activation and aggregation have been observed in aortic stenosis; the latter is thought 
to be due to enhanced cleavage o f vWF multimers, similar to that observed in type 
2b von W illebrand’s disease. Most studies have observed increased platelet 
activation in patients following cardiac valve replacement, particularly in those 
receiving bileaflet mechanical valves (Koppensteiner et al., 1991, Leguyader et al., 
2006, Maugeri et al., 2000).
1.6 The effect of platelet receptor genetic polymorphisms on platelet 
function and susceptibility to disease
Platelet GPIIb/IIIa, GPIb and FcyRIIa receptors are involved in S. aureus-induced 
platelet activation and aggregation (see Section 1.4.3.3.2 and Figure 1.7) (Fitzgerald 
et al., 2006a). Polymorphisms o f these receptors increase the sensitivity to platelet 
aggregation induced by pharmacological agonists and have been associated with 
vascular and immune disease (Meisel et al., 2004, van der Pol & van de Winkel, 
1998), and could therefore influence susceptibility to infective endocarditis.
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1.6.1 Polymorphisms of the platelet GPIIb/llla receptor
GPIIb/IIIa or CD41/CD61 is a heterodimeric integrin protein linked noncovalently 
by disulphide bridges (Phillips et al., 1988). It is capable o f binding fibrinogen, 
fibronectin, vWF and vitronectin (Meisel et al., 2004). GPIIb/IIIa is the most 
abundant platelet receptor, with 80,000 copies per platelet, and genes for both 
components have been mapped to chromosome 17q21.32 (Meisel et al., 2004).
The GPIIIa p iA1/A2 polymorphism was first described in 1989, and consists o f a T to 
C substitution at nucleotide 1565 in exon 2 o f the GPIIIa gene, resulting in a leucine 
to proline substitution at residue 33 (Newman et al., 1989). Approximately 72% o f 
Caucasians are homozygous for P1AI, 26% are heterozygous and 2% are homozygous 
for P1A2 (Table 1.4) (Laule et al., 1999, Newman et al., 1989). The P1A2 allele is 
thought to be dominant (O'Halloran et al., 2006).
1.6.1.1 Correlations between the GPIIIa p|A1/A2 polymorphism and 
platelet aggregation
PlA2 alleles are generally been thought to confer a pro-aggregatory phenotype 
independent o f GPIIb/IIIa receptor expression levels (M ichelson et al., 2000, 
O'Halloran et al., 2006). Ligand-engagement o f  platelet GPIIb/IIIa receptors is 
associated with increased phosphatase PP2A activity, leading to increased activation 
o f the extracellular-signal regulated kinase - 2  signalling pathway and enhanced 
myosin light chain dephosphorylation (Vijayan & Bray, 2006, Wang et al., 2008). 
These actions are more pronounced in the PlA2 variant, collectively resulting in 
enhanced platelet activation and aggregation (Vijayan & Bray, 2006).
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Table 1.4. The observed frequencies of polymorphisms of platelet receptors 
GPIIb/llla, GPIb and FcyRlla in healthy Caucasians. Data adapted from (Baker et 
al., 2001, Jilma-Stohlawetz etal., 2003, Laule etal., 1999, Lehrnbecher etal., 1999, 
Newman et al., 1989)
Platelet Receptor Polymorphisms Genotypes Frequencies
GPIIb/IIIa pjAI/A2 pjAl/Al 72%
pjAl/A2 26%
pjA2/A2 2 %





B/B 1 .0 - 1 .3%
HPA-2 2 a/2 a 84.9%
2 a/2 b 13.7%
2 b/2 b 1.4%
Kozak sequence T/T 75.5%
T/C 22.3%
C/C 2 .2 %




There have been conflicting results from studies examining the effects o f  the p iAI/A2 
polymorphism on susceptibility to platelet aggregation induced by pharmacological 
agonists. One o f the first studies to analyse the influence o f the polymorphism was 
the 1,422 subject Framingham Offspring Study (Feng et al., 1999). The investigators 
identified an increase in susceptibility to epinephrine- and no alteration in response 
to adenosine diphosphate (ADP)-induced aggregation in the presence o f P1AI/A2 
compared to p iAI/A1 platelets. There was no change for P1A2 homozygotes, but this 
was attributed to the low prevalence o f this genotype. M ichelson et al identified a 
larger proportion o f individuals with a p iA2/A2 genotype, which was associated with 
an increase in baseline platelet P-selectin expression (M ichelson et al., 2000). ADP 
stimulation in this group led to significantly raised P-selectin expression, GPIIb/IIIa 
activation and fibrinogen binding, correlating with increased platelet reactivity 
(Michelson et al., 2000). In contrast, Frey et al did not identify any p iAI/A2_ 
dependent difference in platelet function in response to either ADP or epinephrine 
(Frey et al., 2003). Conversely, other investigators have demonstrated increased 
platelet aggregation in P1A1 homozygotes in response to the protease-activated 
receptor-1 (PAR-1) agonist SFLLRN, ADP arachidonic acid, and the thromboxane 
A2 analogue U46619 (Andrioli et al., 2000, Tasne et al., 1997).
1.6.1.2 Associations of the GPIIIa p|A1/A2 polymorphism with clinical 
disease
The PlA2 allele correlates with the development o f acute coronary syndromes (ACS), 
premature myocardial infarction (MI) and ischaemic cerebrovascular disease, 
particularly in otherwise low-risk patients (Carter et al., 1998, Gardemann et al., 
1998, Saidi et al., 2008). However, the influence o f the P1A2 allele on in-stent 
restenosis is unclear (Kastrati et al., 2000, Le Hello et al., 2007). Presence o f a P1A2 
allele is associated with arterial thrombosis in patients with immune-mediated 
heparin-induced thrombocytopaenia (Harris et al., 2008). No correlation was 
identified between piAI/A2 genotype and the development o f intravascular device 
infection (Musher et al., 2002).
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The most recent review o f the GPIIb/IIIa polymorphism analysed the role o f this 
genetic variant in patients with coronary artery disease and ACS (34 studies), 
coronary stent restenosis post-percutaneous coronary intervention (PCI) (6 studies) 
and cerebrovascular disease (6 studies) (Meisel et al., 2004). Only a weak 
association was identified between the p [A1/A2 polymorphism and susceptibility to 
these conditions (Meisel et al., 2004).
1.6.2 Polymorphisms of the platelet GPIb receptor
The GPIb-IX-V complex consists o f four subunits, G PIba, GPIb[3, GPIX and GPV, 
encoded by genes on chromosomes 17pl2, 22ql 1.2 and 3, respectively (M eisel et 
al., 2004, Ware, 1998). G PIba is the active component, binding to vWF at its N- 
terminus (Ware, 1998). Three polymorphisms have been described for the active 
ligand-binding site o f GPIb with frequencies outlined in Table 1.4 (Meisel et al., 
2004, Ware, 1998).
The variable number o f tandem repeat (VNTR) allele codes for 0, 1, 2, 3 or 4 repeats 
o f a 13 amino acid sequence, designated E, D, C, B and A respectively, that 
facilitates extension o f the active ligand-binding site o f G PIba from the platelet 
surface (Lopez et al., 1992, Ozelo et al., 2004a). The presence o f a C to T 
substitution at nucleotide 434 o f the G PIba gene, results in an amino acid change 
from threonine to methionine at residue 145, conferring a change from human 
platelet antigen (HPA)-2a to 2b (Meisel et al., 2004). The HPA-2 variant is in 
linkage disequilibrium with VNTR, with HPA-2a associated with VNTR C/D and 
HPA-2b with VNTR A/B (Meisel et al., 2004). HPA-2b is thought to exert a 
dominant effect, with 84.9% homozygous for HPA-2a, 1.4% homozygous for HPA- 
2b and 13.7% o f individuals heterozygous (Table 1.4) (Baker et al., 2001, Jilma- 
Stohlawetz et al., 2003).
The third polymorphism, known as a Kozak sequence polymorphism, involves a T to 
C substitution 5 positions downstream from the G PIba initiator and the C allele is
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proposed to be dominant (Afshar-Kharghan et al., 1999). Just over three-quarters o f 
the population are homozygous for T/T, 22.3% heterozygous and 2.2% homozygous 
for C/C (Table 1.4) (Baker et al., 2001, Jilma-Stohlawetz et al., 2003).
1.6.2.1 Correlations between GPIb receptor polymorphisms and 
platelet aggregation
Most in vitro studies have demonstrated that neither the number o f surface G P lba 
molecules, nor the efficiency o f vWF binding are affected by the presence o f HPA-2 
polymorphisms (Jilma-Stohlawetz et al., 2003, Li et al., 2000a), whilst Ulrichts et al 
identified increased vWF binding in HPA-2a platelets (Ulrichts et al., 2003). HPA- 
2b/VNTR-A platelets have a slow rolling velocity at high shear, with no effect on 
vWF binding (Matsubara et al., 2005). Conversely, platelet plug formation is 
significantly increased with VNTR C/D platelets (Jilma-Stohlawetz et al., 2003). 
There have been conflicting reports as to the effect o f the Kozak sequence variant on 
GPIb receptor expression and platelet plug formation (Afshar-Kharghan et al., 1999, 
Jilma-Stohlawetz et al., 2003).
1.6.2.2 Associations of GPIb receptor polymorphisms with clinical 
disease
The correlation between VNTR alleles and coronary artery disease is unclear as B, C 
and D alleles have all been implicated in MI (Gonzalez-Conejero et al., 1998, 
Mikkelsson et al., 2001, Ozelo et al., 2004b). Further research has demonstrated that 
HPA-2b predisposes to cerebrovascular disease, but others do not corroborate these 
findings (Baker et al., 2001, Carter et al., 1998, Meisel et al., 2004). The VNTR 
C/D and Kozak sequence T/C genotypes are both associated with intravascular 
catheter infection (Musher et al., 2002).
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A review investigated the impact o f GPIb polymorphisms on clinical disease, 
including 14 studies investigating coronary artery disease, ACS and PCI, and 6 
investigating cerebrovascular disease (Meisel et al., 2004). Overall, there was no 
conclusive link between the presence o f VNTR or HPA-2 alleles and coronary artery 
disease, although a recent meta-analysis identified an association o f the HPA-2b 
allele with the development o f cerebrovascular disease (Maguire et al., 2008, Meisel 
et al., 2004). The C allele o f the Kozak sequence polymorphism is associated with 
increased risk o f ACS, adverse events post-PCI, MI, cerebrovascular disease and 
experimental arterial thrombus formation, suggesting a possible role for this allele in 
acute thrombotic events (Baker et al., 2001, Cadroy et al., 2001, Meisel et al., 2004).
1.6.3 Polymorphisms of the FcyRlla receptor
FcyRIIa is a low affinity IgG-Fc receptor that exhibits stronger binding to 
multimeric as opposed to monomeric IgG (Lehrnbecher et al., 1999). It is present 
on leucocytes where it contributes to phagocytosis o f encapsulated bacteria and S. 
aureus opsonised with IgG2 (Bredius et al., 1993, van der Pol & van de Winkel, 
1998), and is the only Fc receptor on platelets, numbering between 1,300 and 8,500 
on the platelet surface (Chen et al., 2003). A functional polymorphism resulting 
from a G to A point mutation, results in an arginine (R) to histidine (H) change at 
position 131 (van der Pol & van de Winkel, 1998). Approximately 25% of 
individuals are R/R, 31 % H/H and 44% heterozygous, with codominant expression 
o f both alleles (Table 1.4) (Lehmbecher et al., 1999).
1.6.3.1 Correlations between the FcyRlla H131R polymorphism, IgG 
binding and platelet aggregation
The R131 allotype is associated with increased binding to mouse IgGi, while the 
H I31 allotype exhibits increased binding to human IgG2 and IgG 3 (van der Pol & 
van de Winkel, 1998). The presence o f at least one R allele significantly increases
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ADP-induced antibody recognition o f the GPIIb/IIIa-ligand binding site on human 
platelets (Chen et al., 2003). However, H131R genotype has no effect on 
fibrinogen binding, pharmacological agonist-induced platelet aggregation or shear- 
induced platelet activation (Chen et al., 2003).
1.6.3.2 Associations of the FcyRlia H131R polymorphism with clinical 
disease
The H I31 variant was associated with the development o f systemic lupus 
erythematosus on meta-analysis (Lehmbecher et al., 1999). Furthermore, the 
heterozygous state was associated with the development o f thromboembolic 
complications in patients with anti-phospholipid syndrome (Schallmoser et al.,
2005). Although individual studies have identified correlations between the 
presence o f an R131 allele and susceptibility to invasive pneumococcal or 
meningococcal disease, there was no clear association on meta-analysis (Brouwer et 
al., 2009). There was no relationship between H131R genotype and susceptibility 
to coronary artery disease in a recent large study (Karakas et al., 2009). However, 
given the crucial role o f the FcyRIIa receptor in S. aureus-mediated platelet 
aggregation, this polymorphism may influence susceptibility to infective 
endocarditis.
1.7 Treatments targeting platelet function in infective endocarditis
1.7.1 Effect of antibiotics on platelet function
Current treatment options for infection, namely antibiotics, also influence platelet 
function. For example, vancomycin and teicoplanin induce thrombocytopenia, 
possibly via autoimmune mechanisms, as affected individuals have increased serum 
anti-GPIIb/IIIa antibody titres (Gamer et al., 2005, Von Drygalski et al., 2007). 
Furthermore, antibiotics at high concentrations can interact directly with platelet
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phospholipid membranes and receptors, resulting in reduced bacterium-platelet and 
bacterium-vegetation adhesion in rabbit models o f infective endocarditis, and 
reduced platelet activation and aggregation in vitro (Lowy et al., 1983, Pastakia et 
a l,  1993, Shattil et a l ,  1980).
Several studies have analysed the relationship between antibiotic therapy and 
embolic events in infective endocarditis. Most have found embolic rates to be 
reduced by antibiotic treatment (Di Salvo et al., 2001, Steckelberg et al., 1991, 
Thuny et al., 2005, Vilacosta et al., 2002), while others have found either increased 
(Roder et al., 1997) or equivalent rates (Dickerman et al., 2007, Fabri et al., 2006) o f 
embolism pre- and post-antimicrobial therapy. The incidence o f septic emboli 
appears to be highest upon the initiation o f treatment, but this probably reflects the 
fact that emboli are presenting features in 14% to 47% o f cases o f infective 
endocarditis (Dickerman et al., 2007, Fabri et al., 2006, Roder et al., 1997). Overall, 
once antimicrobial therapy is commenced, the frequency o f embolic events 
decreases, even when confounding factors such as surgery are taken into 
consideration (Dickerman et al., 2007, Fabri et al., 2006, Roder et al., 1997, 
Steckelberg et al., 1991, Thuny et al., 2005).
Different classes o f  antibiotics have varying effects on platelet function. For 
example, increased vegetation size and embolic risk are associated with 
cephalosporin therapy, while treatment with penicillin or vancomycin are associated 
with reduction in vegetation size (Rohmann et al., 1997). However, it is unclear 
whether these effects are by virtue o f their antimicrobial or anti-platelet effects.
1.7.2 The role of anti-platelets in the treatment of infective endocarditis
Although the role o f antibiotics in the treatment o f infective endocarditis is well 
established, the role o f anti-platelets is not clear (Habib et al., 2009).
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1.7.2.1 Results from experimental animal models of infective 
endocarditis
High concentrations o f aspirin or salicylate reduce bacterium-platelet and 
bacterium-thrombus binding, bacterium-induced platelet aggregation, vegetation 
weight, vegetation and renal bacterial densities and renal infarction in animal 
models o f S. aureus infective endocarditis (Kupferwasser et al., 1999, N icolau et 
al., 1993). Reductions in vegetation weight alone have been observed with 
ticlopidine therapy, the combination o f early aspirin or ticlopidine with 
vancomycin, or with dual anti-platelet therapy (Nicolau et al., 1999, N icolau et al.,
1998). However, aspirin was reported to have no effect on vegetation and infective 
endocarditis development induced by viridans streptococci in a rabbit model, 
suggesting that the beneficial effects o f aspirin in infective endocarditis may be 
bacterial species specific (Levison et al., 1977).
1.7.2.2 Results from human studies of infective endocarditis
A retrospective study investigating patients with tunnelled haemodialysis catheters, 
found a significant reduction in S. aureus bacteraemia rates in those on aspirin 
therapy (Sedlacek et al., 2007). A small clinical trial o f 9 patients with infective 
endocarditis identified a reduction in vegetation size, embolic events and mortality 
amongst those treated with aspirin (Taha et al., 1992). Furthermore, Adler et al 
reported a case o f Serratia marcescens neonatal infective endocarditis complicated 
by progressively enlarging vegetations that failed to respond to potent intravenous 
antibiotics, but improved with oral aspirin therapy (Adler et al., 2004).
Unfortunately, the beneficial effects o f aspirin observed in case series and animal 
models have not been consistently observed in larger studies. The double-blinded 
placebo-controlled Multi-centre Aspirin Trial in Infective Endocarditis (MATIE) 
study analysed the effect o f treatment with 325 mg o f aspirin daily in 115 patients 
with infective endocarditis (Chan et al., 2003). There was no reduction in embolic
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risk or mortality with early or late aspirin treatment, but there was an apparent trend 
towards increased haemorrhagic complications in those on long-term therapy (Chan 
et al., 2008, Chan et al., 2003). Conversely, in an observational study o f 125 
patients, Anavekar et al discovered that at least 6 months prior anti-platelet therapy 
with aspirin, clopidogrel, ticlopidine or dipyridamole, regardless o f dose, resulted in 
significantly fewer emboli (Anavekar et al., 2007). However, the results o f this 
study should be interpreted with caution, as the investigators were limited by small 
study populations in each treatment group (Anavekar et al., 2007).
Accordingly, recently published studies have investigated the effect o f long-term 
anti-platelet therapy on outcome in infective endocarditis (Eisen et al., 2009, Pepin 
et al., 2009). A single-centre 16-year follow-up study discovered that prior anti­
platelet therapy was associated with reduced mortality, particularly in non-S1. aureus 
infective endocarditis, with no effect on embolism (Pepin et al., 2009). In contrast, 
a retrospective study on 670 patients with S. aureus infective endocarditis 
determined that aspirin therapy was associated with decreased risk o f embolism on 
univariate analysis alone, and correlated with reduced need for surgery during the 
index event (Eisen et al., 2009).
1.7.2.3 Antimicrobial effects of anti-platelets
Some anti-platelet derivatives exhibit antimicrobial effects in vitro. Notably, these 
phenomena have mainly been observed with salicylate, a derivative o f aspirin 
(acetylsalicylic acid) that lacks intrinsic anti-platelet activity (Kupferwasser et al.,
2003). Growth in the presence o f salicylate abrogates bacterial growth, alters 
bacterial metabolism, modulates antimicrobial resistance and reduces attachment to 
valvular endothelium (Kupferwasser et al., 1999, Price et al., 2000, Riordan et al.,
2007). Furthermore, salicylate influences virulence factor expression by 
downregulating S. aureus fnbA , fnbB , hla (encoding a-toxin), sarA promoter and 
agr RNAIII expression, while upregulating exoenzyme and spa  expression through 
(TB-dependent mechanisms (Kupferwasser et al., 2003, Price et al., 2000, Riordan et
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al., 2007). It is not known at present whether similar effects are observed with 
aspirin.
1.8 Conclusions
S. aureus infective endocarditis is a serious condition whose incidence has 
increased globally. However, many patients who contract this disease have no 
known risk factors, and it is not understood why some patients recover rapidly from 
bacteraemia, while others develop infective endocarditis. Considering the high 
morbidity and mortality rates associated with infective endocarditis, it is important 
to understand why it occurs as a complication o f bacteraemia in some cases, but not 
others.
Recent evidence suggests that the outcome o f infection may be related to both host 
and pathogen factors, but our knowledge o f  this is far from complete (Fowler et al., 
2005a, Lowy, 1998). For example, it is unclear whether bacterial factors which are 
implicated in platelet interactions in vitro and in animals, are also relevant to the 
pathogenesis o f  infective endocarditis in humans. In addition, the role o f platelets 
in infective endocarditis is not known, and the relative contribution o f host and 
pathogen factors in susceptibility to infective endocarditis has not been determined. 
It is important to gain an improved understanding o f the host-bacterial interactions 
that contribute to disease outcome as this could facilitate the development o f novel 
therapeutic approaches to the treatment o f S. aureus infective endocarditis.
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1.9 Aims
This research aims to investigate the contribution o f host and pathogen factors to 
the development o f infective endocarditis, with a view to identifying novel targets 
for future therapeutics. The aims are as follows:
1. Examination o f the capacity o f S. aureus clinical isolates to promote platelet 
aggregation after growth in human blood.
2. Investigation into the association o f platelet activation with susceptibility to 
infective endocarditis.
3. Determination o f the influence o f platelet receptor polymorphisms on S. aureus- 
induced platelet aggregation and clinical outcome in infective endocarditis.
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One hundred and ninety-four healthy volunteers with no evidence o f clinically 
significant co-existing conditions, recent infection or drug therapy, were recruited in 
Edinburgh between July 2007 and April 2009. Forty-four patients admitted to the 
Edinburgh Royal Infirmary (ERI) with a diagnosis o f infective endocarditis fulfilling 
the modified Duke criteria (Table 1.2) (Li et al., 2000b), were recruited between 
November 2006 and March 2009. Four patients with S. aureus bacteraemia, defined 
as blood culture positivity for S. aureus not fulfilling the modified Duke criteria, 
were recruited over the same time period.
Exclusion criteria for all subjects included age less than 18 years and the presence o f 
acute or chronic confusional states that precluded capacity to provide consent. 
Written informed consent was obtained from all participants. All studies were 
conducted following approval from the Lothian National Health Service (NHS) 
Research Ethics Committee.
2.2 Clinical outcomes and definitions
Data for infective endocarditis patients were collected prospectively for the index 
presentation and a 3-month period thereafter. The diagnosis o f  embolism was based 
on non-invasive radiological investigations and determined from the patient’s history 
and clinical notes. Cutaneous manifestations were excluded, as their aetiology is 
considered multifactorial (Bashore et al., 2006). Systematic computed tomography 
surveillance was not performed.
Relapse was defined as a new episode o f infective endocarditis caused by a 
microorganism o f the same genus and species, while a recurrence was defined as a 
new episode o f infective endocarditis caused by a different microorganism (Mansur 
et al., 2001). The composite clinical end-point was defined as the presence o f 




Images were acquired in all patients from transthoracic and/or transoesophageal 
echocardiogram windows performed early in the acute phase o f the infective 
endocarditis process using 2 -dimensional transducers capable o f  second and ultra­
harmonic imaging, attached to either Vingmed (GE Healthcare, Bedford, UK) or 
ÍE33 (Philips, Surrey, UK) platforms. All data were stored digitally. Transthoracic 
and transoesophageal echocardiography images for determination o f vegetation size 
and mobility were reviewed on EchoPAC v 7.0.1 for the PC (GE Healthcare 
Vingmed Ultrasound, Bedford, UK) by two independent experienced observers who 
were blinded to patient history, clinical course, platelet activation and platelet 
receptor genotype.
Vegetations were identified as distinctly abnormal echogenic masses attached to the 
endothelial surface o f valves or endocardium. The largest length and width 
obtainable in any one frame throughout the cardiac cycle was measured for the 
largest vegetation if  more than one vegetation was present (De Castro et al., 1997). 
The mobility o f vegetations was classified as previously described: absent, fixed 
vegetation with no detectable independent motion; low, vegetation fixed at the base 
but with a mobile free edge; moderate, pedunculated vegetation that remains within 
the same chamber throughout the cardiac cycle; severe, prolapsing vegetation that 
crosses the coaptation plane o f the leaflets during the cardiac cycle (Di Salvo et al., 
2001).
2.4 Blood sampling
Venepuncture was performed using a 19-gauge (1.1 mm) needle or a 7 French (2.3 
mm) triple-lumen central venous catheter into a 30 ml syringe. Care was taken to
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ensure a smooth blood draw with minimal trauma. Three ml blood was transferred 
into a tube containing the direct thrombin inhibitor D-phenylalanyl-L-propyl-L- 
arginine chloromethylketone (PPACK; Haematologic Technologies Inc, Vermont, 
USA) at a final concentration o f 75 pM  for determination o f platelet activation, and 9 
ml into a tube containing 1.6 mg/ml o f ethylenediamine tetraacetic acid (EDTA) to 
obtain plasma for platelet receptor polymorphism genotyping. Plasma was stored at 
-20°C until use.
Blood samples for isolation o f platelet-rich plasma (PRP) for turbidimetric platelet 
aggregometry and flow cytometry were taken from a subset o f healthy volunteers 
into 50 ml syringes containing 0.38% (w/v) sodium citrate. For isolation o f washed 
platelets, blood was drawn into 50 ml syringes containing 15% (w/v) acid-citrate 
dextrose (7.32 g/1 citric acid anhydrous, 22 g/1 N a citrate, 24.52 g/1 dextrose). For use 
as a growth medium, blood was sampled using a 19-gauge needle into a 60 ml 
syringe containing 5 international units (IU)/ml o f unfractionated heparin (Roche, 
Welwyn Garden City, UK).
2.5 Platelet receptor polymorphism genotyping
Human genomic DNA was extracted from plasma using the bioM erieux NucliSens 
easy Mag (bioMerieux, Basingstoke, UK) according to the m anufacturer’s 
instructions, and adjusted to a final concentration o f 10  ng/pl in deionised water.
GPIIIa p iAI/A2? FcyRlIa H131R, GPIb HPA-2 and Kozak sequence polymorphisms 
were determined using the ABI 7900HT Sequence Detection System (Applied 
Biosystems, Warrington, UK). Primers 5' CTG AA AGGC AAT G AGCT G A AG AC 3' 
and 5' TTGTTAGCCAGACTGAGCTTCTC 3', were used to amplify the 
polymorphic site o f  HPA-2 (Higgins el al., 2004), while other polymorphisms were 
determined with proprietary oligonucleotide sequences and TaqM an® probes 
(Applied Biosystems, Warrington, UK). GPIb VNTR alleles were determined by 
PCR with a Whatman Biometra Tgradient PCR thermal cycler (Thistle Scientific,
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Glasgow, UK). PCR reactions included 200 nM each o f forward prim er 5' 
AC ACTT CAC ATGG AATCC AT 3' and reverse primer 5’
GGGTCATTTCTGGAGCTCTC 3’ (Ishida el al., 1995), 1 U Taq polymerase, 200 
uM deoxynucleotide triphosphate (dNTPs) and 10 ng genomic DNA in buffer 
(Promega, Southampton, UK). Thermocycling parameters included a 5 min initial 
denaturing step at 95°C, followed by 35 cycles consisting o f 1 min at 95°C 
(denaturing), 1 min at 58°C (annealing) and 2 min at 72°C (extension). PCR 
products were resolved by electrophoresis in 2 % (w/v) agarose.
2.6 Generation of platelet-rich plasma (PRP) and washed platelets
Citrated blood was centrifuged at 150 x g  for 10 min with a bench-top 581 OR 
Centrifuge (Eppendorf, Cambridge, UK) to generate PRP. The PRP fraction was 
removed and an aliquot was further centrifuged at 1500 x g  for 10  min to generate 
platelet-poor plasma (PPP). Autologous PPP was used to standardise PRP to a 
platelet count o f 200 x 109/1 after the platelet count was determined on a Coulter® 
A.T1m series analyser (Beckman Coulter Inc., High Wycombe, UK).
For preparation o f washed platelets, PRP was generated from blood anticoagulated 
with acid-citrate dextrose and adjusted to a pH o f 6.5 with acid-citrate dextrose, prior 
to addition o f 1 pM  prostaglandin Ei and 1 U/ml apyrase (both from Sigma, Dorset, 
UK). Samples were centrifuged at 720 x g  for 10 min to obtain a platelet pellet, 
which was gently resuspended in modified HEPES-Tyrode’s (JNL) buffer (6 mM 
dextrose, 130 mM NaCl, 9 mM NaHCCE, 10 mM N a citrate, 10 mM Tris-base, 3 
mM KC1, 0.8 mM KH2PO4, 0.9 mM M gC f; pH 7.4) (O'Brien et ah, 2002a). Washed 
platelet suspensions were standardised to a platelet count o f 200 x 109/l in JNL 
buffer with addition o f 1 mg/ml human fibrinogen (Calbiochem, Nottingham, UK) 
and 2 mM Ca2+. All platelet preparations were used within 2.5 h o f venepuncture.
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2.7 Bacterial strains
A total o f 27 clinical and laboratory S. aureus isolates were used for in vitro 
experiments, including 5 isolates from patients with infective endocarditis, 6 from 
subjects with asymptomatic nasal colonisation, 5 bacteraemia strains and an array o f 
laboratory and deletion mutant strains (Table 2.1). The infective endocarditis and 
commensal strains were obtained from Oxfordshire, United Kingdom between 1997 
and 1998 and kindly gifted by Dr. Nicholas P. Day (Day et al., 2001). S. aureus 
strains Newman, P I, 8325-4 and associated FnBPA and FnBPB knockouts (DU5998 
and DU5883, respectively) were donated by Professor Timothy J. Foster (Moyne 
Institute o f Preventative Medicine, Trinity College, Dublin, Ireland). S. aureus strain 
132 and derivative mutants were kindly gifted by Iñigo Lasa (Instituto de 
Agrobiotecnología, Universidad Pública de Navarra-CSIC, Pamplona, Spain). The 
bacteraemia strains were obtained from patients admitted to the ERI from March to 
July 2007 with positive blood cultures for S. aureus and no evidence o f  infective 
endocarditis on transthoracic echocardiography. The Scottish MRS A Reference 
Laboratory, Glasgow, UK, performed M LST o f the bacteraemia strains. All S. 
aureus strains were methicillin-sensitive apart from strain 132 and its derivative 
mutants.
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Table 2.1. S. aureus strains used for in vitro experiments.
S train C harac teris tics ST R eference
126 Infective endocarditis 8 (Feil et al., 2003)
206 Infective endocarditis 25 (Feil et al., 2003)
207 Infective endocarditis 15 (Feil et al., 2003)
209 Infective endocarditis 30 (Feil et al., 2003)
383 Infective endocarditis 2 2 (Feil et al., 2003)
3005 Commensal 15 (Feil et a l ,  2003)
3010 Commensal 15 (Feil et al., 2003)
3050 Commensal 30 (Feil et al., 2003)
3081 Commensal 76 (Feil et al., 2003)
3117 Commensal 30 (Feil et al., 2003)
3125 Commensal 134 (Feil et al., 2003)
SAB001 Bacteraemia 5 Current study
SAB002 Bacteraemia 3 Current study
SAB003 Bacteraemia 217 Current study
SAB004 Bacteraemia 30 Current study
SAB005 Bacteraemia 487 Current study
Newman Wild type laboratory 
strain
8 (Duthie & Lorenz, 
1952)
PI Wild type. Rabbit 
virulent strain
973 (Sherertz et a l ,  1993)
PI Afnb (fnbA::TcT, 
fnbBv.Emr, DU5998)
FnBPA and FnBPB 
knockout o f strain P 1
973 (Roche et al., 2004)
8 6
Strain C harac teristics ST R eference
DU5998 pFNBA4 DU5998 complemented 973 (Fitzgerald et al.,
{fnbA ::T cr, fnbB: :Emr, with plasmid expressing 2006b)
Pfnba4 :fnbA+ Cmr) FnBPA
DU5998 pFNBB4 DU5998 complemented 973 (Fitzgerald et al.,
(jnbA ::TcT, fribB: :Emr, with plasmid expressing 2006b)
Pfnba4:fnbB+ Cmr) FnBPB
PI clfA5, cl/B: :lacZ[EmT] ClfA, ClfB, Sdr C, Sdr 973 (Fitzgerald et al.,
AsdrCDE::7c spa::Kar D, Sdr E and SpA 2006b)
(DU6011) knockout o f PI
8325-4 NCTC 8325 cured o f 8 (Novick, 1967)
prophages
8325-4Afnb (8325-4 FnBPA and FnBPB 8 (Greene et al., 1995)
fhbA : :Tc \fn b B :  :Emr, knockout o f strain 8325-
DU5883) 4
132 Wild type clinical ND (Vergara-Irigaray et
isolate; MRSA al., 2009)
132AIsdA (sasE::pMAD Insertional IsdA mutant ND (Vergara-Irigaray et
EnT) o f 132 al., 2009)
132AIsdB (sasJ::pMAD Insertional IsdB mutant ND (Vergara-Irigaray et
Emr) o f 132 al., 2009)
ST, sequence type by multi-locus sequence typing; Tcr, tetracycline-resistant; Emr, 
erythromycin-resistant; Cmr, chloramphenicol-resistant; Kar, kanamycin-resistant; 
MRSA, methicillin-resistant S. aureus\ ND, not determined.
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2.8 Bacterial culturing
S. aureus strains were grown on tryptic soy agar (TSA) plates (Oxoid, Basingstoke, 
UK) statically at 37°C and grown in liquid media as outlined below. The following 
antibiotics were incorporated into the media where appropriate (erythromycin 5 or 10 
[ig/ml, chloramphenicol 10  p,g/ml).
2.8.1 Bacterial growth in nutrient broth
Single colonies o f  S. aureus strains were used to inoculate 25 ml o f  brain-heart 
infusion (BHI) (Oxoid, Basingstoke, UK) and incubated overnight at 37°C with 
constant rotation at 200 rpm, to reach the stationary phase o f  growth. A 1:200 
dilution o f overnight culture was made in 25 ml o f BHI, with incubation under the 
same conditions as above and grown to mid-exponential phase (approximately 1.5 h 
to 3 h as determined from growth curves). Bacterial growth was assessed by 
measurement o f the optical density at 600 nm (ODeoo) using a spectrophotometer 
(Cecil Aurius CE2021, Thistle Scientific Ltd., Glasgow, UK).
2.8.2 Bacterial growth in whole human blood
Single colonies o f  S. aureus isolates were inoculated in 5 ml o f  heparinised whole 
human blood at 37°C with shaking at 200 rpm in an orbital shaker, until they reached 
the stationary phase o f growth. Stationary phase cultures were subcultured into 40 
ml o f heparinised whole human blood at 106 CFU/ml and grown to either mid­
exponential or stationary phase, as determined from growth curves, for use in in vitro 
experiments. Bacterial growth was determined by performing viable counts.
8 8
2.9 Processing of bacterial cultures for in vitro studies
S. aureus strains were grown to stationary and mid-exponential phase in BHI and 
blood. Bacteria were isolated from blood cultures as previously described for Group 
A Streptococcus, with modifications (Graham et al., 2005). Briefly, blood cultures 
were resuspended in 5 volumes o f erythrocyte lysis (EL) buffer (Qiagen, Crawley, 
UK) and incubated for 20 min on ice. Following 10 min centrifugation at 4000 rpm 
at 4°C, the supernatant was discarded and the cells were washed with 2 volumes o f 
EL buffer. Cells were washed once in 100 U/ml o f unfractionated heparin and 10 
mM calcium chloride solution to prevent cell clumping (O'Connell et al., 1998, Shin 
et al., 2005), and twice in phosphate-buffered saline (PBS) at 5000 x g  for 3 min. 
Cultures were resuspended in PBS to an OD600 value corresponding to a viable count 
o f 2 x 109 CFU/ml for use in platelet aggregometry.
For bacteria grown in BHI, cultures were centrifuged at 5000 x g  for 3 min, washed 
twice, and resuspended in 1 ml o f PBS to an OD600 o f 1.6, corresponding to 
approximately 2 x 109 CFU/ml, for platelet aggregometry and activation studies, and 
an ODgoo o f 1.0 for fibronectin adherence assays (Fitzgerald et al., 2006b). Culture 
volumes o f 1ml were processed at the stationary phase o f  growth and 25 ml at the 
exponential growth phase.
To process bacteria for S. ¿/«rews-platelet adhesion studies, stationary and 
exponential phase BFII cultures were washed twice in cold 0.05 M Tris-HCl buffer 
containing 0.1 M NaCl and 0.02 M EDTA, pH 7.25 (Yeaman et al., 1992c). Bacteria 
were labelled with 100 p,g/ml o f  Hoechst 33342 (Sigma, Dorset, UK) prior to 
incubation in the dark for 2 h at 4°C, followed by twice washing in Tyrode’s solution 
(137 mM NaCl, 2.7 mM KC1, 1 mM M gCl2, 1.8 mM CaCl2, 0.2 mM Na2H P 0 4, 12 
mM NaHCCL, 5.5 mM dextrose, pH 7.4) and resuspension to an OD600 o f 1.6.
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2.10 Flow cytometry
2.10.1 S. aureus-platelet adhesion
S. aureus-p\ate\et adhesion was determined by incubation o f 9 x 107 Hoechst 33342- 
labelled bacterial cells with 9 x 106 platelets in PRP at room temperature for 5 min, 
followed by labelling with 1% fluorescein isothiocyanate (FITC)-conjugated mouse 
anti-human CD42a antibody (Serotec, Kidlington, UK) for 30 min and fixing with 1 
ml 1 % (v/v) paraformaldehyde. Fluorescent data were determined within 24 h o f 
fixation using a FACS Vantage SE cell sorter (Becton Dickinson, Oxford, UK) with 
FACSDiVa software (Becton Dickinson, Oxford, UK). One hundred thousand 
platelets were collected for each sample and distilled water, flow buffer (Becton 
Dickinson, Oxford, UK) and 0.05 M Tris-HCl buffer containing 0.1 M NaCl and 
0.02 M EDTA, pH 7.25, served as negative controls. S. aureus bound to platelets 
were identified as cells positive for both Hoechst and FITC fluorescent signals, and 
data were analysed using FlowJo v 8 .8.6 (Tree Star Inc., Oregon, USA) to determine 
the percentage o f platelets bound to S. aureus and the percentage o f S. aureus bound 
to platelets.
2.10.2 Baseline and agonist-induced platelet activation
Within 5 min o f transfer into a PPACK tube, blood was labelled at room temperature 
with the appropriate monoclonal antibodies for determination o f baseline platelet 
activation, as previously described (Sarma et a l ,  2002, Gudmundsdottir el al., 2006). 
Briefly, mouse anti-human CD14-phycoerythrin (PE) (Inverness Medical, Stockport, 
UK) and anti-CD42a-FITC were added to 60 pi o f blood at a 1:40 dilution for 
detection o f PMA. Anti-CD42a-FITC and mouse anti-human CD62P-PE (Serotec, 
Kidlington, UK) at a 1:2 dilution were used to label 5 pi o f blood for detection o f 
platelet P-selectin expression. The appropriate isotope mouse IgGi antibodies 
(Serotec, Kidlington, UK) and flow buffer served as negative controls. Following 20 
min o f immunolabelling, PMA and P-selectin samples were fixed with 500 pi FACS
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Lyse solution (Becton Dickinson, Oxford, UK) and 1.425 ml 1% (v/v) 
paraformaldehyde, respectively.
Platelet activation was quantified within 24 h o f  sample fixation using dual-channel 
flow cytometry on the FACSCalibur (Becton Dickonson, Oxford, UK), with at least
2,000 monocytes and 7,500 platelets collected for each sample. PMAs were defined 
as monocytes expressing CD 14 that were also positive for CD42a and P selectin- 
expressing platelets were defined as CD42a-expressing platelets that were positive 
for CD62P. Data were acquired and analysed using CellQuest software (Becton 
Dickonson, Oxford, UK), and results expressed as a percentage o f  the monocyte and 
platelet cell population, respectively.
For determination o f agonist-induced platelet activation, bacterial suspensions were 
added to PRP at a ratio o f 10:1, incubated for 30 min at room temperature, followed 
by labelling with 2% anti-CD42a-FITC, anti-CD62P-PE or the appropriate IgGi 
isotype control for 30 min. Samples were fixed with 1 ml 1% (v/v) 
paraformaldehyde and platelet P-selectin expression determined as described above 
using a FACScan flow cytometer (Becton Dickinson, Oxford, UK). The 
pharmacological protease-activated receptor-1 agonist SFLLRN-NFE (1 pM; 
Clinalfa, Laufelfmgen, Switzerland) was used as a positive control. Baseline platelet 
P-selectin expression was also determined using equivalent volumes o f vehicle alone 
(PBS and 0.9% NaCl instead o f bacterial and pharmacological agonists, 
respectively), in order to calculate relative platelet activation (see Section 5.3.3).
2.11 Platelet aggregometry
Platelet aggregometry was performed as described previously (Fitzgerald et al., 
2006b). Briefly, 5 x 107 bacterial cells (in 25 pi PBS) were added to 4.5 x 107 
platelets (in 225 pi PRP or washed platelets) in siliconised glass cuvettes with 
constant stirring at 37°C. Platelet aggregation was assayed by light transmission in a 
PAP-4 aggregometer (Bio-Data, Alpha Laboratories, Eastleigh, UK) in triplicate.
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PPP and JNL were used as the 100% light transmission references for PRP and 
washed platelets, respectively. S. aureus strain Newman at either the stationary or 
exponential phase o f growth, SFLLRN-NH2 (0.1 pM ) ADP (5 pM ; Trinity Biotech, 
Wicklow, Ireland) and ristocetin (0.1 pM; American Biochemical and 
Pharmaceutical, London, UK) were used as agonist positive controls. The lag time 
to platelet aggregation was measured as the time from addition o f  agonist to the 
initiation o f  platelet aggregation up to a 25 min limit. The maximal percentage 
platelet aggregation and rate o f aggregation were also determined (Figure 2.1).
2.12 Fibrinogen-binding assays
Adherence o f bacteria to immobilised fibrinogen was performed as previously 
described (Hartford el al., 1997). Briefly, 96-well flat-bottomed plates (Nunc, 
Loughborough, UK) were coated with serial dilutions o f 100 pi o f 0 to 50 pg/ml 
human fibrinogen in PBS and incubated at 4°C overnight. Plates were thrice washed 
with 100 pi PBS, and then incubated with 100 pi o f 2 mg/ml filter-sterilised bovine 
serum albumin (Sigma, Dorset, UK) for 1 h at 37°C. Following three washes with 
PBS, 1.25 x 108 S. aureus cells were added to each well and incubated for 2 h at 
37°C under constant rotation, followed by removal o f non-adherent cells by thrice 
washing with 100 pi PBS. Cells were fixed with 100 pi 25% (v/v) formaldehyde 
(VWR, Lutterworth, UK) for 30 min at room temperature, stained with 100 pi 0.5% 
(w/v) crystal violet (Sigma, Dorset, UK) for 1 min, and solubilised with 100 pi 10% 
(v/v) acetic acid (Fisher Scientific, Loughborough, UK). Plates were washed three 
times with 100 pi PBS between each fixing or staining stage.
The absorbance at 590 nm (A590) was determined in an enzyme-linked 
immunosorbent assay (ELISA) plate reader (VERSAmax microplate reader, 
Molecular Devices, Wokingham). S. aureus strain Newman at the stationary phase 
o f growth was used as a positive control, while PBS served as a negative control at 
fibrinogen concentrations o f 50 pg/ml. Experiments were performed in triplicate.
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Figure 2.1. Measures of platelet aggregation. Lag time was taken as the time 
taken from addition of agonist to initiation of platelet aggregation (A), rate of 
aggregation as the gradient during the steepest part of the aggregation curve (B) 
and maximal percentage aggregation as the level of percentage platelet aggregation 
at which the tracing plateaued (C).
A590 readings obtained for the negative control were subtracted for values obtained 
for each strain at each fibrinogen concentration to generate a curve with plateaued 
fibrinogen binding. A 590 readings at saturation o f fibrinogen binding (fibrinogen 
concentration o f 12.5 pg/ml) were used for analyses.
2.13 Bacterial DNA extraction
Genomic DNA was extracted from S. aureus cultures grown to stationary phase in 
BHI. Briefly, 1 ml o f culture was centrifuged at 14000 x g  for 6 min to generate a 
bacterial pellet, which was incubated with 5 pi o f 5 mg/ml lysostaphin (Ambi, New 
York, USA). Bacterial DNA was then extracted using the PurElute Bacterial
Genomic Kit (Edge Biosystems, Gaithersburg, MD, USA) according to 
manufacturer’s instructions. DNA integrity was verified by subjecting samples to 
electrophoresis in 1% (w/v) agarose, and yield quantified using the Nanodrop ND- 
1000 spectrophotometer (Fisher Scientific, Loughborough, UK). Bacterial DNA 
samples were standardised to a concentration o f 350 ng/pl in deionised w ater and 
stored at 4°C until use.
2.14 Bacterial RNA extraction and conversion to complementary DNA 
(cDNA)
For isolation o f  bacteria for RNA extraction, BHI and blood cultures grown to 
stationary phase were pre-treated with RNA protect (Qiagen, Crawley, UK) 
according to manufacturer’s instructions, processed as described in Section 2.9, and 
washed for 10 min at 5000 x g  in 10 mM Tris-HCl, 1 mM EDTA, pH 8.0 (TE buffer, 
Fluka, Dorset, UK). S. aureus cells were then resuspended in 500 pi TE buffer with 
100 pg/ml lysostaphin, followed by incubation at 37°C for 30 min. Bacterial RNA 
was extracted using the RNeasy mini kit (Qiagen, Crawley, UK) according to 
manufacturer’s instructions.
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Removal o f contaminating DNA was performed using the Ambion TURBO DNA- 
free kit (Applied Biosystems, Warrington, UK) as per m anufacturer’s instructions. 
Samples were then centrifuged at 8000 x g  for 2 min and 25 ptl o f supernatant 
retained as DNA-free RNA. The absence o f contaminating DNA was verified by 
negative results when performing PCR on RNA samples with a W hatman Biometra 
Tgradient PCR thermal cycler. PCR reactions included 300 nM each o f forward and 
reverse 16S rRNA primers (Table 2.2), 1 U Taq polymerase, 200 p,M dNTPs and 50 
ng RNA in buffer (Promega, Southampton, UK). Thermocycling parameters 
included a 3 min initial denaturing step at 94°C, followed by 30 cycles consisting o f 
1 min at 94°C (denaturing), 1 min at 60°C (annealing) and 90 s at 72°C (extension) 
with a further 10 min at 72°C (final extension). Positive controls for all PCR 
reactions comprised o f genomic DNA extracted from S. aureus strain Newman, 
while DNA- and RNA-free water served as a negative control. PCR products were 
resolved by electrophoresis in 2% (w/v) agarose.
RNA concentration and quality were determined using the Nanodrop ND-1000 
spectrophotometer, which quantifies nucleic acid yield and A26o:A28o ratios (the latter 
should be approximately 1.8 to 2.0), and by examination o f  the integrity o f RNA 
samples after electrophoresis in a 2% (w/v) agarose gel. Bacterial RNA samples 
were stored at -70°C until use.
RNA (50 ng) was converted to complementary DNA (cDNA) using the 
AffmityScript QPCR cDNA synthesis kit (Agilent, Stockport, UK) according to 
manufacturer’s instructions.
2.15 Quantitative Reverse-Transcriptase PCR (qRT-PCR)
Quantitative reverse-transcriptase PCR (qRT-PCR) was performed using the 
MX3000P quantitative-PCR instrument (Stratagene, Stockport, UK), with the SYBR 
Green Supermix-UDG kit (Invitrogen, Paisley, UK) according to manufacturer’s 
instructions, 300 nM each o f forward and reverse primers for clfA and 16S rRNA
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(Table 2.2) and 100 ng cDNA prepared from S. aureus stationary phase BHI and 
blood cultures. qRT-PCR cycling conditions consisted o f a 10 min initial denaturing 
step at 95 °C, followed by 40 cycles consisting o f 20 s at 94°C (denaturing), 20 s at 
60°C (annealing) and 20 s at 72°C (extension), to generate PCR products o f  115 bp 
(.16SrRN A ) and 276 bp {elfA).
Positive controls included 10-fold serial dilutions o f genomic DNA extracted from S. 
aureus strain Newman, which were used to generate standard curves o f template 
concentration against threshold cycle (Ct; the cycle at which fluorescence is 
determined to be significantly greater than background signal), for both 16S rRNA 
and clfA primers on the MxPro QPCR v. 3.00 software (Stratagene, Stockport, UK). 
Gradients o f  and R2 values derived from standard curves were used to verify primer- 
binding efficiency. Negative controls included RNA treated with the AffmityScript 
QPCR cDNA synthesis kit in the absence o f reverse transcriptase (no-RT) and wells 
containing DNA- and RNA-free water rather than cDNA (non-template controls or 
NTCs).
qRT-PCR product integrity and absence o f  contamination in negative controls were 
verified by analysis o f amplicon melting temperatures in dissociation curves 
generated by the MxPro QPCR v. 3.00 software, and by subjecting qRT-PCR 
products to electrophoresis on a 2% (w/v) agarose gel. qRT-PCR-transcript levels o f 
clfA relative to the normalising gene 16s rRNA were determined using the equation
( 1 + E c l f A l ^ lc lfA  
(1+ E i6s)  C tl6 S
where Ec|fA and Ej6s represent the efficiency o f amplification o f clfA and 16S rRNA 
respectively (value between 0 and 1), and CtcifA and Cti6s represent the threshold 
cycles for clfA and 16S rRNA, respectively.
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O ligonucleotide sequence P roduct 
size (bp)
R eference
ClfU 5' GGCGTGGCTTCAGTGCTTGTA 3' 276 (W olz et
ClfL 5' CACCAGTTACCGGCGTTTCTTC 3' al., 2002)
16SF 5' TATGGAGGAACACCAGTGGCGAAG 3' 115 (Ster et al.,
16SR 5' TCATCGTTTACGGCGTGGACTACC 3' 2005)
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2.16 Statistical analyses
Data analysis was performed using SPSS v. 16.0 (SPSS Inc, Chicago, IL, USA) for 
the Macintosh. Values are reported as mean ± standard deviation and the normality 
o f data distribution determined using the Shapiro-W ilk test.
The chi-squared test was used to compare polymorphism frequencies. Parametric 
data were analysed using the two-tailed Student t-test, analysis o f variance 
(ANOVA) or General Linear Model, and non-parametric data analysed by the 
Kruskal-Wallis test with Mann-Whitney U correction. Linear regression was used to 
compare numerical data and multinomial logistic regression analysis was used to 
determine correlations between categorical variables. Statistical significance was 
taken as P<0.05 for univariate analyses and P O .IO  for multivariate analyses.
98
CHAPTER 3
EXAMINATION OF THE CAPACITY OF S. AUREUS CLINICAL 
ISOLATES TO PROMOTE PLATELET AGGREGATION AFTER 
GROWTH IN HUMAN BLOOD
99
3.1 In tro d u c tio n ...................................................................................................................... 102
3.2 M e th o d s ............................................................................................................................... 102
3.3 R e s u lts ................................................................................................................................. 103
3.3.1 S. aureus grows in whole human b lood ...........................................................103
3.3.2 Growth of S. aureus to stationary phase in blood confers a pro- 
aggregatory phenotype......................................................................................................... 105
3.3.3 Investigation into the bacterial components mediating platelet 
aggregation following S. aureus growth in human b lo o d ....................................... 107
3.3.3.1 clfA expression is downregulated during S. aureus growth to 
stationary phase in human blood................................................................................. 107
3.3.3.2 Deficiency in IsdA and IsdB expression does not influence 
platelet aggregation induced by S. aureus strains grown to stationary  
phase in b lood .................................................................................................................112
3.3.3.3 Deficiency in FnBPA and FnBPB expression increases lag time 
to platelet aggregation induced by S. aureus strains grown to stationary 
phase in b lood ..................................................................................................................... 112
3.3.4 The ability of S. aureus to induce platelet aggregation in vitro  does 
not predict development of infective endocarditis in  v ivo ...................................... 113
3.3.5 Thrombus formation during S. aureus growth in human blood ex 
vivo does not influence platelet aggregation ............................................................... 114
3 .4 D is c u s s io n ........................................................................................................................ 1 17
3.4.1 S. aureus growth in whole human blood..........................................................117
3.4.2 Influence of growth medium on platelet aggregation induced by S. 
aureus ..........................................................................................................................................118
3.4.3 Influence of strain clinical origin on platelet aggregation induced by
S. aureus .....................................................................................................................................122
1 0 0
3.4.4 Host-pathogen interactions contributing to platelet aggregation and 
thrombus form ation................................................................................................................ 124
3.4.5 C onclusions................................................................................................................ 125
101
3.1 Introduction
MSCRAMMs, such as FnBPA, FnBPB, ClfA, ClfB and SpA contribute to S. aureus- 
induced platelet aggregation following bacterial growth in nutrient-rich media 
(Fitzgerald et ah, 2006b, Loughman et al., 2005, Miajlovic et ah, 2007, O 'Brien et 
al., 2002a). However, experimental conditions employed in these studies do not 
reflect the in vivo milieu encountered by bacteria during growth in the human 
bloodstream, and S. aureus growth in human blood may influence MSCRAMM 
expression and functionality (Novick, 2003, Pluym et al., 2008, Schlievert et al., 
2007, W ard et al., 1996). In order to investigate this hypothesis, whole human blood 
was utilised as a bacterial growth medium ex vivo. The ability o f selected S. aureus 
clinical isolates to induce platelet aggregation after growth in human blood was 
compared to results obtained following bacterial growth in BHI.
3.2 Methods
S. aureus strains Newman, 383 and 3081 were grown in BHI and heparinised human 
blood as described in Section 2.8 in order to generate growth curves for S. aureus in 
each medium. Growth curves were used to determine the timing o f mid-exponential 
and stationary phases o f growth for S. aureus in each medium. Strains were grown 
in BHI for 8.5 h and OD600 readings taken every 30 to 60 min, while strains grown in 
human blood were cultured for 36 h, with viable counts determined every 2 h 
following the initial lag phase.
A selection o f S. aureus clinical isolates (Table 2.1) were then grown to stationary 
and mid-exponential phases in blood and BHI, processed as described in Section 2.9 
and used to stimulate aggregation o f platelets in PRP as described in Section 2.11. 
The lag time and percentage platelet aggregation was determined for each agonist, 
with strain Newman at both growth phases used as a positive control.
1 0 2
In order to determine the role o f ClfA in bacterium-platelet interactions, fibrinogen- 
binding assays were performed as described in Sections 2.9 and 2.12 using S. aureus 
clinical isolates grown to stationary phase in human blood and BHI. In addition, clfA 
gene transcription levels were determined for a selection o f  S. aureus strains grown 
to stationary phase in BHI and blood using qRT-PCR as described in Sections 2.14 
and 2.15. The role o f other selected MSCRAMM s in platelet aggregation induced by 
S. aureus was examined by performing platelet aggregometry using wild type, 
deletion mutant and complemented strains (listed in Table 2.1) grown to stationary 
phase in human blood. Strain Newman grown to stationary phase in BHI was used 
as a positive control for these experiments.
3.3 Results
3.3.1 S. aureus grows in whole human blood
In order to compare the growth profiles o f S. aureus in human blood and BHI, 
growth curves were performed for 3 selected S. aureus strains (Newman, 383 and 
3081) in each medium. When S. aureus was grown in blood, there was a lag phase 
o f 10 h, with a mid-exponential phase at 14 h to 20 h and a stationary phase o f 
growth from 32 h onwards (Figure 3.1A). Notably, strain Newman did not grow in 
blood. Bacterial counts at the stationary phase o f growth varied from 7.61 x 108 to 
5.54 x 109 CFU/ml. In contrast, the S. aureus growth curve in nutrient-rich BHI had 
a mid-exponential phase at 2 h to 2.5 h and reached stationary phase after 8 h o f 
growth (Figure 3 .IB), similar to previous findings (O'Brien et al., 2002a). The 
bacterial yield at stationary phase was equivalent to 1.77 x 1010 to 2.22 x 1010 
CFU/ml, with corresponding OD6oo values o f 14.2 to 17.7, while the mid-exponential 
phase o f growth was defined as an OD(,oo value o f between 0.5 and 0.9. Doubling 
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3.3.2 Growth of S. aureus to stationary phase in blood confers a pro- 
aggregatory phenotype
S. aureus strains isolated from cases o f infective endocarditis, nasal colonisation and 
bacteraemia and representing diverse STs (Table 2.1), were grown in both blood and 
BHI and used to induce platelet aggregation. There was strain-dependent variation 
in the ability o f S. aureus to grow in blood (data not shown). However, all strains 
grown in blood were able to induce platelet aggregation at mid-exponential (Figure 
3.2A) and stationary (Figure 3.2B) phases o f growth, whereas 4 strains grown in BHI 
were unable to do so (P=0.096), indicating expression o f bacterial surface 
components stimulating platelet aggregation by all strains grown in blood. Maximal 
percentage platelet aggregation could not be determined for strains grown in blood as 
residual erythrocytes were often present in washed cultures and would interfere with 
readings obtained using an optical aggregometer.
Considering that the protocol for processing S. aureus cultures differed depending on 
the growth media (see Section 2.9), it is feasible that additional washes employed for 
the isolation o f  S. aureus from blood cultures influenced the ability o f  strains to 
induce platelet aggregation. In order to rule out this possibility, a representative S. 
aureus strain (SAB002) was grown to stationary phase in BHI and subjected to 10 
min preincubation in blood, washes with EL buffer, calcium chloride solution or 
heparin, either alone or in combination, representing the different processing stages 
(see Section 2.9). None o f these processing steps influenced the ability o f  S. aureus 
to induce platelet aggregation (data not shown), suggesting that the observed 
variation in platelet aggregation following S. aureus growth in different media was 
due to differential expression o f bacterial surface components.
105
B
/£* ¿S' rtf' oS? ^' ^ ^ ^ 'P <$> ^\ op> «p <ÿ> op O? J?
cf- cf- c? cjr ef- ^ r
Endocarditis strains Nasal commensal strains
S. aureus strains grown to mid-exponential phase
Bacteraemia strains Positive 
control
d? A “ ¿S' «3? ¿S’ <& <& £  &  <pN ¡g' <& <S <§?\  \  T, O- «P op op <jP ¿Pc? & & <$■
Endocarditis strains Nasal commensal strains Bacteraemia strains Positive
control
S. aureus strains grown to stationary phase
Figure 3.2. Lag time to platelet aggregation induced by S. aureus clinical isolates 
grown to mid-exponential (A) and stationary phase (B) in heparinised whole human 
blood (blue) and BHI (grey). Strain Newman grown in BHI served as a positive control. 
Experiments were performed in triplicate using three different platelet donors. * Unable to 
isolate sufficient bacterial cells for aggregometry f  Absence of platelet aggregation at 25 min
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3.3.3 Investigation into the bacterial components mediating platelet 
aggregation following S. aureus growth in human blood
The ability o f some S. aureus strains to induce platelet aggregation after growth to 
stationary phase in blood but not BHI, indicates that bacterial components mediating 
platelet aggregation, such as MSCRAMMs, may be upregulated after bacterial 
growth in blood. In order to determine the role o f MSCRAMM s in platelet 
aggregation induced by S. aureus strains grown in blood, plasma protein-binding 
assays, qRT-PCR and platelet aggregometry with wild type and MSCRAMM 
deletion mutant strains were performed.
3.3.3.1 clfA expression is downregulated during S. aureus growth to 
stationary phase in human blood
As ClfA binds platelets via fibrinogen (see Section 1.4.3.3.2), fibrinogen-binding 
assays were performed to ascertain whether fibrinogen binding and hence ClfA 
expression was upregulated following S. aureus growth to stationary phase in blood. 
For strains grown to stationary phase in BHI, all clinical isolates, including those that 
did not induce platelet aggregation, bound immobilised fibrinogen (Figure 3.3). 
However, strains that did not induce platelet aggregation exhibited reduced binding 
to 12.5 pg/ml fibrinogen (P=0.008). A representative S. aureus strain (207) grown in 
human blood did not bind immobilised fibrinogen, independent o f EL, heparin and 
calcium washes (data not shown). The inability o f cultures grown in ex vivo media 
to bind immobilised plasma proteins has previously been observed following S. 
aureus growth in peritoneal dialysate, and attributed to bacterial coating with plasma 
proteins during growth (Massey et al., 2002). It is likely that the same phenomenon 
occurs during bacterial growth in human blood ex vivo.
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Endocarditis strains
S. aureus  strains grown to stationary phase in BHI
Nasal commensal 
strains
Bacteraemia strains Positive 
control
Figure 3.3. Binding of S. aureus clinical isolates grown to stationary phase in 
BHI to 12.5 pg/ml immobilised fibrinogen. Fibrinogen binding was determined as 
the absorbance at 590nm (A59o) for each bacterial agonist at a range of fibrinogen 
concentrations, but only data for 12.5 pg/ml fibrinogen were analysed. Strain 
Newman was used as a positive control. Experiments were performed in triplicate.
* Strains that did not induce platelet aggregation after growth to stationary phase in 
BHI.
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Considering that ClfA is implicated in platelet aggregation induced by S. aureus 
cultures grown to stationary phase in nutrient broth (see Section 1.3.5.2), and that 
some strains grown to stationary phase in BHI which did not stimulate platelet 
aggregation had reduced fibrinogen binding, it was hypothesised that ClfA surface 
expression might be upregulated during growth in blood, conferring the ability to 
stimulate platelet aggregation.
Initial attempts to quantify ClfA expression on the S. aureus cell surface using flow 
cytometry were unsuccessful due to technical reasons (data not shown). qRT-PCR 
was therefore used to determine levels o f clfA gene transcription during S. aureus 
growth to stationary phase in different media. Representative strains were selected, 
based on their ability to induce platelet aggregation after growth in both BHI and 
blood (strain 209) and blood only (strain SAB002) (Figure 3.4A). Standard curves 
for clfA and 16S rRNA demonstrated efficient primer binding, and dissociation 
curves revealed that negative controls did not contain amplified PCR products (data 
not shown). Transcript levels for 16S rRNA did not differ between cultures grown in 
blood and BHI (P=0.49 and P=0.42 for 209 and SAB002 respectively, data not 
shown), indicating that 16S rRNA is an appropriate constitutively expressed control 
for qRT-PCR.
Unexpectedly, clfA transcription levels relative to the normalising gene 16S rRNA 
were downregulated in blood as compared to BHI for both strains (Figure 3.4B). 
Further, there was no difference in lag time to platelet aggregation induced by the 
wild type S. aureus strain PI and a derivative strain containing deletions o f  the genes 
encoding ClfA, ClfB, SdrCDE and SpA (DU6011) grown to stationary phase in 
blood (P=D.252, Figure 3.5).
Collectively, these data suggest that ClfA is unlikely to account for the increased 
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S. a u re u s  s tra in s  g row n to  s ta tio n a ry  phase
Figure 3.4. clfA expression during S. aureus growth in human blood. Electrophoresis 
of bacterial RNA extracted from S. aureus strain Newman grown in BHI and strains 209 and 
SAB002 grown in human blood on a 2% (w/v) agarose gel (A). Normalised clfA transcript 
levels for S. aureus strains 209 and SAB002 grown to stationary phase in BHI (blue) and 
heparinised human blood (grey) (B). Values are depicted above each bar. Strain Newman 
grown to stationary phase in BHI was used as a positive control. Experiments were 
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S. aureus wild-type, gene mutation and complemented strains grown to 
stationary phase in blood/positive control
Figure 3.5. Lag time to platelet aggregation induced by S. aureus strains P1, 
8325-4 and 132 and derivative mutants grown to stationary phase in blood.
Lag times for wild type strains (dark blue), fnbA and fnbB deletion mutants of P1 and 
8325-4 (DU5998 and DU5883 respectively, grey), the single fnbA (red) and fnbB 
(yellow) complements of DU5998 and the clfA, clfB, sdrCDE and spa deletion 
mutant of P1 (green) grown to stationary phase in heparinised whole human blood 
are depicted. Aggregometry was also performed using strain 132 (dark blue), isdA 
(light blue) and isdB (brown) single gene mutants. Strain Newman grown to 
stationary phase in BHI (black) served as a positive control for all experiments. 
Experiments were performed in triplicate using three different platelet donors.
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3.3.3.2 Deficiency in IsdA and IsdB expression does not influence 
platelet aggregation induced by S. aureus strains grown to 
stationary phase in blood
Other selected bacterial surface components may influence platelet aggregation 
induced by S. aureus grown in blood. For example, Isd proteins bind to plasma 
proteins, are expressed after growth in human serum and contribute to disease in 
animal models o f infection (Clarke et al., 2004, Pishchany et al., 2009, Wiltshire & 
Foster, 2001). Accordingly, the role o f Isd proteins in platelet aggregation was 
examined using wild type, isdA- and /.vr/Zi-deficient mutant strains grown to 
stationary phase in blood.
S. aureus strain 132 and its isdA and isdB  single mutants grew in blood with no 
significant effect o f either mutation on bacterial growth (data not shown). There was 
no difference in lag time to platelet aggregation induced by the isdA and isdB 
mutants in comparison to the wild type strain (P=0.163 for the isdA mutant and 
P=0.308 for the isdB mutant, Figure 3.5). Additionally, mutations o f clfB, sdrCDE  
and spA genes in strain PI did not influence the ability o f S. aureus to induce platelet 
aggregation following growth in blood (P=0.252, Figure 3.5).
3.3.3.3 Deficiency in FnBPA and FnBPB expression increases lag time 
to platelet aggregation induced by S. aureus strains grown to 
stationary phase in blood
A previous study has demonstrated important roles for FnBPA and FnBPB in 
stimulation o f platelet aggregation following S. aureus growth in nutrient broth 
(Fitzgerald et al., 2006b). Here, the contribution o f the fibronectin-binding proteins 
to platelet aggregation induced by S. aureus grown in blood was examined. Lag time 
was significantly increased with the double fn b  mutant (DU5998) as compared to the 
wild type strain PI (P=0.002, Figure 3.5), suggesting that either FnBPA or FnBPB
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alone or in combination contribute to platelet aggregation induced by S. aureus 
grown to stationary phase in blood. The same trend was not observed with strain 
8325-4 and its double fn b  knockout (P=0.206, Figure 3.5).
To elucidate which o f the two FnBPs was responsible for platelet aggregation 
induced by S. aureus strain PI grown in blood, single fn b  A and fn b  B  complements o f 
strain DU5998 were used for platelet aggregometry. Complementation o f DU5998 
with fn b B  but not fnbA  reduced lag time, but this was not statistically significant as 
compared to DU5998 (P=0.368 and P=0.786 respectively, Figure 3.5). Furthermore, 
DU5998 complementation with plasmid encoding fnbB  did not restore lag time to 
levels observed for the wild type strain PI (Figure 3.5), suggesting that both FnBPA 
and FnBPB contribute to S. aureus-induced platelet aggregation following bacterial 
growth to stationary phase in blood. The capacity o f DU5998 to induce platelet 
aggregation despite deletion o f both fn b  genes, suggests that other bacterial surface 
components are involved in S. ¿mrew.v-induced platelet aggregation following growth 
in blood.
3.3.4 The ability of S. aureus to induce platelet aggregation in vitro 
does not predict development of infective endocarditis in vivo
Considerable variation has been observed in the ability o f clinical S. aureus strains to 
induce platelet aggregation in vitro, but it is not known how this correlates with 
disease association (Rindi et al., 2006). Given that S. aureus-induced platelet 
aggregation is thought to contribute to vegetation formation in infective endocarditis 
(see Section 1.4.3.3), the association o f the capacity o f S. aureus strains to induce 
platelet aggregation in vitro with the development o f infective endocarditis was 
examined. It was hypothesised that S. aureus infective endocarditis strains would 
have a greater propensity to induce platelet aggregation than either nasal commensal 
or bacteraemia strains.
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For S. aureus strains that grew in blood, there was no correlation between the source 
o f S. aureus isolation (infective endocarditis, nasal commensal or bacteraemia) and 
lag time to platelet aggregation at both stationary (P=0.948) and mid-exponential 
phases o f growth (P=0.265, Figure 3.2). Additionally, there was no correlation 
between S. aureus strain origin and lag time to platelet aggregation in vitro after 
growth to stationary (P=0.715) and exponential phase (P=0.235) in BHI (Figure 3.2). 
Similarly, there was no association between strain origin and maximal percentage 
platelet aggregation for strains grown to stationary (P=0.253) and mid-exponential 
phase (P=0.826) in BHI (Figure 3.6).
3.3.5 Thrombus formation during S. aureus growth in human blood ex 
vivo does not influence platelet aggregation
Ex vivo thrombus formation was observed during bacterial growth in blood, 
particularly at the mid-exponential phase o f  growth. In order to exclude the 
possibility that presence o f a blood clot affected lag time to aggregation (due to 
plasma protein sequestration within the thrombus), platelet aggregometry was 
performed using S. aureus strain 207 grown to stationary phase in blood, either in the 
presence or absence o f a thrombus in the flask. The presence o f a blood clot did not 
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Figure 3.6. Maximal percentage platelet aggregation induced by S. aureus 
clinical strains grown to mid-exponential (blue) and stationary phase (grey) in 
BHI. Strain Newman served as a positive control. Experiments were performed in 
triplicate using three different platelet donors.
* Absence of platelet aggregation at 25 min.
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Figure 3.7. Lag time to platelet aggregation induced by S. aureus strain 207 
grown to stationary phase in whole human blood, either in the presence or 
absence of a thrombus in the culture. Strain Newman grown to stationary phase 
in BHI (grey) served as a positive control. Experiments were performed with one 




S. aureus induces platelet aggregation after growth in nutrient broth (Fitzgerald el 
al., 2006a), but the capacity o f S. aureus strains grown in human blood to stimulate 
platelet aggregation has not been previously examined. Bacterial growth in human 
blood ex vivo represents the in vivo conditions more closely than nutrient broth, and 
is likely to have a profound influence on bacterial gene expression and phenotype 
(Novick, 2003), particularly as recent research has demonstrated variation in S. 
aureus gene transcription and translation following growth in nutrient-deplete media 
(Clarke et al., 2004, Schlievert et al., 2007, Torres et al., 2006, Wertheim et al., 
2008, Wiltshire & Foster, 2001). This is the first study to analyse the capacity o f S. 
aureus to induce platelet aggregation following growth in whole human blood and 
determine its correlation with strain clinical origin.
3.4.1 S. aureus growth in whole human blood
Differences were observed in the capacity o f  S. aureus strains to grow in human 
blood as compared to BHI. Notably, strains grew at a slower rate and to a lower 
yield in blood, with bacterial counts at the stationary phase o f growth similar to those 
observed by Schlievert et al, in their study examining the bacterial factors implicated 
in toxic shock syndrome (Schlievert et al., 2007). Growth o f  S. aureus is abrogated 
in other nutrient-deplete m edia such as Roswell Park Memorial Institute (RPMI) and 
chemically-defined metal limitation (CL) media and may be due to the low levels o f 
free nutrients, such as iron, in these growth media (Mazmanian et al., 2003, Torres et 
a l ,  2006).
There was strain-dependent variation in the ability o f S. aureus to grow in blood, 
which has not previously been examined. Specifically, S. aureus strains 3010, 
SAB003, SAB004 and Newman, the latter o f which has been widely used as a model 
strain in functional, genetic and in vitro studies (Grundmeier et al., 2004), did not 
grow in blood. This is consistent with work by Mazmanian el al, who reported that
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strain Newman failed to grow in media containing less than 300 nM free iron 
(Mazmanian et al., 2003). It is likely that the ability o f strain Newman to grow in 
blood has been attenuated through long-term serial passage in vitro.
It is feasible that genetic variation in factors facilitating iron acquisition influences 
the ability o f clinical S. aureus isolates to grow in blood. Haem iron contained 
within haemoglobin is the preferred iron source for S. aureus during growth in 
minimal media and is obtained via the Isd pathway (see Section 1.3.5.5) (Skaar et al.,
2004). S. aureus can also scavenge iron within siderophores via staphylococcal 
siderophore-transporters, staphylococcal iron-regulated uptake and fem e 
hydroxamate uptake systems (Skaar et al., 2004). It is possible that iron transporters 
such as the Isd pathway are important for growth in blood, although neither isdA nor 
isdB mutations affected the ability o f S. aureus to grow in blood in the current study. 
Furthermore, S. aureus Newman, which did not grow in blood, expresses functional 
IsdA, IsdB, IsdC and IsdH (Mazmanian et al., 2003, Mazmanian et al., 2002, Torres 
et al., 2006). This suggests that variation in genes encoding other factors that 
facilitate nutrient acquisition or evasion o f innate immune defence may modulate S. 
aureus survival in the human bloodstream, and contribute to the strain-dependent 
variation in growth observed in the current study.
3.4.2 Influence of growth medium on platelet aggregation induced by 
S. aureus
In the current study, all S. aureus strains grown in human blood were able to induce 
platelet aggregation, whereas 4 strains grown in BHI were unable to do so at the 
stationary phase o f growth. This difference in phenotype is most likely due to 
differential expression o f bacterial surface components such as MSCRAMMs 
following bacterial growth in blood.
The current study indicates that bacterial factors other than ClfA, ClfB, SdrCDE, 
IsdA, IsdB and SpA mediate platelet aggregation induced by S. aureus strains grown
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in human blood. Notably, platelet aggregation was attenuated in a strain containing 
double fnbA  and fn b B  gene deletions (DU5998), suggesting that both FnBPs induce 
platelet aggregation. This is consistent with current knowledge regarding the central 
role o f FnBPs in the pathogenesis o f infective endocarditis, as they facilitate S. 
aureus binding to valvular endothelium, while the A 4 16 domain o f FnBPA alone is 
capable o f initiating vegetation formation by a combination o f fibrinogen and 
fibronectin binding (see Section 1.3.5.1) (Heying et al., 2007, Piroth et al., 2008). A 
putative role o f the FnBPs in platelet aggregation during growth in blood may extend 
the predicted importance o f both FnBPA and FnBPB in the pathogenesis o f infective 
endocarditis.
S. aureus DU5998 retained the ability to induce platelet aggregation despite deletion 
o f both fn b  genes, suggesting that other bacterial factors contribute to S. aureus- 
induced platelet aggregation following growth in blood. Although proteins such as 
Efb or Pis inhibit fibrinogen binding and platelet aggregation, altered expression o f 
these factors is unlikely to account for the phenotypic effects observed in this work 
(Juuti et al., 2004, Shamion & Flock, 2004). Specifically, Efb is an anchorless 
protein which can reattach to the S. aureus cell wall after secretion, but is 
predominantly present in the culture supernatant and is unlikely to be present in high 
concentrations in the washed bacterial preparations used for aggregometry (Shannon 
& Flock, 2004). In addition, Pis is encoded on Type I SCCmec and is only expressed 
by MRSA strains, whereas the clinical S. aureus isolates used in this study were all 
MSSA (Juuti et al., 2004, Shannon & Flock, 2004). Furthermore, although S. aureus 
capsule inhibits ClfA-platelet interactions at the stationary phase o f growth, it is 
unlikely to account for the reduced aggregation induced by cultures grown in BHI, as 
all strains used in these assays retained the ability to bind fibrinogen (Figure 3.3) 
(Risley et al., 2007). It has also been demonstrated that the presence o f capsule does 
not influence S. aureus-induced platelet aggregation (Risley et al., 2007). It is likely 
that other surface components facilitate S. aureus-induced platelet aggregation after 
growth in blood, but the nature o f these factors remains to be identified.
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In the current study, there was evidence o f altered gene transcription following S. 
aureus growth in blood. Specifically, clfA gene transcription was downregulated 
during growth in blood, consistent with findings by a number o f  investigators who 
observed downregulation o f clfA transcription in animal models o f infection 
(Josefsson et al., 2008, Nanra et al., 2009, Wolz et al., 2002). Meanwhile, the ability 
o f FnBPs to induce platelet aggregation at the stationary phase o f growth, suggests 
that these M SCRAM M s are expressed during stationary phase in blood, although it 
is not known how transcription and expression levels compare with bacteria grown in 
nutrient broth (Peacock et al., 1999). Notably, Yarwood et al identified increased 
transcription o f fnbA  following S. aureus growth in human serum ex vivo in 
comparison to S. aureus grown in nutrient-replete conditions (Yarwood et al., 2001), 
and transcription o f fnbA  has recently been demonstrated to be independent o f sae in 
rabbit models o f infective endocarditis (Cheung et al., 2009).
Altered S. aureus gene transcription has also been observed in a number o f studies 
using bacteria grown in nutrient-deplete media (Pishchany et al., 2009, Torres et al., 
2006, Wertheim et al., 2008). Transcription o f genes encoding Isd proteins is 
upregulated after growth in minimal media (Pishchany et al., 2009, Torres et al., 
2006), while ClfB is present on the S. aureus cell surface late into stationary phase 
when strains are grown in minimal, but not nutrient-rich media (W ertheim et al.,
2008). However, deficiencies in IsdA, IsdB and ClfB did not alter platelet 
aggregation in the current work. Other studies have examined alteration in global S. 
aureus gene transcription during growth in serum in vitro, and have identified 
upregulation o f genes involved in amino acid and antimicrobial peptide synthesis, 
with downregulation o f  agr (Wiltshire & Foster, 2001, Yarwood et al., 2001).
Schlievert et al examined changes in transcription and translation following S. 
aureus growth in heparinised whole human blood (Schlievert et al., 2007). Growth 
o f a range o f S. aureus strains in human blood was associated with reduced 
production o f  TSST-1, a -  and 8-toxins, lipase and staphylococcal enterotoxin C 
(Schlievert et al., 2007). Alterations in gene transcription were mediated by the 
effects o f the a -  and (3-globin chains o f haemoglobin on transcriptional regulators
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SrrA-SrrB  and agr (see Section 1.3.6) (Schlievert et al., 2007). S. aureus 
interactions with host tissue also influence bacterial gene expression, as in the 
presence o f endothelial cells, S. aureus genes involved in amino acid and peptide 
transport, peptidase synthesis, biosynthesis and DNA repair are upregulated 
(Vriesema et al., 2000).
A number o f investigators have identified altered transcription o f selected S. aureus 
genes following bacterial growth in vivo. Goerke et al used qRT-PCR to analyse the 
transcription o f agr in S. aureus isolates obtained from the sputum o f patients with 
cystic fibrosis (Goerke et al., 2000). They identified low levels o f RNAIII expression 
within sputum, which unlike growth in nutrient broth, did not influence transcription 
o f genes encoding a-toxin  and SpA (Goerke et al., 2000). The genes encoding IsdA, 
IsdB, SdrD and SpA are expressed in vivo in animal models o f infection, but the role 
o f these M SCRAM M s in the pathogenesis o f infective endocarditis in humans is 
unknown (Cheng et al., 2009, Pishchany et al., 2009, Torres et al., 2006). In 
addition, crB, the transcriptional regulator o f ClfA, plays a lesser role in vivo than the 
regulator sae, which upregulates expression o f ECM -binding proteins Eap, Emp, 
FnBPA and a-toxin  (Cheung et al., 2009, Goerke el al., 2005, Harraghy et al., 2005, 
Xiong et al., 2006). It has already been demonstrated that FnBPA and a-toxin  
induce platelet aggregation, but it is not known whether Eap or Emp are able to do so 
(Bhakdi et al., 1988, Piroth et al., 2008). However, Emp has been implicated in 
biofilm formation under low iron conditions and may potentially contribute to 
vegetation formation (Johnson et al., 2008).
DNA microarrays can be used to elucidate genome-wide variation in S. aureus gene 
transcription following growth in human blood. For example, Group A and B 
streptococcal growth in blood was associated with increased expression o f factors 
facilitating survival in the host, including those enabling immune evasion, 
carbohydrate and amino acid metabolism, adhesins and transcriptional and stress- 
response regulators (Graham et al., 2005, Mereghetti et al., 2008). Transcriptomic 
analysis o f S. aureus grown in human blood has not been performed to date, but 
results from the current study demonstrate that this is imperative to elucidate the
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bacterial factors essential for pathogen survival in the human host. Furthermore, if  
genes encoding surface factors are upregulated following bacterial growth in blood, 
these may account for the observed variation in the ability o f S. aureus strains to 
induce platelet aggregation after growth in different media in vitro, and may 
ultimately predict the factors implicated in infective endocarditis pathogenesis in 
vivo.
3.4.3 Influence of strain clinical origin on platelet aggregation induced 
by S. aureus
Correlations have been identified between the capacity o f S. aureus and S. sanguinis 
to stimulate platelet aggregation in vitro and induce infective endocarditis in animal 
models (Flerzberg et al., 1992, Kessler et al., 1987, Sullam et al., 1996). For 
example, Kessler et al performed platelet aggregometry using a range o f organisms 
and found the lag time to be significantly reduced in strains causing infective 
endocarditis compared to bacteraemia (Kessler et al., 1987). However, it is unclear 
whether such an association is observed with strains isolated from human infection.
The relationship between strain disease association in humans and lag time or 
percentage aggregation was examined in the current study. There were no 
differences in platelet aggregation induced by S. aureus infective endocarditis, nasal 
commensal and bacteraemia strains, regardless o f growth phase or growth medium. 
These observations are consistent with our understanding o f the population genetics 
o f S. aureus, which indicate that there are no significant differences in pathogenic 
potential between commensal and clinical isolates. For example, Feil et al used 
MLST to demonstrate that S. aureus genotype did not correlate with ability to cause 
disease in vivo in a study examining 334 commensal and infection strains (Feil et al.,
2003). Similarly, Lindsay et al did not identify any variation in gene prevalence 
between 100 commensal and 61 invasive isolates using microarrays (Lindsay et al.,
2006). However, other investigators have reported that strains o f  clonal lineage 
CC30 were more prevalent in invasive disease than colonisation (W ertheim et al.,
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2005b). It is commonly thought that most S. aureus invasive diseases occur 
following infection by nasal commensal strains (van Belkum et a l ,  2009), which 
may account for the lack o f association between strain genotype, platelet aggregation 
and disease causation both in the current study and in previously published research 
(Feil et al., 2003, Lindsay et al., 2006).
Results from the current research also suggest that the ability o f isolates to induce 
platelet aggregation in vitro does not predict development o f infective endocarditis in 
patients with bacteraemia. These observations are consistent with findings by 
Fowler et al in their study analysing the contribution o f host and pathogen factors to 
adverse outcome in 324 cases o f S. aureus bacteraemia, where there was no 
correlation between M SCRAM M  gene prevalence and development o f 
haematogenous complications o f S. aureus bacteraemia (Fowler et al., 2005a). 
Conversely, the same investigators found that patients with haematogenous 
complications o f  S. aureus bacteraemia were more likely to be infected with S. 
aureus strains o f clonal lineages CC5 and CC30, than bacteraemic patients without 
disseminated infection (Fowler et al., 2007). However, it is not known whether strain 
clonal origin correlated with expression levels o f bacterial surface components in 
either o f  these studies (Fowler et al., 2005a, Fowler et al., 2007).
Collectively, these results suggest that the ability o f S. aureus to induce platelet 
aggregation in vitro does not correlate with development o f infective endocarditis in 
vivo, possibly due to M SCRAM M redundancy (see Section 1.3.5), indicating that 
other host and pathogen factors may influence susceptibility to infective 
endocarditis. For example, the ability o f S. aureus strains to induce infective 
endocarditis may depend on their ability to secrete toxins or evade immune defences, 
for example, by prevention o f platelet microbicidal protein (PMP) release (see 
Section 1.5.2). In support o f this theory, Ruotsalainen et al discovered that S. aureus 
strains associated with infective endocarditis had reduced haemolytic activity, which 
may result in reduced PMP release, enhanced bacterial survival and bacterium- 
platelet interactions, facilitating vegetation development in vivo (Ruotsalainen et al.,
2008). In keeping with this, the ability o f bacteria to resist PMP correlates with the
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development o f staphylococcal and streptococcal infective endocarditis in humans 
(Wu et al., 1994).
Host factors such as variation in innate immunity, platelet activation and platelet 
receptor polymorphisms may have a more profound influence on the outcome o f 
bacterium-platelet interactions than pathogen factors (Brouwer et al., 2009, Gawaz et 
al., 1995, Meisel et al., 2004). Alternatively, the lack o f a correlation between strain 
clinical origin and in vitro platelet aggregation in the current study may reflect the 
low shear conditions in the platelet aggregometer, which differ from the high shear 
environment found near the valve surface in vivo (Kerrigan et al., 2007). It is also 
feasible that some o f the infective endocarditis isolates used in the current study were 
not associated with vegetations, as is the case with 5% to 25% o f cases o f infective 
endocarditis (De Castro et al., 1997, Di Salvo et al., 2001), accounting for the lack o f 
a correlation with in vivo platelet aggregation. It is evident from these results that the 
clinical outcome o f infection depends upon the dynamic interaction between 
bacterial and host factors, rather than each in isolation.
3.4.4 Host-pathogen interactions contributing to platelet aggregation 
and thrombus formation
Thrombus formation was observed within the flasks used for bacterial culturing. The 
factors contributing to this blood clot are unknown, but may include MSCRAMMs 
facilitating bacterium-platelet binding, siaylated protein inducing bacterium- 
erythrocyte interactions, the effects o f coagulase, or downregulation o f the 
fibrinolytic effects o f staphylokinase and aureolysin (Beaufort et al., 2008, Bokarewa 
et al., 2006, Fitzgerald et al., 2006a, Shin et al., 2005). Notably, thrombi were less 
evident during the stationary phase o f growth, possibly due to the actions o f 
staphylokinase, which is expressed during the late-exponential phase o f growth and 
dissolves blood clots (Bokarewa et al., 2006).
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It would be intriguing to further characterise this possible ‘ex vivo vegetation’ in 
real-time, to further elucidate the host and pathogen factors contributing to its 
development. Further understanding o f bacterium-induced thrombus formation ex 
vivo may help identify relevant factors mediating vegetation formation in vivo. 
Although some insight into bacterium-platelet interactions has been gained from in 
vitro assays, it is known that bacteria in free suspension behave differently from 
those present in a biofdm which may exist in a vegetation (George et al., 2009). For 
example, S. aureus strains grown to mid-exponential phase in biofdms in vitro 
exhibit a greater ability to bind immobilised platelets at low shear rates than 
suspension-grown cells, while the converse is true at the stationary phase o f growth 
under high shear conditions (George et al., 2009). The ex vivo thrombus identified in 
the current study may represent a novel model for the analysis o f host-pathogen 
interactions in infective endocarditis, particularly as qRT-PCR has recently been 
used to determine inter-vegetation bacterial gene transcription in a rabbit model o f 
infective endocarditis (Cheung et al., 2009).
3.4.5 Conclusions
In summary, this study demonstrates that S. aureus growth in blood significantly 
alters bacterial gene expression and phenotype. All S. aureus strains grown in blood 
induced platelet aggregation and this process may involve FnBPA, FnBPB and other 
bacterial surface components at the stationary phase o f growth. The current data are 
more likely to be representative o f the in vivo situation than previous studies that 
used nutrient broth as a growth medium. Flowever, this research was limited by the 
low shear conditions present in the aggregometer. Future studies should incorporate 
the use o f high shear systems such as parallel-plate flow chambers and cone-and- 
plate rheometers to characterise the dynamic host-pathogen interactions contributing 
to vegetation formation in infective endocarditis (Mascari & Ross, 2003, Pawar et 
al., 2004). Such studies should also attempt to simulate in vivo conditions as far as 
possible, which include culturing bacteria in the presence o f ex vivo materials such as 
human blood.
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The nature o f the bacterial factors implicated in platelet aggregation induced by S. 
aureus strains grown in blood has not been fully characterised, but may be identified 
by further experiments with deletion mutant strains, in parallel to the use o f 
expression microarray analysis. For example, creation o f strains deficient in the 
expression o f FnBPA, FnBPB and other bacterial surface components, in the 
background o f the 4 S. aureus strains that were able to induce platelet aggregation 
after growth in blood but not BHI, would indicate their role in the stimulation o f 
platelet aggregation by those strains following growth in blood.
It is clear that global transcriptomic and proteomic studies o f  organisms that are 
common causes o f infective endocarditis, such as staphylococci, streptococci and 
enterococci (M oreillon & Que, 2004) grown in human blood, within a thrombus or in 
the presence o f  host tissue such as valvular endothelium, are now necessary to 
determine the factors implicated in bacteraemia and infective endocarditis. Such 
studies may result in the identification o f novel targets for vaccine or antimicrobial 
development in the fight against invasive bacterial infection.
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Platelet activation is increased in prothrombotic conditions such as unstable angina 
and myocardial infarction (MI) (Sarma et al., 2002). Considering the importance o f 
vegetations in the pathogenesis o f infective endocarditis, and the contribution o f 
bacterium-induced platelet activation and aggregation to this process (Di Salvo et ah, 
2001, Fitzgerald et ah, 2006a, Herzberg et ah, 1992, Sullam et ah, 1996), it was 
hypothesised that in vivo platelet activation would be raised in patients with infective 
endocarditis. Platelet activation was determined using well-characterised flow 
cytometric markers, and levels compared to those obtained from age- and sex- 
matched healthy volunteers and patients with bacteraemia, to take into account the 
effects o f age, gender, sepsis and antibiotic treatment on platelet function (Faraday et 
al., 1997, Gawaz et al., 1995, Russwurm et al., 2002, Shattil et al., 1980).
4.2 Methods
Forty-four patients with infective endocarditis (73% male, 56±17 years), 4 patients 
with S. aureus bacteraemia (75% male, 46±28 years) and 30 age- and sex-matched 
healthy volunteers (70% male, 54±17 years) were recruited into the study between 
November 2006 and April 2009 using the inclusion and exclusion criteria outlined in 
Section 2.1. Clinical data were collected prospectively for patients with infective 
endocarditis and outcomes defined as described in Section 2.2. Transthoracic and/or 
transoesophageal echocardiography were performed on patients with infective 
endocarditis and bacteraemia, and analysed as outlined in Section 2.3.
Venepuncture was performed on all recruited subjects as described in Section 2.4, 
with 3 ml o f blood drawn into a tube containing the anticoagulant PPACK for 
determination o f whole blood platelet-monocyte aggregates (PMA) and platelet P- 
selectin expression as outlined in Section 2.10.2.
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4.3 Results
Baseline characteristics o f recruited patients with infective endocarditis are outlined 
in Table 4.1. The majority o f patients had community-acquired infection o f  native 
valves and at least one risk factor for the development o f infective endocarditis. 
Notably, 20% had underlying congenital heart disease, 16% had a previous episode 
o f infective endocarditis and 11% were intravenous drug abusers. O f the patients 
with infective endocarditis, 36% were immunocompromised due to underlying 
disease, drug therapy or alcohol abuse. Additionally, 30% o f patients had an 
identified source o f infection, with most cases associated with arterial or venous line 
placement or recent invasive dental work. A past medical history o f arterial or 
venous thromboembolism unrelated to infective endocarditis, defined as a 
documented history o f MI, unstable angina, ischaemic cerebrovascular disease, 
peripheral vascular disease, deep venous thrombosis or pulmonary embolism, was 
evident in 48% o f patients.
O f the infective endocarditis study population, 23 subjects (52%) were transferred to 
the Edinburgh Royal Infirmary (ERI) from district general hospitals for consideration 
o f surgery. There was an approximate 3- to 4-week delay between symptom onset 
and patient presentation, but clinical diagnosis and institution o f antibiotic therapy 
occurred within 2 d o f presentation (Table 4.1). One subject was recruited prior to 
antibiotic therapy, the remainder being recruited approximately 2 weeks after the 
introduction o f antimicrobial therapy. Peripheral blood samples were obtained with a 
19-gauge needle in most patients.
4.3.1 Characteristics of the study population
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Table 4.1. Baseline characteristics of 44 patients with infective 
endocarditis at the time of recruitment






Risk factors for infective endocarditis
35 (80%)
Prosthetic valve 15 (34%)
Bioprosthetic 8
Mechanical 7
Early prosthetic valve infective endocarditis 2 (5%)
Valvular heart disease * 16(36% )
Congenital heart disease 9
Bicuspid aortic valve 4
Rheumatic heart disease 2
Degenerative valve 2
Previous episode o f infective endocarditis 7(16% )
Intravenous drug abuser 5 (11%)
Immunocompromised * 16(36% )
Alcoholism 9
Disease 7
Immunosuppressive drug therapy 4






Demographic and risk factors of the infective 
endocarditis study population
Number (%)
Recent vascular instrumentation 6(14% )
Past medical history
Dialysis dependent end stage renal failure 2 (5%)
Past history o f thromboses 21 (48%)
Arterial 16
Venous 3
Arterial + venous 2
Time from symptom onset to presentation, d 23 ± 3 8
Time from symptom onset to diagnosis, d 25 ± 4 0
Recruitment
Blood sampling via peripheral venepuncture 35 (80%)
Time from diagnosis to recruitment, d 12± 14
Days o f antibiotics prior to recruitment, d 14±14
* Sub-categories are not mutually exclusive and patients may have had more than 
one cause o f  valvular heart disease or reason for being immunocompromised.
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Table 4.2 contains patient data from routine haematology and biochemistry blood 
tests at the time o f recruitment and electrocardiograph (ECG) results during the 
course o f their in-patient stay. Most patients were anaemic with some degree o f 
intravascular fluid depletion as evidenced by raised haematocrit levels. There was 
marked variation in platelet count, CRP, urea and creatinine levels. The mean white 
cell count, electrolyte levels, body temperature, mean arterial pressure and heart rate 
were within normal limits. First, second or third degree atrioventricular heart block 
was present in 41% o f patients, while 27% o f subjects developed atrial fibrillation 
during the course o f their illness.
Results o f  blood and histopathological cultures are outlined in Table 4.3. Valvular 
tissue from 18 patients was sent for histopathology, o f which 8 had positive results. 
Unlike several recent studies, Streptococcus was the most frequently isolated 
organism, and included viridans streptococci (S. mitis, S. oralis, S. sanguinis, S. 
gordonii and Streptococcus salivarius), as well as species Streptococcus bovis and 
Streptococcus agalactiae. O f the 4 identified S. bovis infective endocarditis cases in 
the current study, 2 were associated with benign colonic polyps, while none were 
associated with colorectal cancer (Bashore et al., 2006). Staphylococcal species that 
were isolated include S. aureus, Staphylococcus hominis, Staphylococcus capitis, 
Staphylococcus epidermidis and Staphylococcus lugdunensis. Enterococcus spp. 
were isolated from 4 patients, while Aerococcus urinae, Aerococcus viridans, 
Enterobacter cloacae, Gemella sanguinis, Granulicalella adiacens, Haemophilus 
parainfluenzae, Propionibacterium acnes, S. marcescens and Stenotrophomonas 
maltophilia were isolated from blood or valve cultures from a single patient each. 
Four patients had polymicrobial infection, predominantly involving culture positivity 
for different species o f staphylococci and streptococci. Blood cultures were negative 
in 7% o f subjects.
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Table 4.2. Results of blood tests (haematology and biochemistry) and 
electrocardiographs (ECGs) in 44 recruited patients with infective 
endocarditis.
Investigation results for the infective 
endocarditis study population
Number (%) Reference range *
Baseline blood results at time o f  admission 
to or diagnosis at ERI 
Haemoglobin, g/1 99 ±  14 1 3 0 - 1 8 0  (M)
Haematocrit, % 30.5 ± 4 .0
1 1 5 - 1 6 5  (F) 
40 -  54 (M)
W hite cell count, x 109/l 10.0 ± 5 .0
3 7 - 4 7  (F) 
4 . 0 - 1 1 . 0
Platelet count, x 109/l 311 ± 127 1 5 0 -  350
CRP, mg/1 80 ± 6 8 < 5
Venous H C O 3, mmol/1 25 ± 8 2 2 - 3 0
Sodium, mmol/1 136.8 ± 3 .0 1 3 5 - 1 4 5
Potassium, mmol/1 4.3 ± 0 .6 3 . 6 - 5 . 0
Creatinine, umol/I 117 ± 129 6 0 - 1 2 0
Urea, mmol/l 5.5 ± 3 .5 2 . 5 - 6.6
Temperature, °C 36.9 ± 0 .4 N /A
Mean arterial pressure, m m H g 84 ± 9 N /A
Heart rate, beats per minute 88 ±  12 N/A
Positive ECG findings N/A
Atrioventricular block 18 (41%)
Atrial fibrillation 11 (27%)
Paced rhythm 2 (5%)
Values represent the mean ± standard deviation. The mean temperature, arterial 
pressure and heart rate were determined once weekly during the patient’s 
admission up to a maximum 6-week period. * Reference ranges for blood tests 
performed at the Edinburgh Royal Infirmary (ERI) clinical laboratories were taken 
from the Lothian University Hospitals Division Department of Laboratory Medicine 
Guidelines for Users of Biochemistry and Haematology (ERI), 2009 edition, v 4.2. M, 
male; F, female; CRP, C-reactive protein. N/A, not applicable.
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Table 4.3. Microbiological and immunological results in 44 patients 
with infective endocarditis.
M ic ro b io lo g ic a l and  im m u n o lo g ic a l f in d in g s N u m b e r o f  sub je c ts  (% )
Histopathological criteria (n=18) * 
O rg a n i s m s f
8 (44% )














Enterococcus faecalis/faecium 4 (9% )
O thers ' 9 (20% )
Polym icrobial * 4 (9% )
Culture  negative 3 (7% )
Im m unological p he n o m en a  ^ 18 (41% )
* Histopathological data was available for 18 patients. T Sub-groups for causative 
organism are not mutually exclusive. Other isolated organisms include Aerococcus 
urinae, Aerococcus viridans, Enterobacter cloacae, Gemella sanguinis, 
Granulicatella adiacens, Haemophilus parainfluenzae, Propionibacterium acnes, 
Serratia marcescens, Stenotrophomonas maltophilia, (n=1 for each). 1 Polymicrobial 
infections were caused by S. capitis + S. epidermidis, S. oralis + S. hominis, S. 
lugdunensis + S. mitis, S. aureus + E. faecalis. Immunological phenomena 
identified include rashes, splinter haemorrhages, arthropathy and Janeway’s 
lesions.
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Transthoracic or transoesophageal echocardiograms for diagnosis o f infective 
endocarditis were performed at an average o f 3±3 d after patient presentation and 
results outlined in Table 4.4. Sixteen patients had transthoracic echocardiograms 
alone, 5 had transoesophageal echocardiograms and 18 subjects had both. The mitral 
valve was most commonly affected (41%), followed by the aortic valve, either alone 
(30%) or in combination with the mitral valve (16%), and the tricuspid or pulmonary 
valves were involved in 13% o f cases o f infective endocarditis. Vegetations were 
identified in 77% o f patients, fistulae in 14% and abscesses in one quarter o f cases. 
Approximately one-third o f patients with vegetations had multiple vegetations. Valve 
destruction due to dehiscence or perforation occurred in 17 subjects, while new 
valvular regurgitation occurred in 86% o f cases.
Transthoracic and transoesophageal echocardiograms used for measurement o f 
vegetation length, width and mobility in the current study were performed at a mean 
o f 7±8 d after diagnosis and were available for 32 o f the 34 patients with vegetations 
(94%). Nine subjects had transthoracic echocardiograms alone, 6 had 
transoesophageal echocardiograms and 14 patients had both imaging modalities 
performed. Mean vegetation length and width were 15 ± 7 mm and 9 ± 4 mm 
respectively, and over 80% o f vegetations were mobile.
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Table 4.4. Echocardiogram results in 44 patients with infective
endocarditis.





Aortic + mitral 7(16% )




Vegetation length (n=32) * 15 ± 7 mm
Vegetation width (n=32) * 9 ± 4 mm











Valve destruction 17(39% )
* Characteristics of the largest vegetation were determined on transoesophageal 
and/or transthoracic echocardiograms in 32 of the 34 patients with infective 
endocarditis.
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Treatment modalities in the infective endocarditis cohort are outlined in Table 4.5. 
All patients were treated with appropriate antibiotics according to culture 
sensitivities, mainly comprising o f benzylpenicillin in combination with gentamicin. 
Surgical treatment in the form o f valve replacement or repair was performed in 59% 
o f subjects, main indications being the presence o f heart failure, emboli, abscesses or 
fistulae and poor response to medical therapy. A large number o f patients were 
treated with anti-platelets or anticoagulants, but there was no consistency in their use 
in the management o f infective endocarditis.
As outlined in Table 4.6, 41% o f patients developed acute renal failure during the 
course o f  their infection, while approximately one-third o f patients developed heart 
failure or multi-organ failure alone. Septic emboli that were identified on non- 
invasive radiological examinations performed at the clinician’s discretion, 
complicated infective endocarditis in 41% o f patients, with most cases affecting the 
cerebral vasculature. Relapses or recurrences occurred in 11% o f cases during the 3- 
month follow-up period, while the mortality rate attributed to infective endocarditis 
over the same time period was 23%.
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Table 4.5. Treatment modalities in the 44 patients with infective
endocarditis.
Treatment Number o f subjects (%)
Antibiotics * +
Penicillins 31 (70% )
A m inoglycosides 26 (59% )
V ancom ycin 11 (25% )
Rifampicin 10 (2 3 % )
Cephalosporins 2 (5% )
Others 4 (9% )
Surgery 26 (59% )
Replacem ent 20
Repair 5
Replacem ent +  repair 1
Anti-platelets * 17 (39%)
Aspirin 15
Clopidogrel 1
N SA ID 1
Anticoagulants * ' 26 (59% )
Low -m olecular-w eight heparin 11
Unfractionated heparin 9
Warfarin 9
* Antibiotic, anticoagulant or anti-platelet therapy was documented for the time of 
recruitment. 1 Treatment with different sub-groups of antibiotics and anticoagulants 
was not mutually exclusive. Other antim icrobials used in the treatment of infective 
endocarditis included meropenem in 2 patients, ciprofloxacin in 1 patient and 
daptomycin in 1 patient. NSAID, non-steroidal anti-inflammatory drug
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Table 4.6. Complications in 44 recruited patients with infective
endocarditis.
Complications o f infective endocarditis Number of subjects (%)
Heart failure 13 (30%)
Acute renal failure 18 (41%)
Multi-organ failure 13 (30%)






Relapse or recurrence 5 (11%)
Death 14 (23%)
* The presence of embolic complications was determined from patients’ clinical 
notes. Two patients had more than one site of septic embolism.
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Platelet activation was determined by measurement o f percentage whole blood PMA 
and platelet P-selectin expression in 44 (100%) and 41 (93%) o f the infective 
endocarditis cohort, respectively. Patients with infective endocarditis had PMA 
levels o f 26.8 ± 16.0 % and platelet P-selectin expression levels o f 3.7 ± 3.3 %. 
PMA did not vary between patients with infective endocarditis, bacteraemia or age- 
and sex-matched healthy volunteers (P=0.576, Figure 4.1 A), and there was no 
difference in platelet activation between patients with infective endocarditis or 
bacteraemia caused by S. aureus alone (P=0.385 for PMA and P=0.877 for platelet 
P-selectin expression, data not shown). However, platelet P-selectin expression was 
reduced in patients with infective endocarditis in comparison to healthy volunteers 
(P=0.003, Figure 4 .IB).














Infective endocarditis Healthy volunteers 
Study population
S. aureus bacteraemia
Figure 4.1. Comparison of percentage platelet-monocyte aggregate formation (A) and 
platelet P-selectin expression (B) between patients with infective endocarditis (n=44), 
healthy volunteers (n=30) and patients with S. aureus bacteraemia (n=4).
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4.3.2.1 Platelet activation is increased in intravenous drug abusers 
and patients with staphylococcal and culture-negative infective 
endocarditis
To determine possible reasons for reduced platelet activation in the infective 
endocarditis cohort, the association between platelet activation and clinical 
characteristics was examined (Tables 4.7 and 4.8). Intravenous drug abuse and a past 
history o f venous thromboses were both associated with increased platelet P-selectin 
expression (PO.OOl and P=0.012 respectively, Table 4.8). Additionally, there was a 
trend towards increased platelet activation in patients with positive blood cultures for 
staphylococci or those with negative blood cultures (P=0.053 for PMA, Figure 4.2A 
and P=0.057 for platelet P-selectin expression, Figure 4.2B). Antibiotic treatment 
also influenced platelet P-selectin expression, which was lower for patients receiving 
aminoglycosides (P=0.009, Figure 4.3).
Importantly, anti-platelet therapy did not influence platelet activation (Tables 4.7 and 
4.8). There were no correlations between gender, age, nature o f the underlying 
valve, presence o f  valvular heart disease, route o f venepuncture, CRP, anticoagulant 
therapy and platelet activation (Tables 4.7 and 4.8, data for linear variables not 
shown). Duration o f antibiotic treatment correlated with PMA but not platelet P- 
selectin expression, however, this relationship was not linear and instead appeared as 
a scattergram (P=0.049, R2=0.089, Figure 4.4).
143
Table 4.7. Correlation between percentage platelet-monocyte 
aggregates (PMA) and clinical characteristics in 44 patients with 
infective endocarditis.
Clinical variable Yes No P value
Male gender 26.9 ± 15.4 26.9 ± 19.1 0.966
Prosthetic valve 29.6 ±20.3 25.6 ± 14.0 0.659
Bioprosthetic 28.5 ± 16.3 30.7 ± 2 5 .0 0.906
Valvular heart disease 26.0 ± 19.8 27.5 ± 14.3 0.479
Intravenous drug abuse 33.8 ± 9 .9 26.2 ± 16.8 0.232
Past history o f thromboses ' 28.3 ± 12.3 25.6 ± 19.6 0.472
Arterial 25.2 ± 10.2 27.2 ± 18.8 0.772
Peripheral venepuncture 28.8 ± 17.2 20.3 ± 11.2 0.113
Anti-platelets 24.9 ± 14.4 28.2 ± 17.6 0.449
Anticoagulants 28.0 ± 17.1 25.3 ± 15.4 0.719
Yes indicates that the clinical characteristic was present in the patient sub-group; no 
indicates that the clinical characteristic was absent.
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Table 4.8. Correlation between percentage platelet P-selectin 
expression and clinical characteristics in 44 patients with infective 
endocarditis.
Clinical variable Yes No P value
Male gender 4.2 ± 3 .4 3.3 ± 3 .0 0.435
Prosthetic valve 3.8 ± 3 .2 4.0 ± 3 .4 0.762
Bioprosthetic 3.1 ± 2 .8 4.4 ± 3 .6 0.752
Valvular heart disease 3.5 ± 2 .8 4.2 ± 3 .5 0.524
Intravenous drug abuse 9.9 ± 3 .3 3.3 ± 2 .5 <0.001
Past history o f  thromboses 4.3 ± 3.9 3.6 ± 2 .6 0.950
Arterial 2.9 ± 2 .9 8.5 ± 2 .8
0.012
Peripheral venepuncture 4.1 ± 3 .3 3.4 ± 3 .3 0.478
Anti-platelets 3.1 ± 2 .4 4.5 ± 3 .7 0.227
Anticoagulants 3.7 ± 2 .8 4.3 ± 3 .9 0.826
Yes indicates that the clinical characteristic was present in the patient sub-group; no 













Viridans S. aureus CNS Enterococcus Others Culture negative
streptococci
Causative organism
Figure 4.2. Effects of causative organism, treated as a group, on percentage 
platelet-monocyte aggregates, P=0.053 (A) and percentage platelet P-selectin 
expression, P=0.057 (B) in 44 patients with infective endocarditis. Post-hoc 
analysis could not be performed due to the limited study population size. CNS, 
coagulase-negative staphylococci; other organisms, Aerococcus urinae, Aerococcus 
viridans, Enterobacter cloacae, Gemella sanguinis, Granulicatella adiacens, Haemophilus 







Pencillins Aminoglycosides Vancomycin Rifampicin Cephalosporins Other
Antibiotics
Figure 4.3. Effect of antibiotic treatment on percentage platelet P-selectin 
expression in patients with infective endocarditis, P=0.009 when treated as a 
group. Post-hoc analysis could not be performed due to the limited study 
population size. Other antibiotics include meropenem, ciprofloxacin, daptomycin.
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Figure 4.4. Scattergram of duration of antibiotic treatment prior to subject 
recruitment and platelet-monocyte aggregates in 44 patients with infective 
endocarditis. P=0.049, R2=0.089.
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4.3.3 Increased platelet activation is associated with need for valve 
replacement in infective endocarditis
The association o f  platelet activation with outcome in infective endocarditis was 
determined in the current study population (Table 4.9). Increased PMA was 
associated with adverse outcome as determined by the development o f heart failure 
(P=0.081, Table 4.9) and need for valve replacement in infective endocarditis 
(P=0.003, Table 4.9). However, patients were variably recruited pre- and post- 
operatively and no assumptions could be made as to whether this was a predictive 
relationship.
There were no correlations between PMA or platelet P-selectin expression and 
development o f  vegetations, vegetation size or mobility, embolic events, renal 
failure, multi-organ failure or death when analysed individually (P>0.05 for all, 
Table 4.9). Analysis may have been limited by the modest study population and 
adverse outcome was therefore defined as the composite clinical end-point o f 
embolism, heart failure, need for surgery and mortality. However, platelet activation 
did not correlate with development o f the composite clinical end-point in patients 
with infective endocarditis (P=0.335 for PMA and P=0.899 for platelet P-selectin 
expression, Table 4.9).
Variables that significantly correlated with platelet activation on univariate analysis 
were further analysed by multivariate analysis. Presence o f  negative blood cultures 
and need for valve replacement remained significant for PMA, while coagulase- 
negative staphylococcal infection, intravenous drug abuse and treatment with 
aminoglycosides were correlated with platelet P-selectin expression on regression 
analysis (Table 4.10).
149
Table 4.9. Correlation between percentage platelet-monocyte  
aggregates (PMA), platelet P-selectin expression and clinical outcome  
in 44 patients with infective endocarditis.
Clinical outcome Yes No P value
PMA
Echocardiography
Vegetation observed 26.3 ± 20.0 29.1 ± 11 .5 0.382
M ultiple vegetations 24.9 ± 15.7 27.4 ± 16.9 0.726
Valve destruction 27.0 ± 15.2 26.9 ± 17.3 0.883
Surgery 26.5 ±  15.6 27.6 ± 17.8 0.733
Replacement 30.5 ± 15.0 11.1 ± 4 .8 0.003
Complications
Heart failure 33.6 ± 2 0 .4 24.2 ± 13.8 0.081
Acute renal failure 29.3 ±  20.3 25.4 ± 13.4 0.777
M ulti-organ failure 25.5 ± 12.6 27.6 ± 17.9 0.885
Embolism 22.5 ±  10.8 30.0 ± 18.9 0.171
Relapse or recurrence 21.9 ± 5 .6 27.6 ± 17.2 0.702
Death 23.1 ± 11.2 28.2 ± 17.6 0.475
Composite clinical end­
point 1
25.7 ± 14.3 30.4 ± 19.3 0.335
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Clinical outcome Yes No P value
P-selectin expression 
Echocardiography
Vegetation observed 3.9 ± 3 .4 3.9 ± 2 .9 0.847
Multiple vegetations 2.8 ± 2 .3 4.3 ± 3 .5 0.477
Valve destruction 4.5 ± 3 .0 3.5 ± 3 .4 0.237
Surgery 3.7 ± 2 .6 4.3 ±4.1 0.978
Replacement 4.2 ± 2 .7 1.7 ± 1.0 0.428
Complications
Heart failure 4.9 ± 3 .2 3.5 ± 3 .3 0.193
Acute renal failure 3.2 ± 2 .4 4.4 ± 3 .7 0.390
Multi-organ failure 3.0 ± 2 .3 4.3 ± 3 .6 0.328
Embolism 3.4 ± 3 .2 4.3 ± 3 .3 0.289
Relapse or recurrence 4.5 ±  1.6 3.8 ± 3 .4 0.411
Death 3.4 ± 2 .9 4.1 ± 3 .4 0.606
Composite clinical end- 3.8 ± 2 .5 4.3 ± 4 .7 0.899
p o in t1
Yes indicates that the clinical characteristic was present in the patient sub-group; no 
indicates that the clinical characteristic was absent. * Vegetation dimension and 
mobility data were available for 32 of the 34 patients with infective endocarditis f 
Composite clinical end-point, embolism, heart failure, need for surgery or mortality
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Table 4.10. Multivariate analysis of the clinical features predictive of 
platelet-monocyte aggregate formation and platelet P-selectin 
expression in 44 patients with infective endocarditis.
Clinical variable P value R*
Platelet-monocyte aggregates
Valve replacement 0.008 0.265
Culture-negative 0.018 0.138
Coagulase-negative staphylococci 0.218 0.040
Platelet P-selectin expression
Aminoglycoside treatment 0.003 0.308
Coagulase-negative staphylococci 0.037 0.128
Intravenous drug abuse 0.084 0.090
S. aureus 0.259 0.040
Venous thromboses 0.523 0.040
P was taken as <0.10.
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4.4 Discussion
Activated platelets have been identified within the luminal layer o f vegetations and 
are thought to arise following bacterium-induced activation (Fitzgerald et al., 2006a, 
Rouzet et ah, 2008). However, platelets also contribute to immune defence 
(Yeaman, 1997), and it is not known whether platelets play a predominant role in 
thrombus formation or host immunity in infective endocarditis. This is the first study 
to use flow cytometry to determine platelet activation in patients with native and 
prosthetic valve infective endocarditis.
4.4.1 Study population
The age and gender demographics o f recruited patients with infective endocarditis 
were similar to those observed in studies from different geographical regions (Heiro 
et al., 2008, Murdoch et al., 2009). There was large variation in time to patient 
presentation, consistent with known acute and sub-acute presentations o f infective 
endocarditis (Bouza et al., 2001). Prevalence o f  community-acquired disease, native 
valve involvement, history o f previous infective endocarditis and intravenous drug 
abuse were similar to published studies (Bouza et al., 2001, Heiro et al., 2008, 
M urdoch et al., 2009). However, rates o f underlying congenital heart disease were 
almost twice those observed by other investigators, possibly due to regional variation 
(Alestig et al., 2000, Fowler et al., 2005b). In some cases, there was a time delay 
from diagnosis or initiation o f treatment to patient recruitment, largely due to the 
majority o f  patients being transferred from other hospitals for consideration o f 
surgery. Approximately half o f patients had a past history o f arterial or venous 
thrombotic disease, which may place them at increased risk o f infective endocarditis.
There has been recent controversy regarding the role o f dental procedures as risk 
factors for infective endocarditis, resulting in changes in both national and 
international guidelines (Habib et al., 2009, National Institute for Health and Clinical 
Excellence, 2008). In the current study, dental risk factors were identified in less than
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7% o f patients, similar to the levels observed by Fowler et al (Fowler et al., 2005b). 
However, it is unclear whether a history o f recent dental work in patients with 
infective endocarditis is a causal relationship, or purely an association (National 
Institute for Health and Clinical Excellence, 2008).
In the current study, most cases o f infective endocarditis were due to streptococci, 
conflicting with observations from recent large-scale studies (Cabell et al., 2002, 
Heiro et al., 2008, Moreillon & Que, 2004, Murdoch et al., 2009). These discrepant 
findings may be due to the modest infective endocarditis cohort, the increased 
prevalence o f S. aureus infective endocarditis in the USA, or due to the increased 
rates o f  congenital heart disease identified in this research. O f the 16 staphylococcal 
infective endocarditis cases, 6 were caused by coagulase-negative staphylococci, 
consistent with the recent increase in incidence o f both native- and prosthetic-valve 
coagulase-negative staphylococcal infective endocarditis, which has been attributed 
to a rise in invasive procedures (Chu et al., 2009, Chu et al., 2008). In contrast to 
other published research, all o f the S. aureus strains causing infective endocarditis in 
the current study were MSSA, which may be due to the small infective endocarditis 
study population and regional variation (Bouza et al., 2001, Cabell et al., 2002, 
Fowler et al., 2005b).
Cases affecting the mitral valve just outnumbered those affecting the aortic valve, 
similar to observations by Murdoch et al in their multicentre study on 2,781 patients 
with infective endocarditis (Murdoch et al., 2009). Vegetations were present in 
three-quarters o f  cases, lower than frequencies observed in other studies, although 
abscesses or fistulae were present in a large number o f  patients in the current cohort 
(Murdoch et al., 2009, Nadji et al., 2005). There was evidence o f cardiac conduction 
defects in approximately two-thirds o f patients, higher than levels observed by other 
investigators (Bouza et al., 2001, Murdoch et al., 2009).
Approximately 60% o f subjects required surgery for infective endocarditis, higher 
than rates observed in other series (Bouza et al., 2001, Murdoch et al., 2009). 
Flowever, there was a referral bias as the ERI is a tertiary referral centre with a
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cardiac surgery unit serving a large catchment area. Incidence o f heart failure, acute 
renal failure and emboli were comparable to other studies, and mortality was within 
the range reported by other authors (Chu et ah, 2004, Fowler et ah, 2005b, Nadji et 
ah, 2005).
4.4.2 Platelet activation in infective endocarditis
Platelet activation, measured as PMA and platelet P-selectin expression, was 
determined in 44 patients with infective endocarditis, 4 patients with bacteraemia and 
30 age- and sex-matched healthy controls. Percentage PMA did not vary between 
patients with infective endocarditis and recruited controls, consistent with 
observations from a study o f 76 patients with native valve infective endocarditis, 
where there were no associations between platelet activation, measured by (3- 
thromboglobulin and platelet factor-4, and a diagnosis o f infective endocarditis (Ileri 
et al., 2003).
PMA is generally considered to be a more reliable marker o f platelet activation than 
platelet surface receptor expression, presumably because platelets rapidly utilise 
surface-expressed factors such as P-selectin and GPIIb/IIIa in leucocyte-binding, 
reducing the number o f sites available for antibody binding in flow cytometry 
(Michelson et al., 2001, Spangenberg et al., 1993). However, monocytes play a 
critical role in infective endocarditis and may influence the reliability o f PMA as a 
marker o f  platelet activation. Specifically, monocytes are activated by 
staphylococci, phagocytose bacteria, release tissue factor, destroy valvular tissue and 
contribute to vegetation fonnation and propagation, all o f  which could modulate 
baseline PMA in infective endocarditis, regardless o f platelet function 
(Chorianopoulos et al., 2009, Durack, 1975, Veltrop et al., 2000). Furthermore, 
there are large numbers o f circulating monocytes in sepsis, which may result in lower 
percentages o f  platelet-bound monocytes than expected (Ogura et al., 2001).
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Although it has been reported that the formation o f PMAs is dependent upon platelet 
and not leucocyte activation, it is not known how the presence o f  activated 
monocytes influences PMA formation (Ogura et al., 2001, Russwurm et al., 2002). 
In addition, agonist-stimulated platelets are themselves able to induce monocyte 
activation upon binding, but it is unclear whether this influences the course o f sepsis 
(Bournazos et al., 2008). Taking these factors into account, it may be that PMA is a 
less sensitive marker o f platelet activation in infective endocarditis than other 
measures. A range o f other platelet activation markers have been described, 
including CD40L, platelet factor-4 activated GPIIb/IIIa and platelet P-selectin 
expression (Harding et al., 2004, Ileri et al., 2003, Michelson, 1996, M ichelson et 
al., 2001). In the current study, platelet P-selectin expression was measured in 
addition to PMA.
A negative association was identified between P-selectin expression on circulating 
platelets and the development o f infective endocarditis, consistent with observations 
by Yaguchi et al who identified reduced platelet activation and aggregation in 
patients with sepsis (Yaguchi et al., 2004). However, most investigators have 
demonstrated increased platelet activation in sepsis, but their observations may not 
be comparable to the current study due to the use o f different experimental 
techniques such as enzyme-linked immunosorbent assay (ELISA), or the use o f 
different anticoagulants during venepuncture (Gawaz et al., 1997, Gawaz et al., 
1995, Ogura et al., 2001, Russwurm et al., 2002).
Caution is required in the interpretation o f results from this study, as analysis was 
limited by the study population size, large inter-subject variability in platelet 
activation and the presence o f confounding factors. However, it can be hypothesised 
that platelet P-selectin expression was reduced in patients with infective endocarditis 
due to sequestration o f activated platelets within vegetations or due to generalised 
platelet consumption, leaving fewer, less activated platelets to circulate in the 
bloodstream. Alternatively, reduced platelet activation may contribute to the 
pathogenesis o f  infective endocarditis by inhibition o f platelet microbicidal protein 
(PMP) release from platelets, leading to enhanced bacterial growth and interactions
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with thrombi in infective endocarditis (see Section 1.5.2). Antibiotic or anti-platelet 
treatment may have also contributed to reduced platelet activation in infective 
endocarditis (see Section 1.7).
4.4.3 Factors influencing platelet activation in infective endocarditis
In order to elucidate the possible reasons for reduced platelet activation in the 
infective endocarditis patient cohort, univariate and multivariate analyses o f the 
correlations between PMA and platelet P-selectin expression and clinical 
characteristics in recruited patients were performed. On univariate analysis, platelet 
surface P-selectin expression was raised in intravenous drug abusers, consistent with 
a previous study which identified increased platelet activation in subjects with a 
history o f  cocaine use (Heesch et al., 2000). Furthermore, platelet activation was 
increased in patients with a history o f venous thromboses, correlating with other 
studies have determined platelet activation in both the early and late stages o f  deep 
venous thrombosis and pulmonary embolism (Blann et al., 2000, Chung et al., 2007). 
However, the observed correlation between venous thromboembolism and platelet P- 
selectin expression in the current study was no longer significant on multivariate 
analysis, possibly due to linkage with intravenous drug abuse or causative organisms 
such as S. aureus or coagulase-negative staphylococci (Fowler et al., 2005b, 
Moreillon & Que, 2004).
Platelet activation appeared to be influenced by pathogen-related factors in infective 
endocarditis as levels varied with causative organism. In the current study, the 
presence o f staphylococci, particularly coagulase-negative species in blood cultures, 
was associated with increased platelet activation, correlating with the increased 
propensity o f these organisms to induce platelet aggregation in vitro in comparison to 
organisms such as streptococci or enterococci (Kerrigan et al., 2002, O'Brien et al., 
2002a, Usui et al., 1991a, Usui et al., 1991b). The mechanisms o f S. <wi?«.y-induced 
platelet aggregation following growth in nutrient broth have been identified (see 
Section 1.4.3.3.2), while the mechanisms contributing to coagulase-negative
157
staphylococcus-induced platelet aggregation are still being determined. S. 
epidermidis induces platelet aggregation via the MSCRAMM SdrG (Brennan et al.,
2009), while the mechanisms o f platelet aggregation induced by S. lugdunensis, 
which has been implicated in aggressive forms o f infective endocarditis, are yet to be 
determined, but may involve the fibrinogen-binding protein Fbl (Mitchell et al., 
2004). Treatment with aminoglycosides was associated with reduced platelet 
activation in the current study, possibly due to its use in the treatment o f 
streptococcal, rather than staphylococcal infective endocarditis (Habib et al., 2009). 
The presence o f  negative blood cultures was associated with increased platelet 
activation, but there were a small number o f subjects in this group (n=2).
There were also some important negative associations. CRP stimulates platelet 
activation, particularly in the context o f ischaemic heart disease (Danenberg et al., 
2007), but there was no correlation between CRP levels at the time o f sampling and 
PMA or platelet P-selectin expression. Additionally, the presence o f anti-platelet 
therapy in patients with infective endocarditis did not influence platelet activation. 
There were concerns that route o f venepuncture may influence platelet activation 
levels as this has been previously described, but no such trend was observed in the 
current study (Rubens et al., 1998). Presence o f a prosthetic valve at time o f 
recruitment did not correlate with platelet activation, and in contrast to previous 
work, there was no significant correlation betweens underlying valvular heart disease 
and platelet activation (Chen et al., 2004, Chirkov et al., 2002, Pareti et al., 2000, 
Tse et al., 1997). Time o f subject recruitment was marginally associated with 
increased PMA however, this was not a linear relationship and could have been 
influenced by other factors such as antibiotic and anti-platelet therapy and causative 
organism.
4.4.4 Platelet activation and outcome in infective endocarditis
Considering that cardiac vegetations are thought to form as a direct result o f platelet 
aggregation (Bashore et al., 2006, Fitzgerald et al., 2006a), it was hypothesised that
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patients with vegetations would have increased platelet activation. However, no 
correlation was observed between the presence o f a vegetation, vegetation size or 
mobility and platelet activation, consistent with findings by Ileri et al (Ileri et al., 
2003). A possible explanation for these results is that vegetations are dynamic and 
undergo continuous change. For example, larger vegetations may fragment at any 
time such that a vegetation may appear small immediately after major embolisation 
has occurred (Ileri et al., 2003). It is well established that the risk o f embolisation is 
proportional to vegetation size (Di Salvo et al., 2001, Fabri et al., 2006, Thuny et al., 
2005, Tischler & Vaitkus, 1997).
One previous study has identified increased platelet activation in patients with
infective endocarditis complicated by embolic phenomena, but the investigators 
excluded patients with prosthetic heart valves and those treated with anti-platelets or 
anticoagulants, which comprise a large proportion o f patients present in a clinical 
setting (34% and 59% of the current study population respectively) (Ileri et al., 
2003). There was no correlation between platelet activation and development o f 
emboli in the current study, possibly due to patient treatment with anti-platelets,
anticoagulants and antibiotics prior to blood sampling.
Unfractionated heparin and warfarin increase platelet activation (Harding et al., 
2006a, M ieszczak & Winther, 1996, Wahba et al., 1996), while clopidogrel, a 
platelet ADP antagonist, reduces PMA (Harding et al., 2006b). However, detailed 
analyses o f the patient cohort revealed no differences in platelet activation with anti­
platelet or anticoagulant therapy in the current study, but such conclusions may be 
invalid due to the limited population size.
Need for valve replacement was associated with increased platelet activation in the 
infective endocarditis study population. However, the validity o f this relationship is 
questionable as patients were recruited at various time-points during the disease 
process. It is feasible that increased platelet activation was associated with the 
underlying complication necessitating surgery (for example uncontrolled sepsis or 
valve degeneration), rather than valve replacement itself. Alternatively, temporary
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rises in platelet activation during the early post-operative period may have 
confounded the issue (Goldsmith et al., 2001, Leguyader et al., 2006). Consistent 
recruitment o f patients at defined intervals pre- or post-operatively would have 
enabled accurate determination o f the predictive role o f platelet activation in patients 
requiring valve replacement, and should be explored in future studies.
Platelet activation is thought to contribute to the development o f DIC and multi­
organ failure in patients with sepsis, and patients with organ failure may therefore be 
expected to have increased platelet activation levels (Gawaz et al., 1997). However, 
PMA is paradoxically lower in septic patients with multi-organ failure and death, 
presumably due to peripheral sequestration o f platelets (Gawaz et al., 1995, 
Sunakawa et al., 1988). In the current study, there was a trend towards increased 
percentage PMA in patients with heart failure but no associations with multi-organ 
failure, mortality or the composite clinical end-point o f embolism, heart failure, need 
for surgery and mortality. Similarly, fieri et al did not identify correlations between 
platelet activation and mortality (fieri et al., 2003).
4.4.5 Conclusions
In summary, this study is the first to demonstrate a link between platelet activation 
and disease development in infective endocarditis, as platelet P-selectin expression 
was reduced in patients with infective endocarditis in comparison to healthy 
volunteers. The low platelet P-selectin expression observed in patients with infective 
endocarditis may be due to platelet sequestration within vegetations or due to the role 
o f platelets in immune defence, which should be analysed further by measuring PMP 
levels in patients with bacteraemia and infective endocarditis in comparison to 
healthy subjects (Dankert et al., 2001, Tang et al., 2002).
This research was severely limited by the modest study populations in the infective 
endocarditis and control groups, and by the variable timing o f  subject recruitment 
and blood sampling. Ideally, this study should have characterised the temporal
1 6 0
variation in platelet activation during the course o f infective endocarditis in relation 
to factors such as antibiotic therapy, surgery, vegetation size and development o f 
embolic complications, with correction for confounding factors such as causative 
organism, anti-platelet and anticoagulant treatment. Such methodological 
modifications should be incorporated in future studies, which should also aim to 
analyse platelet activation in large numbers o f subjects, including controls with other 
causes o f bacteraemia and underlying valvular heart disease or intravenous drug 
abuse without evidence o f infective endocarditis, in order to determine the predictive 
role o f PMA and platelet P-selectin expression in this condition.
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CHAPTER 5
DETERMINATION OF THE INFLUENCE OF PLATELET 
RECEPTOR POLYMORPHISMS ON S. AUREUS-INDUCED 
PLATELET AGGREGATION AND CLINICAL OUTCOME IN 
INFECTIVE ENDOCARDITIS
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5.1 Introduction
Previous studies have observed host variation in susceptibility to bacterium-induced 
platelet aggregation in vitro. For example, Miajlovic et al found that l out o f 3 
donors had attenuated S. aureus-induced platelet aggregation, but did not elucidate 
the underlying mechanisms contributing to this (Miajlovic et al., 2007). McNicol et 
al identified donor variation in response to S. sanguinis-induced platelet aggregation, 
which could not be fully explained by variation in IgG titres (McNicol et al., 2006). 
Considering the role o f specific platelet receptors in bacterium-induced platelet 
aggregation, it is feasible that platelet receptor polymorphisms influence host 
susceptibility to platelet aggregation and clinical outcome in infective endocarditis.
Genetic risk factors have previously been identified for infectious and inflammatory 
diseases. For example, heterozygosity for the factor V Leiden mutation has been 
associated with increased risk o f urinary tract infections in a Danish population 
(Benfield et al., 2005). M annan-binding lectin-2 polymorphisms have been 
associated with increased risk o f carditis in patients with rheumatic fever 
(Schafranski et al., 2008). Furthermore, a number o f studies have identified genetic 
risk factors for infections caused by Streptococcus pneumoniae and Neisseria  
meningitidis (Brouwer et al., 2009).
Following the success o f the Fluman Genome Project, the single nucleotide 
polymorphism (SNP) consortium was founded, with the aim o f discovering novel 
SNPs contributing to human disease, thus potentially identifying individuals that 
would benefit most from tailored treatment or prophylaxis (Topol, 2008). Although 
numerous genome-wide association studies have focused on cardiovascular diseases 
such as MI or atrial fibrillation, none have investigated genetic predispositions to 
infective endocarditis (Topol, 2008).
Bacterium-platelet adhesion, activation and aggregation contribute to vegetation 
formation and the pathogenesis o f infective endocarditis (see Section 1.4.3.3). In
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addition, platelet receptor polymorphisms influence pharmacological agonist- 
induced platelet activation and aggregation, as well as the development o f vascular 
and immune disease (see Section 1.6). However, the effects o f polymorphic platelet 
receptors on bacterium-platelet interactions and outcome in infective endocarditis are 
unknown. Using a combination o f flow cytometry and platelet aggregometry, the 
influence o f  platelet receptor polymorphisms on S. aureus-platelet adhesion, 
activation and aggregation was examined in the current study. The effects o f platelet 
receptor genotype on susceptibility to and clinical outcome in infective endocarditis 
were also determined.
5.2 Methods
Platelet receptor genotype was determined for 164 healthy volunteers and 44 patients 
with infective endocarditis (see Sections 2.1 and 4.3.1). Venepuncture was 
performed on all subjects to obtain plasma for determination o f platelet receptor 
polymorphisms as outlined in Sections 2.4 and 2.5.
S. awrerM'-induced aggregation o f platelets in platelet-rich plasma (PRP) and washed 
platelet preparations was analysed by performing platelet aggregometry using blood 
from 88 and 31 healthy volunteers, respectively (see Section 2.11), selected on the 
basis o f their platelet receptor genotype. Platelets were processed as described in 
Section 2.6. S. aureus strains Newman, 207 and 209 grown to stationary and m id­
exponential phase in BHI were selected as agonists for aggregation studies and 
processed as described in Sections 2.8 and 2.9. The pharmacological agonists 
SFLTRN-NH2, ADP and ristocetin were used as positive controls. S. aureus-platelet 
adhesion, baseline and S. aureus-induced platelet activation were determined using 




5.3.1 Distribution of platelet receptor genotypes in healthy volunteers 
is similar to published studies
164 healthy volunteers were recruited for genotyping o f platelet receptor 
polymorphisms. Results for the GPIb Kozak sequence polymorphism were obtained 
for 158 healthy volunteers (96%), GPIIIa platelet antigen (P1A1/A2) and GPIb variable 
number o f tandem repeat (VNTR) (Figure 5.1) polymorphisms for 160 subjects each 
(98%), and GPIb human platelet antigen-2 (HPA-2) and FcyRIIa HI 3 1R for 100% of 
subjects. Complete results for all five polymorphisms were obtained for 153 o f  the 
164 healthy volunteers (93% total, 33% male, 30±10 years) and are outlined in Table 
5.1. All polymorphisms were in Hardy-W einberg equilibrium (data not shown).
Frequencies o f  platelet receptor polymorphisms in the healthy volunteer population 
were similar to those observed in published studies (Table 1.4) (Baker et al., 2001, 
Laule et al., 1999, Lehmbecher et al., 1999, Newman et al., 1989, Jilma-Stohlawetz 
et al., 2003). In the current study there was incomplete linkage disequilibrium 
between the GPIb VNTR and HPA-2 polymorphisms as 21 o f  22 (95%) o f  VNTR A 
or B subjects carried an HPA-2b allele, while 23 out o f 25 (92%) o f HPA-2b-positive 
individuals carried a VNTR A or B allele, similar to frequencies observed by Ozelo 
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Figure 5.1. Representative agarose gel electrophoresis of PCR products  
used for determination of GPIb variable number of tandem repeat (VNTR) 
polymorphisms. Allele sizes are as follows: A (506 bp), B (467 bp), C (428 bp), D 
(389 bp) and E (250 bp). Lanes 1 and 2 are the positive controls with genotypes 
C/C and B/D, respectively, lane 3 is the negative control (distilled water) and the 
remainder are samples from recruited subjects.
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Table 5.1. Frequencies of GPIIIa platelet antigen (PIA1/A2), GPIb Kozak 
sequence, human platelet antigen (HPA)-2, variable number of tandem repeat 
(VNTR) and FcyRlla H131R platelet receptor polymorphisms in 153 genotyped  
healthy volunteers and 88 subjects selected for platelet aggregometry.





pjAl/Al 119(78% ) 58
pjAl/A2 30 (20%) 26
pjA2/A2 4 (2%) 4
GPIb Kozak sequence
T/T 119(78% ) 57
T/C 34 (22%) 31
C/C 0 (0%) 0
GPIb HPA-2
2a/2a 130 (85%) 67
2a/2b 22(14% ) 20
2b/2b 1 (1%) 1
GPIb VNTR
D/D 2(1% ) 1
C/D 15 (10%) 11
C/C 114(75% ) 55
B/D 2(1% ) 2
B/C 19(12% ) 18
A/D 1 (1%) 1
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R/R 47 (31%) 25
H/R 70 (46%) 40
H/H 36 (23%) 23
* Platelet receptor genotype for 88 of the 153 subjects selected for platelet 
aggregation studies. Subject selection was based on the presence of a variant 
allele.
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Healthy volunteers were selected for platelet aggregation studies based on the 
presence o f a variant allele. Using these criteria, 99 healthy subjects were suitable 
for platelet aggregometry using PRP. However 11 (11%) had to be excluded because 
o f long-term anti-platelet therapy (n=2), existing antibiotic therapy (n= l), loss to 
follow-up (n=5) and 3 were outliers as their results were greater than 3 standard 
deviations from the mean, leaving a study population o f 88 healthy volunteers (40% 
male, 30±9 years, Table 5.1).
Additional studies were performed to determine whether the GPIIIa P1A1/A2, GPIb 
Kozak sequence and FcyRIIa H131R polymorphisms influenced S. aureus-]Aa\.z\e\ 
adhesion, activation or solely aggregation. To exclude the effects o f variation in 
plasma factors such as fibrinogen or IgG between different donors, platelet 
aggregometry was performed with washed platelets from representative subjects. 
Although 33 subjects were identified as being suitable for these studies, 2 o f the 4 
individuals with the p]AI/A2 T/C genotype were lost to follow up, leaving a study 
population o f 31 subjects (52% male, 33±9 years, Table 5.2).
5.3.2 Selection of healthy volunteers for platelet aggregation and flow
cytometric studies
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Table 5.2. GPIIIa platelet antigen (PIA1/A2), GPIb Kozak sequence and 
FcyRlla H131R platelet receptor genotypes in 31 healthy volunteers 
selected to participate in studies determining the effect of platelet 
receptor polymorphisms on S. aureus-platelet adhesion, activation and 
aggregation of washed platelets.














S. aureus strains Newman, 209 and 207 grown to stationary and mid-exponential 
phase in BHI were selected for in vitro assays, to enable determination o f the effects 
o f platelet receptor polymorphisms on platelet adhesion, activation and aggregation 
induced by strains that were rapid, medium and slow inducers o f platelet 
aggregation, respectively (Figure 5.2). Note that S. aureus strain 207 grown to 
stationary phase only induced platelet aggregation within 25 min with 1 out o f the 88 
donors’ PRP (Figure 5.2) and was therefore excluded from subsequent analyses. 
Furthermore, only 4 subjects’ washed platelet preparations aggregated in response to 
strain 207 at the exponential phase o f growth (data not shown). Pharmacological 
agonists ADP, ristocetin and SFLLRN-NFF were used as positive controls in 
aggregation studies and were specifically used at high concentrations to induce rapid 
and high percentage platelet aggregation (data not shown) (Lasne et al., 1997).
Multivariate analysis using a general linear model could only be performed on data 
from PRP aggregation studies that fit a normal distribution. Lag time to aggregation 
induced by strain Newman grown to stationary and exponential phase and strain 209 
grown to exponential phase could be transformed to fit a normal distribution. 
Percentage platelet aggregation induced by strain Newman at the stationary and 
exponential phases o f growth and strain 209 grown to stationary phase also met the 
assumptions o f normality. However, rate o f aggregation could not be transformed to 
fit a normal distribution. Only the effects o f two genotypes in combination could be 
analysed due to small study population sizes, particularly for the rare genotypes.
5.3.3 Selection of S. aureus strains for platelet aggregation and flow
cytometric studies
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N e w m an , 2 0 7 , 2 0 9 , N ew m an , 2 0 7 , 2 0 9 ,
s ta tio n a ry  s ta tio n ary  s ta tio n ary  exponentia l expo n en tia l expo n en tia l
phase phase phase phase phase phase
S. aureus stra in  and g ro w th  phase
Figure 5.2. Distribution of lag time to platelet aggregation induced by S. 
aureus strains using platelets in platelet-rich plasma from 88 healthy 
volunteers. Circles and asterisks represent data points more than 2 and 3 standard 
deviations from the median, respectively.
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S. aureus-platelet adhesion was determined by calculating the percentage o f S. 
aureus cells bound to platelets and the percentage o f platelets bound to S. aureus as 
outlined in Figure 5.3. Consistent with findings by Yeaman et al, there was 
heterogeneity in the ability o f different S. aureus strains to bind platelets, possibly 
representing variation in M SCRAM M expression (data not shown) (Yeaman et al., 
1992c).
Baseline percentage platelet activation was determined using whole blood platelet- 
monocyte aggregates (PMA) and platelet P-selectin expression, while S. aureus- 
induced platelet activation was determined by measurement o f P-selectin expression 
in PRP. Both absolute (Figure 5.4A) and relative (Figure 5.4B) platelet activation in 
response to S. aureus were determined, the latter measured by subtraction o f values 
obtained for vehicle alone from those obtained for each agonist.
Platelet activation induced by S. aureus did not approach levels associated with the 
positive control SFLLRN-NFI2, despite experimental modifications such as shaking 
platelet-51, aureus incubations, performing incubations at 37°C, using increased 
concentrations o f fluorescent-conjugated antibodies or increasing incubation periods 
for the 5. aureus-PRP mixture in the dark (data not shown). Most o f the obtained 
relative values were negative, and absolute values were therefore used for analysis. 
Bacterium-induced platelet activation was greater for strain Newman, particularly at 
the stationary phase o f  growth as compared to other strains, correlating with the 









Figure 5.3. Flow-cytometric analysis of S. aureus-platelet binding for strain 
Newman grown to stationary phase. Dot blots of forward scatter (FSC-A) against 
side scatter (SSC-A) were used to identify cell populations (A); S. aureus (red), 
platelets (green). Quadrant plots of unstained samples (B) and samples stained 
with anti-CD42a-FITC alone (representing platelets) (C) were used to align gates. 
Cells stained with both anti-CD42a-FITC and Hoechst 33342, (represented on axes 
labelled FITC and UV-1 respectively), represent platelets bound to S. aureus cells 
(D).
176
£ • 1 0 0 -
c0
*ü5

















N e w m a n , 2 0 9 ,  N e w m a n , 2 0 7 ,  2 0 9 ,
s ta t io n a ry  s ta t io n a ry  e x p o n e n tia l e x p o n e n tia l ex p o n e n tia l
p h a se  phase ph a se  p h a se  phase




















 ! , , , , !--------
N ew m an, 209 , stationary New m an, 2 0 7 , 209 , SFLLRN-NH2
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Bacterial or pharm acological agonist
Figure 5.4. Data distribution for absolute (A) and relative (B) S. aureus-platelet 
activation, measured by platelet P-selectin expression in platelet-rich plasma from 31 
healthy volunteers. R ela tive  va lues  w e re  obta ined  by subtracting p la te le t P -se lectin  
expression  for veh ic le  a lo n e  (P B S  for b acteria  and  0 .9 %  N a C I for S F L L R N -N H 2) from  results  
obta ined  for ea ch  agonist. S F L L R N -N H 2 w as  used as  the positive control. C irc les and  
asterisks represen t d a ta  points m ore than 2 and  3 standard  devia tions from  th e  m edian  
respectively.
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5.3.4 Platelet receptor polymorphisms influence S. aureus-induced  
platelet activation and aggregation, but not S. aureus-platelet 
adhesion
5.3.4.1 The GPIIIa PIA1 allele is associated with increased S. aureus-
induced platelet aggregation independent of plasma factors
In studies using PRP, lag time to platelet aggregation induced by S. aureus was 
shorter for GPIIIa P1AI carriers as opposed to P1A2/A2 platelets, but this was not 
statistically significant (P1AI/A1 6.09 ±  1.40 min vs. p iA1/A2 6.63 ± 1.20 min, p iA2/A2 
6.92 ±  1.03 min for strain Newman grown to exponential phase, P=0.060, Table 
S5.1). Additionally, there was a trend towards increased percentage platelet 
aggregation in response to strain 209 grown to stationary phase in platelets 
expressing GPIIIa PlAi/A1 compared to P1A2 (P1AI/A1 68 ± 9 % vs. P1AI/A2 63 ± 10% vs. 
P1A2/A2 63 ± 33 %, P=0.060). There were no significant correlations between p iA1/A2 
genotype and rate o f aggregation (Table S5.2), or maximal percentage platelet 
aggregation induced by pharmacological agonists (Table S5.3).
Using various combinations o f GPIIIa piA1/A25 GPIb Kozak sequence, HPA-2, VNTR 
and FcyRIIa H131R polymorphisms, there was variation in the ability o f the p jAI/A2 
polymorphism to influence S. aureus-induced platelet aggregation on multivariate as 
compared to univariate analysis. Specifically, the piAI/AI genotype was associated 
with reduced lag time to platelet aggregation in response to strains Newman grown 
to stationary phase and 209 grown to mid-exponential phase (P=0.011 and 0.001 
respectively, Figure 5.5), while it no longer influenced lag time to aggregation 
induced by strain Newman at the exponential phase o f growth (P=0.147). This 
difference may be attributed to correction for other polymorphisms or the use o f non- 
parametric tests for the analysis o f univariate data and parametric tests for the 
analysis o f multivariate data.
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P=0.045




A l/A l A1/A2
GPIIIa p|AI'A2 genotype
A2/A2
Figure 5.5. Effect of GPIIIa p|A1/A2 genotype on lag time to platelet aggregation 
induced by S. aureus strain Newman grown to stationary phase (blue, 
P=0.011) and strain 209 grown to mid-exponential phase (grey, P=0.001) on 
multivariate analysis when using platelets in platelet-rich plasma from 88 
subjects. Only results for the latter were significant on post-hoc analysis.
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In studies using washed platelets, the P1AI allele was associated with reduced lag 
time to aggregation in response to strain Newman grown to stationary phase 
(P=0.034, Figure 5.6A). Conversely, platelets from subjects homozygous for the 
P1AI allele did not aggregate in response to strain 207 grown to exponential phase 
(P1A1/A1 25 min vs. P1A1/A2 19.24 ± 8.78 min vs. P1A2/A2 22.93 ± 4.14 min, P=0.047, 
Table S5.4). Rate o f aggregation was increased with the p iAI/A2 genotype (P=0.042, 
Figure 5.6B, Table S5.5). Percentage platelet aggregation did not vary with p iAI/A2 
genotype for bacterial agonists (Table S5.6), but there was a trend towards increased 
platelet aggregation in P1A1 carriers in response to ADP (P1AI/AI 29 ± 20 % vs. p iAI/A2 
36 ± 17 % vs. P1A2/A2 12 ± 16 %, P=0.062).
Baseline platelet activation did not vary with p iA1/A2 genotype (PMA: p jA1/A1 27.1 ±
9.2 % vs. P1A!/A2 24.4 ±15.1  % vs. P1A2/A2 28.5 ± 8.3 %, P=0.457; platelet P-selectin 
expression: P1A1/A1 4.1 ± 2.0 % vs. P1A1/A2 3.0 ± 1.4 % vs. P1A2/A2 3.3 ±  1.0 %, 
P=0.296). There were no significant correlations between GPIIIa p iA1/A2 genotype 










A l/A l A1/A2 A2/A2
GPIIIa p|A1/A2 genotype
Figure 5.6. Effect of GPIIIa p|A1/A2 genotype on lag time to platelet aggregation 
induced by S. aureus strain Newman grown to stationary phase (A) and rate of 
platelet aggregation induced by S. aureus strain 209 grown to stationary phase
(B) Studies were performed using washed platelets from 31 subjects. P values were 
derived from post-hoc analysis.
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5.3.4.2 The GPIb Kozak sequence polymorphism influences S. aureus- 
induced platelet aggregation in PRP
Results for variation in lag time, rate and percentage aggregation o f platelets in PRP 
by GPIb Kozak sequence genotype are outlined in Tables S5.10-S5.12. Lag time to 
platelet aggregation was shorter for the Kozak sequence T/T as compared to the T/C 
variant in response to strain Newman grown to exponential phase (P=0.021, Figure
5.1 A). There was no association between Kozak sequence genotype and rate o f 
platelet aggregation (Table S 5 .ll) , while percentage platelet aggregation was 
significantly increased in T/C platelets in response to strain 209 at the stationary 
phase o f growth (P=0.033, Figure 5.7B). The GPIb Kozak sequence polymorphism 
had no influence on platelet aggregation induced by pharmacological agonists 
(Tables S5.11-S5.12). The effects o f the GPIb Kozak sequence polymorphism on 
lag time and maximal percentage platelet aggregation induced by S. aureus were not 
present on multivariate analysis (P=0.196 and P=0.056, respectively) and were not 
reproduced in studies using washed platelets (Tables S5.13-S5.15).
Baseline platelet activation did not vary with Kozak sequence genotype (PMA: T/T
26.3 ± 12.2 % vs. T/C 26.6 ±  9.6 %, P=0.685; platelet P-selectin expression: T/T 3.6 
± 2.1 % vs. T/C 3.6 ± 1.2 %, P=0.478). There were no correlations between GPIb 
Kozak sequence genotype and S. awreus-platelet adhesion (Tables S5.16 and S5.17) 







Figure 5.7. Effect of GPIb Kozak sequence genotype on lag time to platelet 
aggregation induced by S. aureus strain Newman grown to exponential phase 
(A) and percentage platelet aggregation induced by S. aureus strain 209 
grown to stationary phase (B) using platelets in platelet-rich plasma from 88 
healthy volunteers.
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5.3.4.3 The GPIb HPA-2 polymorphism does not influence S. aureus- 
induced platelet aggregation
There were no correlations between HPA-2 genotype and lag time, rate and 
percentage platelet aggregation induced by S. aureus strains or pharmacological 
agonists in studies using PRP (Table S5.19-S5.21). Consequently, aggregation 
studies using washed platelets and flow cytometric analysis o f bacterium-platelet 
adhesion and activation were not performed.
5.3.4.4 The GPIb VNTR D allele is associated with increased S. aureus- 
induced platelet aggregation
There were no significant associations between VNTR genotype and lag time or rate 
o f  platelet aggregation in studies using PRP (Tables S5.22 and S5.23). Maximal 
percentage platelet aggregation was increased for platelets heterozygous for a D 
allele in response to strain 209 grown to stationary phase (P=0.030, Figure 5.8A), 
which remained significant on multivariate analysis (P=0.007), and a similar trend 
was observed with most other strains (Table S5.24). Percentage aggregation was 
also significantly increased for B/D, C/C and C/D, as compared to B/C platelets, for 
the pharmacological agonist ristocetin (Figure 5.8B, P=0.016). As a number o f 
individuals carrying the D allele were lost to follow up, studies determining 
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Figure 5.8. Effect of GPIb variable number of tandem repeat (VNTR) genotype 
on percentage platelet aggregation induced by S. aureus strain 209 grown to 
stationary phase (A) and percentage platelet aggregation induced by 
ristocetin (B) when using platelet-rich plasma from 88 healthy volunteers.
A/D and D/D genotypes were present in platelets from one individual each.
5.3.4.5 The FcyRlla H131 allele is associated with increased S. aureus- 
induced platelet aggregation
In studies using PRP, lag time to platelet aggregation was reduced with FcyRIIa H/H 
platelets and this approached significance for strain Newman at the exponential 
phase o f growth (H/R 6.67 ± 1.29 min vs. H/H 5.90 ± 1.61 min vs. R/R 5.92 ±  1.07 
min> P—0.077, Table S5.25). In addition, rate o f platelet aggregation was increased 
for HI 31 platelets in response to 5. aureus strain 209 grown to stationary phase 
(P=0.038, Figure 5.9A, Table S5.26). H I31 platelets were associated with increased 
percentage aggregation induced by strain 209 at the exponential phase o f growth on 
univariate analysis (P=0.043, Figure 5.9B, Table S5.27), and strain 209 grown to 
stationary phase on multivariate analysis (H/H 68 ± 9% vs. H/R 67 ± 10 % vs. R/R 
64 ± 14%, P=0.017). The effects o f the FcyRIIa H131 allele on S. aureus-induced 
platelet aggregation were not reproduced in studies using washed platelets (Tables 
S5.28-S5.30).
S. aureus-platelet adhesion (Tables S5.31 and S5.32) and baseline platelet activation 
did not vary with H131R genotype (PMA: H/H 28.5 ± 11.3 % vs. H/R 26.9 ± 12.5 % 
vs. R/R 24.2 ± 8.8 %, P=0.719; platelet P-selectin expression: H/H 4.4 ±  1.1 % vs. 
H/R 3.5 ± 2.2 % vs. R/R 3.4 ± 1.2 %, P=0.198). However, there was a trend towards 
increased S. aureus-induced platelet activation with H/H platelets (H/H 49 ± 24% vs. 
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Figure 5.9. Effect of FcyRlla H131R genotype on rate of platelet aggregation 
induced by S. aureus strain 209 at the stationary phase of growth (A) and 
percentage platelet aggregation induced by S. aureus strain 209 at the 
exponential phase of growth (B) using platelet-rich plasma from 88 healthy 
volunteers. P values were obtained from post-hoc analysis.
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5.3.4.6 GPIIIa p|A1/A2 and GPIb Kozak sequence polymorphisms have 
an interactive effect on S. aureus-induced platelet aggregation
Regression analysis revealed an interactive effect o f GPIIIa p iAI/A2 and GPIb Kozak 
sequence genotypes on lag time to platelet aggregation (Figure 5.10). In addition to 
P1AI homozygotes, aggregation was more rapid with p jA1/A2 t / T  and p iA2/A2 T/C 
platelets in response to strain Newman at the stationary phase o f growth (P=0.042) 
and strain 209 grown to exponential phase (P=0.012). However, the ability o f 
GPIIIa p iA1/A2 and GPIb Kozak sequence to collectively influence S. aureus-platelet 
adhesion, activation and aggregation o f washed platelets could not be determined due 
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Figure 5.10. Interactive effects of the GPIIIa p|A1/A2 and GPIb Kozak sequence 
genotypes on lag time to platelet aggregation induced by S. aureus strain 209 
grown to mid-exponential phase when using platelet-rich plasma from 88 
healthy volunteers.
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5.3.5 Platelet receptor polymorphisms are associated with adverse 
outcome in infective endocarditis
In order to determine the correlation between polymorphic platelet receptors and 
disease severity in infective endocarditis, platelet receptor genotypes were 
determined for 44 patients with infective endocarditis (see Section 4.3.1). Results 
for GPIIIa p iAI/A2 and FcyRIIa HI31R were obtained for 41 subjects each (93%), 
GPIb HPA-2 for 40 subjects (91%), Kozak sequence for 39 subjects (89%) and 
VNTR for 38 patients (86%). Complete results were obtained for 35 subjects (80%). 
There was no difference in the distribution o f these polymorphisms in comparison to 
a healthy population (Figure 5.11).
The association o f each o f these polymorphisms with the severity o f infective 
endocarditis was determined.
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GPIIb/llla p |A1'AZ GPIb Kozak G PIbHPA-2 G PIbVN TR  FcyRlla H131R
Platelet receptor genotype
Figure 5.11. Distribution of GPIIIa p|A1/A2, GPIb Kozak sequence, human 
platelet antigen-2 (HPA-2), variable number of tandem repeat (VNTR) and 
FcyRlla H131R platelet receptor polymorphisms in patients with infective 
endocarditis (IE, n=44) as compared to healthy volunteers (HV) for whom a 
complete platelet receptor genotype profile was available (n=153).
5.3.5.1 The GPIIIa PIA1 allele is associated with increased platelet 
activation and infective endocarditis causation by 
staphylococci and streptococci
Consistent with results from in vitro studies, platelet activation measured by both 
PMA and P-selectin expression was significantly increased for p iAI/A1 subjects 
compared to p iAI/A2 subjects (P=0.001 and 0.026, respectively, Figure 5.12A). The 
one p iA2/A2 patient had high PMA and platelet P-selectin expression levels o f  84.0 % 
and 7.9 % respectively. The piAl/AI genotype was associated with development o f 
Staphylococcus- or Streptococcus-induced endocarditis, while the p]AI/A2 variant was 
linked to endocarditis caused by Enterococcus spp. or other organisms detailed in 
Section 4.3.1 (P=0.004, Figure 5.12B).
All patients who suffered relapse or recurrence o f infective endocarditis possessed 
the p iAI/A1 genotype, but this was not significant (P1A1/A1 17% vs. p iAI/A2 o%, pjA2/A2 
0%, P=0.352). Paradoxically, the piA1/A2 variant was associated with increased 
development o f septic emboli (P1A,/AI 30% vs. P1A1/A2 70% vs. P1AI/A2 0%, P=0.058). 
There was no association between piA1/A2 genotype and presence o f  vegetations, 
vegetation size or mobility, need for surgery, heart failure and mortality when 
analysed individually (Tables 5.3 and 5.4). Furthermore, the GPIIIa p iA1/A2 
polymorphism did not influence development o f the composite clinical end-point o f 
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Figure 5.12. Correlation between GPIIIa p|A1/A2 genotype and platelet 
activation (platelet-monocyte aggregate (PMA) formation and platelet P- 
selectin expression) (A) and causative organism (B) in 40 patients with 
infective endocarditis. P=0.004 for causative organism. Data for the one p i ^ 2 
individual are not included. CNS, coagulase-negative staphylococci. See also Table 
5.3.
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Table 5.3. Correlation between GPIIIa p|A1/A2 genotype and clinical
characteristics in 41 patients with infective endocarditis for whom
genotypic information was available.
Clinical characteristics
GPIIIa P1A1/A2 genotype 




PM  A , % 27.9  ±  14.1 17.9 ± 8 .8 84.0 0.001
P-selectin  expression , % 3.9 ± 3 .3 1.5 ± 1 .1 7.9 0.026
C ausative organism
Streptococci 1 5 (5 0 % ) 2 (20 %)
S', aureus 7 (23 % ) 1 (1 0 % )
C oagu lase-negative 4 (1 3  %) 0 (0 % )
staphylococci 0.004
Enterococcus 1 (3 %) 1 (1 0 % )
O ther 2 (7 %) 5 (50 %)
C ulture  negative 1 (3 % ) 1 (10 %) 1 (100 % )
V egetations 23 (77 %) 8 (80 %) 1 (1 0 0 % ) 0.845
M ultip le  vegetations 7 (23 %) 3 (30 %) 0 (0 % ) 0.774
V egetation  length, m m  * 14 ±  5 20 ±  12 10 0.166
V egetation  w idth, m m  * 9 ±  4 9 ±  3 8 0.946
V egetation  m obility  *
A bsent 4 0 1
Low 11 1 0.110
M oderate 4 1
Severe 4 4
* Data on vegetation size and mobility were available for 30 of the 32 subjects
(94%) with vegetations and a determined p|A1/A2 genotype. PMA, platelet-monocyte
aggregates
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Table 5.4. Correlation between GPIIIa p|A1/A2 genotype and clinical
outcome in 41 patients with infective endocarditis for whom genotypic
information was available.
Clinical outcome
GPIIIa PlA,/A2 genotype 
A l/A l A1/A2 A2/A2 P value
IIc®IIaofOIIc
Emboli 9 (30 %) 7 (70 %) 0 (0 %) 0.058
Surgery 18 (60% ) 7 (70 %) 0 (0 %) 0.384
Heart failure 10(33 %) 1 (10% ) 1 (100% ) 0.108
Recurrence or relapse 5 (16% ) 0 (0 %) 0 (0 %) 0.352
Death 6 (20 %) 3 (30 %) 0 (0 %) 0.696
Composite clinical end­
point
22 (73 %) 8 (80 %) 0 (0 %) 0.227
Composite clinical end-point, emboli, surgery, heart failure or death
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5.3.5.2 The GPIb Kozak sequence polymorphism is not associated 
with clinical outcome in infective endocarditis
There were no significant correlations between the GPIb Kozak sequence 
polymorphism and clinical characteristics or outcome in patients with infective 
endocarditis (Tables 5.5 and 5.6), although there was a trend towards increased heart 
failure in patients with a C allele (P=0.064, Table 5.6).
5.3.5.3 The HPA-2a/2a genotype is associated with adverse outcome 
in infective endocarditis
The HPA-2a/2a genotype was associated with increased incidence o f the composite 
clinical end-point o f embolism, heart failure, need for surgery and mortality 
(P=0.020, Table 5.8). Conversely, there was a trend towards increased PMA in 
patients with the HPA-2a/2b genotype (P=0.056, Table 5.7). There were no 
associations between GPIb HPA-2 genotype and causative organism, presence o f 
vegetations, vegetation size or vegetation mobility (Tables 5.7 and 5.8).
5.3.5.4 The GPIb VNTR B allele is associated with increased 
vegetation formation in infective endocarditis
In contrast to results from in vitro studies, all patients with VNTR B alleles had 
vegetations (P=0.006, Table 5.9). Furthermore, there were trends towards increased 
emboli in patients with the VNTR C/C genotype (P=0.053, Table 5.10). There were 
no associations between GPIb VNTR genotype and causative organism, vegetation 
size or mobility or development o f the composite clinical end-point (Tables 5.9 and 
5.10).
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Table 5.5. Correlation between GPIb Kozak genotype and clinical
characteristics in 39 patients with infective endocarditis for whom
genotypic information was available.
GPIb Kozak genotype




PM A, % 28.5 ±  17.4 24.2 ±  14.7 24.3 0.826
P-selectin expression, % 3.9 ± 3 .4 2.7 ± 3 .0 3.0 0.596
C ausative organism
Streptococci 12 (39 %) 3 (43 % )
S. aureus 7 (23 %) 1 (1 4 % ) 1 (100 %)
C oagulase-negative 3 (1 0 % ) 1 (1 4 % )
staphylococci 0.830
E nterococcus 2 (6 %) 0 (0 %)
O ther 5 (1 6 % ) 2 (29 %)
C ulture negative 2 (6 %) 0 (0 %)
V egetations 23 (74 %) 6 (86 %) 1 (100 %) 0.693
M ultiple vegetations 7 (23 %) 1 (14 %) 1 (100 %) 0.162
V egetation length, m m  * 15 ±  8 15 ±  5 15 0.986
V egetation w idth, m m  * 9 ±  4 11 ± 5 10 0.599
V egetation m obility  *
A bsent 4 1
Low 9 1 1 0.829
M oderate 3 0
Severe 7 4
* Data on vegetation size and mobility were available for 23 of the 30 subjects
(77%) with vegetations and a determined GPIb Kozak sequence genotype. PMA,
platelet-monocyte aggregates
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Table 5.6. Correlation between GPIb Kozak sequence genotype and
clinical outcome in 39 patients with infective endocarditis for whom
genotypic information was available.
GPIb Kozak sequence genotype 
Clinical outcome T/T T/C C/C P value
n=31 n=7 n=l
Emboli 12 (39 %)
Surgery 1 8 (58% )
Heart failure 7 (23 %)
Recurrence or relapse 3 (10% )
Death 5 (16 %)
Composite clinical end­ 22 (71 %)
point
3 (43 %) 0 (0 %) 0.711
5 (71 %) 1 (100% ) 0.585
4 (57 %) 1 (100% ) 0.064
1 (14% ) 0 (0 %) 0.883
2 (29 %) 1 (100% ) 0.104
5 (71 %) 1 (100% ) 0.817
Composite clinical end-point, emboli, surgery, heart failure or death
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Table 5.7. Correlation between GPIb human platelet antigen (HPA)-2
genotype and clinical characteristics in 40 patients with infective
endocarditis for whom genotypic information was available.
GPIb HPA-2 genotype
Clinical characteristics 2 a/2 a 2a/2b P value
n=34 n=6
P latelet activation
PM A , % 25.2 ±  14.3 39.4 ± 2 3 .8 0.056
P-selectin  expression, % 3.4 ± 3 .2 4.2 ± 4 .2 0.983
C ausative organism
Streptococci 15 (44 % ) 2 (33 %)
S. aureus 7 (21 %) 1 (17 %)
C oagulase-negative staphylococci 3 (8 % ) 1 (17 %) 0.858
Enterococcus 2 (6 %) 1 (1 7 % )
O ther 5 (15 % ) 0 (0 %)
C ulture negative 2 (6 %) 1 (1 7 % )
V egetations 26 (76 % ) 6 (100 %) 0.184
M ultiple vegetations 9 (26 %) 1 (17 %) 0.609
V egetation length, m m  * 16 ±  8 11 ± 3 0.128
V egetation  w idth, m m  * 9 ±  5 7 ±  1 0.336
V egetation  m obility  *
A bsent 3 2
Low 10 1 0.306
M oderate 5 0
Severe 7 2
* Data on vegetation size and mobility were available for 30 of the 32 subjects
(94%) with vegetations a determined GPIb HPA-2 genotype. PMA, platelet-
monocyte aggregates
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Table 5.8. Correlation between GPIb human platelet antigen (HPA)-2
genotype and clinical outcome in 40 patients with infective endocarditis
for whom genotypic information was available.
GPIb HPA-2 genotype
Clinical outcome 2 a/2 a 2a/2b P value
■'ttoIIc n=6
Emboli 15 (44% ) 1 (17% ) 0.206
Surgery 23 (68 %) 2 (33 %) 0.109
Heart failure 9 (26 %) 3 (50 %) 0.246
Recurrence or relapse 4 (1 2 % ) 0 (0 %) 0.376
Death 9 (26 %) 0 (0 %) 0.152
Composite clinical 27 (79 %) 2 (33 %)
end-point
Composite clinical end-point, emboli, surgery, heart failure or death
2 0 0
Table 5.9. Correlation between GPIb variable number o f tandem repeat 
(VNTR) genotype and clinical characteristics in 38 patients with 
infective endocarditis for whom genotypic information was available.
GPIb VNTR genotype
Clinical B/C B/D C/C C/D P value
characteristics n=3 n=l n=29 a il Ul
Platelet activation
PM A, % 24.9 ± 10.0 39.9 26.6 ± 17.9 32.4 ±  14.1 0.674




Streptococci 1 (33 %) 1 (100 10 (35 %) 3 (60 %)
S. aureus %) 8 (28 %)
Coagulase- 1 (33 %) 1 (3 %) 1 (20 %)
negative
staphylococci 0.499
Enterococcus 1 (33 %) 1 (3 %)
Other 7 (24 %)
Culture 2 (7 %) 1 (20 %)
negative
Vegetations 3 (100% ) 1 (100 
%)
25 (86 %) 1 (20 %) 0.006
M ultiple 1 (33 %) 0 (0 %) 7 (24 %) 1 (20 %) 0.918
vegetations
Vegetation 9 ±  4 14 16 ± 8 17 ± 4 0.486
length, m m f




GPIb VNTR genotype 
B/D C/C C/D P value
characteristics n=3 n=l n=29 n=5
Vegetation 
mobility 1 
Absent 1 2 0
Low 1 9 2 0.115
M oderate 0 1 2 2
Severe 0 7 0
* P-selectin values were not available for the one B/D patient + Data on vegetation 
size and mobility were available for 28 of the 30 subjects (93%) with vegetations 
and a determined GPIb VNTR genotype. PMA, platelet-monocyte aggregates
2 0 2
Table 5.10. Correlation between GPIb variable number of tandem  
repeat (VNTR) genotype and clinical outcome in 38 patients with 
infective endocarditis for whom genotypic information was available.
GPIb VNTR genotype
Clinical outcome B/C B/D C/C C/D P value
n=3 n=l n=29 n=5
Emboli 0 (0 %) 0 (0 %) 15 (52% ) 0 (0 %) 0.053
Surgery 1 (33 %) 1 (100% ) 19(6 6 % ) 3 (60 %) 0.610
Heart failure 1 (33 %) 1 (100% ) 7 (24 %) 3 (60 %) 0.188
Recurrence or 0 (0 %) 0 (0 %) 3 (10% ) 1 (20 %) 0.814
relapse
Death 0 (0 %) 0 (0 %) 6 (21 %) 2 (40 %) 0.542
Composite 1 (33 %) 1 (100% ) 22 (76 %) 4 (80 %) 0.384
clinical end-point
Composite clinical end-point, emboli, surgery, heart failure or death
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5.3.5.5 The FcyRlla H131 allele is associated with clinical outcome in
infective endocarditis
There were no correlations between H131R genotype and platelet activation, 
causative organism, presence o f vegetations, vegetation characteristics, emboli and 
the composite clinical end-point (Tables 5.11 and 5.12). However, consistent with 
the association o f the H I31 allele with increased bacterium-induced platelet 
aggregation in vitro , presence o f this allele was associated with the development o f 
heart failure (P=0.018, Table 5.12). Furthermore, only individuals with an FcyRIIa 
H131 allele suffered recurrence, relapse or mortality although this was not 
statistically significant (Table 5.12). The H/R genotype was associated with reduced 
need for surgery in patients with infective endocarditis (P=0.009, Table 5.12).
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Table 5.11. Correlation between FcyRlla HI31R genotype and clinical
characteristics in 41 patients with infective endocarditis for whom
genotypic information was available.
Clinical characteristics H/H
n = ll







PM A, % 24.1 ±  13.7 29.1 ±  17.2 27.3 ±  18.2 0.656
P-selectin  expression, % 3.1 ± 3 .3 3.7 ± 2 .9 2.9 ± 4 .4 0.891
C ausative organism
Streptococci 4 (37 % ) 7 (36 %) 5 (45 %)
S. aureus 2 ( 1 8 % ) 4(2 1  % ) 3 (27 % )
C oagulase-negative
staphylococci
1 (9 % ) 2 (1 1  %) 1 (9 % )
0.988
Enterococcus 2 ( 1 8 % ) 0 (0 %) 0 (0 % )
O ther 1 (9 %) 4 (21 %) 2 ( 1 9 % )
C ulture negative 1 (9 %) 2 (1 1  %) 0 (0 % )
V egetations 9 (82 % ) 14 (74 %) 9 (82 % ) 0.821
M ultiple vegetations 3 (27 %) 5 (26 % ) 2 (18 % ) 0.853
V egetation length, mm * 21 ±  14 13 ±  5 16 ±  7 0.210
V egetation w idth, m m  * 8 ±  2 8 ±  4 10 ±  5 0.503
V egetation m obility  *
A bsent 0 5 0
Low 2 6 4 0.074
M oderate 0 4 0
Severe 2 2 5
* Data on vegetation size and mobility were available for 30 of the 32 subjects
(94%) with vegetations and a determined FcyRlla H131R genotype. PMA, platelet-
monocyte aggregates
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Table 5.12. Correlation between FcyRlla HI31R genotype and clinical










Emboli 2 (1 8 % ) 8 (42 %) 6 (55 %) 0.202
Surgery 10(91 %) 7 (37 %) 8 (73 %) 0.009
Heart failure 6 (55 %) 6 (32 %) 0 (0 %) 0.018
Recurrence or relapse 1 (9 %) 4 (21 %) 0 (0 %) 0.221
Death 4 (36 %) 5 (26 %) 0 (0 %) 0.098
Composite clinical end­
point
10(91 %) 12 (63 %) 8 (73 %) 0.255
Composite clinical end-point, emboli, surgery, heart failure or death
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5.4 Discussion
Host factors such as age, intravenous drug abuse, haemodialysis, valvular heart 
disease and presence o f prosthetic valves increase susceptibility to infective 
endocarditis (Bashore et al., 2006). However, the influence o f host genetic factors 
on S. aureus-induced platelet aggregation and outcome in infective endocarditis are 
unknown. This study is the first to examine the contribution o f platelet receptor 
polymorphisms to S. awrews-platelet interactions, development o f  and clinical 
outcome in patients with infective endocarditis.
5.4.1 Effects of the GPIIIa p|A1/A2 polymorphism on S. aureus-platelet 
interactions and outcome in infective endocarditis
The GPIIb/IIIa receptor has been implicated in S. awreus-platelet adhesion and S. 
aureus-induced platelet aggregation under both low and high shear conditions 
(Fitzgerald et al., 2006b, George et al., 2006, Pawar et al., 2004). Polymorphisms o f 
this receptor may therefore impact on multiple stages o f S. aureus-mduczd  platelet 
aggregation under multiple rheological conditions.
In the current study, the GPIIIa p iAl/A1 genotype was associated with increased 
susceptibility to S. aureus-induced platelet aggregation in vitro, measured by reduced 
lag time to platelet aggregation. Importantly, the effect o f the P1AI variant on lag 
time was present in studies using washed platelets, suggesting that the observed 
effects were independent o f differences in plasma protein concentrations (Feng et al., 
2001). The effect o f the p iA1/A2 polymorphism was confined to the final stage o f 
platelet aggregation and did not influence levels o f S. aureus-\Aa\e\et binding or 
activation in healthy volunteers, indicating that this polymorphism modulates cross- 
linking o f fibrinogen to GPIIb/IIIa receptors, similar to its influence on platelet 
aggregation induced by pharmacological agonists (Feng et al., 1999, Lasne et al., 
1997, M ichelson et al., 2000).
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The piA1/A- genotype was associated with increased aggregation as compared to the 
P1A2/A2 genotype, suggesting the P1A1 allele is dominant. This is in contrast to 
observations by O ’Halloran et al, who identified increased transcription o f P1A2- 
rather than PlA1-bearing alleles in heterozygotes, but transcription levels may not 
correlate with phenotypic effects (O'Halloran et al., 2006).
These observations are consistent with those from published studies, which have 
identified increased platelet aggregation in response to SFLLRN, ADP, arachidonic 
acid and the thromboxane A2 analogue U46619 in P1A1 homozygotes (Andrioli et al., 
2000, Lasne et al., 1997). However, most studies have demonstrated increased 
platelet aggregation and activation at baseline and in response to ADP and 
epinephrine in P1A2 carriers (Feng et al., 1999, Michelson et al., 2000). These 
discrepancies may be explained by the use o f bacterial agonists and different study 
populations. There were no significant correlations between GPIIIa p]A1/A2 genotype 
and platelet aggregation induced by ADP or SFLLRN-NH2 in the current study, 
possibly due to the use o f saturating concentrations o f  pharmacological agonists 
(Michelson et al., 2000).
In addition to its association with increased S. aureus-induced platelet aggregation in 
vitro, the p iAI/AI genotype was associated with blood culture positivity for 
staphylococci, and streptococci, the commonest causes o f infective endocarditis 
(Murdoch et al., 2009). These data are consistent with our understanding o f the 
central role o f the platelet GPIIb/IIIa receptor in the initial adherence o f 
staphylococci and streptococci to platelets leading to platelet aggregation (see 
Section 1.4.3.3) (Fitzgerald et al., 2006a, Pampolina & McNicol, 2005). In contrast, 
the platelet receptors involved in interactions with all o f the other organisms, 
including enterococci, isolated from cases o f infective endocarditis in the current 
study have not yet been identified (Fitzgerald et al., 2006a, Usui et al., 1991a). The 
GPIIIa p iA1/AI genotype also correlated with increased platelet activation in patients 
with infective endocarditis but not healthy volunteers, suggesting that platelet 
activation in infective endocarditis may be directly related to the interaction between 
pathogenic bacteria and polymorphic platelet receptors in vivo under high shear
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conditions (Fitzgerald et al., 2006a). The negative correlation between the p iAI/AI 
genotype and risk o f embolic phenomena may also be explained by the increased 
bacterium-induced platelet aggregation observed with this genotype in vitro, which 
could result in the formation o f less mobile and friable vegetations that are less likely 
to embolise (Di Salvo et al., 2001, Thuny et al., 2005). Admittedly, these 
correlations may no longer be present on analysis o f larger study populations.
Although the GPIIIa p iA1/A2 polymorphism correlated with platelet activation and 
causative organism in patients with infective endocarditis, there was no correlation 
between genotype and susceptibility to infective endocarditis, consistent with studies 
that have examined the role o f this polymorphism in thrombotic disease and 
intravascular device infection (Di Castelnuovo et al., 2001, Meisel et al., 2004, 
M usher et al., 2002). These data indicate that the GPIIIa P1AI/A2 polymorphism does 
not represent a risk factor for the development o f infective endocarditis, but may be a 
predictor o f  causative organism in affected patients.
5.4.2 Effects of the GPIb Kozak sequence polymorphism on S. aureus- 
platelet interactions and outcome in infective endocarditis
The platelet GPIb receptor is implicated in S. aureus-platelet adhesion under high 
shear (Fitzgerald et al., 2006a, George et al., 2006) and polymorphisms o f this 
receptor may influence the development o f S. aureus-induced platelet aggregation.
With the use o f PRP, the GPIb Kozak sequence T/T genotype was associated with 
more rapid S. aureus-induced platelet aggregation but reduced percentage 
aggregation on univariate analysis. These findings indicate that the polymorphism 
may influence different stages o f platelet aggregation, particularly as the lag time is 
considered to be a composite o f the time taken for S. awrews-platelet adhesion and 
platelet activation to occur, while percentage aggregation represents the capacity o f 
fibrinogen to cross-link host GPIIb/IIIa platelet receptors. However, GPIb Kozak 
sequence genotype did not influence S. awrei/^-platelet adhesion or activation,
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possibly due to the small study population and the static nature o f these assays. 
Furthermore, the Kozak sequence polymorphism did not influence platelet 
aggregation on multivariate analysis or when using washed platelets, suggesting that 
its effects may be mediated via other platelet receptor polymorphisms, for example 
GPIIIa p iA1/A25 or influenced by plasma protein (e.g. vWF) concentration.
These observations are consistent with a study which found the T/T genotype to be 
associated with increased platelet plug formation in vitro (Jilma-Stohlawetz et al., 
2003). In the current study, there was no correlation between GPIb Kozak sequence 
genotype and platelet aggregation induced by ristocetin, a pharmacological agonist 
which is known to induce platelet aggregation via vWF binding to GPIb, although 
this association has never previously been determined.
The Kozak sequence polymorphism did not influence the development o f  infective 
endocarditis, but there were trends towards increased heart failure in those with a C 
allele. Previous studies have identified increased risk o f ischaemic heart disease, 
stroke and intravascular device infection in individuals with a C allele (Baker et al., 
2001, Kenny et al., 2002, Musher et al., 2002), which may exert its effects via 
increased platelet surface expression o f the GPIb receptor (Afshar-Kharghan et al., 
1999).
5.4.3 Effects of the GPIb HPA-2 polymorphism on S. aureus-platelet 
interactions and outcome in infective endocarditis
There were no significant correlations between FIPA-2 genotype and S. aureus- or 
ristocetin-induced aggregation o f platelets in PRP, consistent with studies which did 
not identify correlations between HPA-2 genotype and vWF or ristocetin binding or 
platelet plug formation in vitro (Jilma-Stohlawetz et al., 2003, Li et al., 2000a). 
Given these negative findings, further studies determining S. awrews-platelet 
adhesion, activation and aggregation o f washed platelets were not performed.
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Prevalence o f  HPA-2 alleles did not vary between the general healthy population and 
patients with infective endocarditis, consistent with studies that have failed to 
demonstrate a correlation between the HPA-2 polymorphism and the development o f 
thromboembolic disease (Meisel et al., 2004, Ozelo et al., 2004b). However, the 
HPA-2a/2a genotype was associated with increased incidence o f the composite 
clinical end-point o f embolism, heart failure, need for surgery and mortality, 
indicating that this genotype may represent a risk factor for adverse outcome in 
infective endocarditis. However, the results o f this study need to be interpreted with 
caution due to the limited study population size.
5.4.4 Effects of the GPIb VNTR polymorphism on S. aureus-platelet 
interactions and outcome in infective endocarditis
There was increased S. aureus- and ristocetin-induced aggregation o f platelets 
heterozygous for a D allele, consistent with previous studies that identified 
associations o f the C/D genotype with platelet plug formation (Jilma-Stohlawetz et 
al., 2003) and the development o f MI or intravascular device infection (M usher et 
al., 2002, Ozelo et al., 2004b). A possible mechanism for the pro-aggregatory 
effects o f  the D allele includes closer proximity o f the GPIb receptor to the platelet 
surface, facilitating platelet aggregation. Given the small number o f individuals with 
D alleles in the current study, the effects o f GPIb VNTR genotype on aggregation o f 
washed platelets, S. awrews-platelet adhesion or activation in vitro were not 
characterised. A larger study population will be required to ascertain whether the 
VNTR D allele influences S. aureus-platelet interactions, particularly under high 
shear conditions.
Prevalence o f VNTR alleles did not predict the development o f  infective 
endocarditis, consistent with observations from studies examining vascular disease 
(Baker et al., 2001, Cadroy et al., 2001, Carter et al., 1998, Kenny et al., 2002). In 
contrast to aggregation studies, presence o f a B allele was significantly associated 
with vegetation development in patients with infective endocarditis, while all
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patients who developed embolic complications had the C/C genotype. The pro- 
aggregatory role o f B or C alleles has been identified in other studies (Gonzalez- 
Conejero et al., 1998, Mikkelsson et al., 2001).
5.4.5 Effects of the FcyRlla H131R polymorphism on S. aureus-platelet 
interactions and outcome in infective endocarditis
The FcyRIIa receptor plays a central role in S. aureus-induced platelet activation 
(Fitzgerald et al., 2006a). An association o f the FcyRIIa HI 31 allele with increased 
S. aureus-induced platelet aggregation was identified in the current study. 
However, these findings were not reproduced in studies using washed platelets, 
suggesting that the effects o f the H131R polymorphism may be influenced by 
plasma components, such as IgG, which cross-links with the FcyRIIa receptor to 
induce platelet activation (Fitzgerald et al., 2006a). Alternatively, the small study 
population may have been a limiting factor in washed platelet studies.
The data generated with PRP in the current study are consistent with other platelet 
studies which have demonstrated increased binding o f the H I31 FcyRIIa platelet 
receptor to human IgG2 and IgG 3, accounting for the increased S. aureus-platelet 
interactions observed with this allele in the current study (Chen et al., 2003, van der 
Pol & van de Winkel, 1998). However, Chen et al did not identify any increase in 
platelet aggregation with the H I31 allele (Chen et a l ,  2003). A previous study by 
McNicol et al failed to identify a correlation between FcyRIIa H I3 1R genotype and 
ability o f S. sanguinis strains to induce platelet aggregation in vitro, but they were 
limited by a small study population o f 14 donors (McNicol et al., 2006).
Baseline platelet activation in the current study did not vary with FcyRIIa H131R 
genotype, similar to observations by Chen et al (Chen et al., 2003). Consistent with 
observations from in vitro studies, all patients who suffered heart failure, relapse, 
recurrence or mortality carried an H I31 allele, but this was not statistically 
significant.
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Prevalence o f H131R alleles in patients with infective endocarditis was similar to 
healthy volunteers, consistent with studies analysing invasive pneumococcal or 
meningococcal disease and coronary artery disease (Brouwer et al., 2009, Karakas 
et al., 2009). The role o f the FcyRIIa receptor in sepsis is complex as it is also 
expressed on the surface o f leucocytes and plays a central role in the recognition o f 
opsonising antibody leading to phagocytosis (Bredius et al., 1993, van der Pol & 
van de Winkel, 1998). Furthermore, the H131 allele has been associated with 
increased phagocytosis o f encapsulated organisms and S. aureus (Bredius et al.,
1993, Sanders et al., 1995). Thus, the apparent pro-aggregatory role o f the FcyRIla 
H I31 allele identified in vitro, may be counteracted to an extent by its importance 
in innate immune defence, which could account for the protective effect o f the 
homozygote state on need for surgery in this study.
5.4.6 Multivariate analysis of the role of platelet receptor 
polymorphisms in S. aureus-platelet interactions
Although most o f  the polymorphic platelet receptors had an influence on S. aureus- 
induced platelet aggregation in the current study, statistical significance may have 
been exaggerated by the multiple comparisons performed on univariate analysis. It is 
feasible that some o f these correlations were identified as a chance finding amongst 
multiple assessed variables. In order to address these issues, multivariate analysis o f 
the results obtained from PRP aggregation studies was conducted. The same could 
not be done for results obtained from washed platelet, flow cytometric or patient 
studies due to small population sizes.
On multivariate analysis, the GPIIIa P1AI, VNTR D and FcyRIIa H I31 alleles were 
significantly associated with increased platelet aggregation. In addition, there was an 
interactive effect o f the GPIIIa P1A1/A2 and GPIb Kozak sequence polymorphisms on 
S. aureus-induced platelet aggregation. Specifically, time to aggregation was 
reduced in platelets with the P1AI/AI genotype, P1A,/A2 and Kozak sequence T/T 
genotype or P1A2/A2 platelets carrying the Kozak sequence T/C genotype.
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The possible mechanisms for this interaction can be examined by understanding 
platelet receptor interactions at the molecular level. vWF binding to GPIb and 
clustering o f the GPIb receptor increase GPIIb/IIIa ligand-binding affinity via 
increased ‘inside-out’ signalling, mediated by calcium oscillations and 
phosphorylation o f kinases (Arya et al., 2003, Kasirer-Friede et al., 2004, Kasirer- 
Friede et al., 2002). Furthermore, the ability o f GPIb to bind vWF results in 
increased availability o f the GPIIb/IIIa receptor to bind fibrinogen alone, potentiating 
thrombus formation (Wu et al., 2000). It therefore appears that there is a synergistic 
effect between these two platelet integrin receptors, but the mechanisms by which 
they are influenced by platelet receptor polymorphisms are unknown. It can be 
speculated that increased platelet plug formation with the Kozak sequence T/T 
genotype may enhance activation o f GPIIIa P1AI/A2 platelets, while increased surface 
expression o f the GPIb receptor conferred by the Kozak sequence C allele may 
facilitate ligand-binding to piA2/A2 platelets.
Additive effects o f polymorphisms have been observed in other studies. GPIIIa 
P1AI/A2 and GPIa/IIa receptor polymorphisms together represent risk factors for the 
development o f  arterial thrombosis in patients with primary or secondary anti­
phospholipid syndrome (Jimenez et al., 2008). In addition, Saidi et al, identified 
correlations between the presence o f variant alleles in GPIIIa p iAI/A2? GPIb HPA-2 
and GPIIb/IIIa HPA-3 and the development o f ischaemic stroke in a large study 
(Saidi et al., 2008). Iniesta et al determined that combinations o f  polymorphisms o f 
GPIIIa piA1/A2 and GPIb HPA-2 influenced the development o f subarachnoid 
haemorrhage (Iniesta et al., 2004). However, this is the first time that an interactive 
effect between GPIIIa piA,/A2 and GPIb Kozak sequence polymorphisms has been 
observed. It will be important to determine whether these interactive effects are 
present with larger study populations o f healthy volunteers for in vitro studies, as 
well as clinical outcome in patients with infective endocarditis.
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5.4.7 Conclusions
In summary, the GPIIIa P1A1, VNTR and FcyRIIa H I31 alleles are associated with 
enhanced S. aureus-platelet interactions and adverse outcome in infective 
endocarditis. Furthermore, the HPA-2a/2a genotype was associated with increased 
development o f the composite clinical end-point o f embolism, heart failure, need for 
surgery and mortality in infective endocarditis
However, there were limitations to the current study. Some o f the observations from 
PRP aggregation studies were not reproduced in washed platelet studies, possibly 
due to the small study population in the latter cohort. Population size also limited the 
ability to conduct multivariate analysis on acquired data. The contrasting findings 
regarding the role o f GPIb polymorphisms in vitro and in vivo in the current study 
highlight the drawbacks o f using a low shear system for functional platelet assays, 
particularly as the GPIb receptor has been implicated in S. aureus-platelet 
interactions under high shear conditions (George et al., 2006, Pawar et a i ,  2004). 
High shear assays, such as those outlined in Section 3.4.5 may help to further 
characterise the influence o f platelet receptor polymorphisms on S. aureus-induced 
platelet aggregation.
Nevertheless, this study has identified that platelet receptor polymorphisms may be a 
determinant o f S. aureus-platelet interactions in vitro and outcome in infective 
endocarditis. These observations merit further investigation with large numbers o f 
patients with infective endocarditis, to determine the role o f platelet receptor 
polymorphisms as prognostic markers in bacteraemia and infective endocarditis. 
Given these observations, anti-platelets targeting the GPIIb/IIIa, GPIb and FcyRIIa 
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This aim o f this research was to determine the influence o f selected host-pathogen 
interactions on susceptibility to infective endocarditis. Specifically, the objectives 
were to analyse the effect o f S. aureus growth in blood on platelet aggregation in 
vitro, the correlation between platelet activation levels in vivo and the development 
o f infective endocarditis and the influence o f platelet receptor polymorphisms on S. 
aureus-induced platelet aggregation and outcome in infective endocarditis. Figure 
6.1 depicts the host and bacterial factors investigated in the current research and their 
impact on the various stages o f S. m/rew,v-platelet interactions contributing to the 
pathogenesis o f infective endocarditis. The implications o f these findings are 
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6.2 Host-pathogen interactions influence susceptibility to and 
outcome in infective endocarditis
This research demonstrates that S. aureus-induced platelet aggregation does not 
predict the development o f infective endocarditis, that platelet receptor genotype is 
associated with clinical outcome in infective endocarditis and that in vivo platelet 
activation inversely correlates with the development o f infective endocarditis and 
associated complications. Collectively, these data suggest that the pathogenesis and 
outcome o f infective endocarditis may be more dependent on host factors than the 
bacterial factors investigated in the current study.
The fact that S. aureus-induced platelet aggregation did not correlate with the 
capacity o f strains to cause infective endocarditis in humans, suggests that the 
development o f S. aureus infective endocarditis may instead have a greater 
dependence on bacterial platelet microbicidal protein (PMP)-resistance, which has 
been demonstrated to correlate with the development o f staphylococcal and 
streptococcal infective endocarditis (Wu et al., 1994). Alternatively, host factors 
such as variation in innate immunity, plasma protein concentration, platelet-specific 
factors and underlying endothelial damage may have a more profound influence on 
the outcome o f bacterium-platelet interactions (Brouwer et al., 2009, Feng et al., 
2001, Meisel et al., 2004, van der Pol & van de Winkel, 1998).
Consistent with this theory, host factors examined in the current study correlated 
with adverse outcome in infective endocarditis. Specifically, platelet receptor 
genotype was associated with S. aureus-induced platelet aggregation in vitro and the 
development o f complications in patients with infective endocarditis. However, 
platelet receptor polymorphisms did not predict the development o f infective 
endocarditis, suggesting that polymorphic platelet receptors solely correlate with 
outcome in infective endocarditis, while other host factors influence susceptibility to 
infective endocarditis.
2 2 0
In this study, reduced in vivo platelet activation, likely representing the outcome o f 
bacterium-platelet interactions in the host, correlated with the development o f 
infective endocarditis. In contrast, platelet activation was increased in patients 
requiring valve replacement for infective endocarditis. These discrepant findings are 
most likely due to the variable timing o f patient recruitment and the small study 
population sizes. However, these observations are also consistent with the dual role 
o f  platelets, which are known to interact with bacteria leading to vegetation 
formation in infective endocarditis, while also contributing to host innate immunity 
(Fitzgerald et al., 2006a, Yeaman, 1997). It can be speculated that the presence o f 
reduced platelet activation in patients with infective endocarditis may lead to 
decreased PMP release, reducing innate immunity and increasing the risk o f 
developing infective endocarditis. Conversely, the association o f increased platelet 
activation and polymorphic platelet receptors with bacterium-induced platelet 
aggregation and clinical outcome in patients with infective endocarditis, suggests 
that platelets may predominantly contribute to thrombosis in the later stages o f  the 
disease process.
Temporal adaptation o f the role o f platelets in infective endocarditis may be due to 
fluctuation in the dynamics o f host-pathogen interactions, such as variation in the 
bacterium:platelet ratio during the course o f disease (Trier et al., 2008). 
Alternatively, the institution o f antimicrobial therapy, which enhances host immunity 
and in some cases alters platelet count and function, may account for variable platelet 
function in infective endocarditis (Rohmann et al., 1997, Von Drygalski et al., 2007). 
Either way, it appears that platelets play a complex role in the pathogenesis o f 
infective endocarditis, which may account for the failure o f aspirin to consistently 
reduce embolism and mortality in clinical trials o f infective endocarditis (Chan et al., 
2003, Chan et al., 2008, Eisen el al., 2009, Pepin et al., 2009). It is feasible that the 
benefits o f anti-platelet therapy in infective endocarditis may depend upon the 
presence o f  underlying host risk factors or the stage o f the disease process.
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6.3 Novel therapeutic approaches targeting host-pathogen 
interactions in infective endocarditis
In addition to conventional treatment modalities, such as antibiotics, valve 
replacement or repair (Habib et al., 2009), these results highlight the potential benefit 
o f  additional therapeutics in infective endocarditis. Such treatments should focus on 
targeting different stages and factors predisposing to infective endocarditis, with 
specific aims to prevent the development o f infective endocarditis and reduce 
complication rates.
M inimisation o f  complication rates in infective endocarditis may result from 
therapeutics that inhibit bacterium-platelet interactions at later stages o f  the disease 
process. Although the potential benefits o f aspirin therapy in infective endocarditis 
have been evaluated, the results from clinical trials have been disappointing and 
inconclusive, largely due to small study populations and the retrospective nature o f 
such studies (see Section 1.7.2). Future studies should examine the clinical efficacy 
o f  both short- and long-term aspirin therapy in large, multi-centre, randomised 
controlled trials.
A number o f in vitro studies have demonstrated that antibodies against GPIIb/IIIa, 
GPIb and FcyRIIa platelet receptors inhibit staphylococcal- and streptococcal- 
induced platelet activation and aggregation (Fitzgerald et ah, 2006b, Kerrigan et ah, 
2002, O 'Brien et ah, 2002a, Sjobring et ah, 2002), but it is not known whether they 
have a role in the treatment o f infective endocarditis in animal models or in humans. 
However, GPIIb/IIIa antagonists are extensively used in the treatment o f  thrombosis 
in acute coronary syndromes, myocardial infarction and post-percutaneous coronary 
intervention (Tricoci & Peterson, 2006), while anti-GPIb monoclonal antibodies 
significantly reduced infarct size and improved functional outcome in an 
experimental animal model o f cerebrovascular disease (Kleinschnitz et al., 2007). It 
is feasible that anti-platelets targeting the GPIIb/IIIa, GPIb and FcyRIIa receptors 
may also reduce the severity o f infective endocarditis and their therapeutic potential 
should be explored in multi-centre clinical trials. However, the efficacy o f anti­
2 2 2
platelet therapy in infective endocarditis may depend upon underlying host platelet 
receptor genotype.
Pharmacogenetics, or the influence o f genetic variation on response to drug therapy, 
is a recently identified phenomenon, illustrated by the influence o f  platelet receptor 
genotype on anti-platelet efficacy (Topol, 2008). GPIIIa P1A1 carriers are more 
sensitive to the effects o f GPIIb/IIIa receptor antagonists, clopidogrel and aspirin 
than GPIIIa P1A2/A2 individuals (Feher et al., 2009, M otovska et al., 2009), and as 
increased S. aureus-induced platelet activation and aggregation has been identified in 
P1A1/A1 platelets, it can be speculated that use o f anti-platelets in patients carrying this 
genotype may improve outcome in infective endocarditis. In addition, aspirin 
sensitivity is increased in GPIb VNTR C/C patients with cerebrovascular disease (Jin 
et al., 2009). Considering that patients with infective endocarditis carrying VNTR C 
alleles were more likely to develop emboli in the current study, these individuals 
may derive greater benefit from aspirin therapy. Furthermore, three human 
monoclonal antibodies against FcyRJIa bind more avidly to the H131 form o f 
FcyRIIa than the R131 form, and may prevent platelet activation, aggregation and 
minimise adverse outcome in patients with infective endocarditis (Bachelot et al., 
1995). Pharmacogenetics may account for the variable effects o f aspirin on clinical 
outcome in patients with infective endocarditis (Chan et al., 2003, Chan el al., 2008, 
Eisen et al., 2009, Pepin et al., 2009), and it is feasible that determination o f platelet 
receptor genotype in patients with infective endocarditis could help identify those 
that would derive the greatest benefit from tailored anti-platelet therapy.
The prevention o f infective endocarditis and minimisation o f related complications 
may also involve enhancement o f innate immunity with immunomodulatory drugs or 
vaccines (Ballow & Nelson, 1997). Although the ability o f S. aureus strains to 
induce platelet aggregation in vitro did not correlate with disease causation in the 
current study, the ability of bacteria to interact with platelets is likely to contribute to 
vegetation formation, which may ultimately influence clinical outcome in infective 
endocarditis. The capacity o f FnBPs to mediate platelet aggregation following S. 
aureus growth in blood suggests that they may represent therapeutic targets in
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infective endocarditis. Current vaccines against S. aureus capsule and ClfA have 
been unsuccessful in clinical trials o f S. aureus infection (Schaffer & Lee, 2008). 
Anti-FnBP antibodies reduce bacterial vegetation densities in rat models o f infective 
endocarditis (Rennermalm et al., 2001, Schennings et al., 1993), and vaccination o f 
mice with the A domains o f FnBPA and ClfA reduces aortic patch infection 
(Arrecubieta et al., 2008), but their ability to prevent disease in humans is unknown. 
Unfortunately, development o f functional monoclonal antibodies against FnBPs has 
proven to be a challenge, partly due to sequence diversity o f the A domain, resulting 
in antigenic variation (Loughman et al., 2008). Furthermore, although the 
fibronectin-binding D domains are largely conserved in FnBPs, they have low 
immunogenicity when unbound, as an immunogenic neoepitope is only formed after 
M SCRAM M  adherence to fibronectin, resulting in the formation o f the ligand- 
induced binding site that is recognised by antibodies (Casolini et al., 1998, Flock, 
1999, Sinha & Flerrmann, 2005). The dependence on a ligand-induced binding site 
for monoclonal antibody binding to FnBPs may limit vaccine efficacy.
The benefits o f  antibiotic prophylaxis in infective endocarditis have recently been 
questioned in national and international guidelines, primarily due to the lack o f 
convincing evidence to date (Habib et al., 2009, National Institute for Health and 
Clinical Excellence, 2008). Cardiologists and dentists have attempted to implement 
these new guidelines, often with inconsistency and judicious use on a case-by-case 
basis, resulting in confusion for patients and clinicians alike. Given the results from 
the current study, and the ability o f antimicrobials to interfere with bacterial gene 
transcription and platelet function (see Section 1.7.1) (Smith et al.), it can be 
speculated that in addition to their bacteriocidal and bacteriostatic effects, 
prophylactic antibiotics may also interfere with bacterium-platelet interactions that 
culminate in vegetation formation. The potential benefits o f prophylactic 
antimicrobials may also vary with underlying host susceptibility such as the presence 
o f  valvular heart disease or platelet receptor polymorphisms. Following the change 
in local and international guidelines on antibiotic prophylaxis for infective 
endocarditis, several large national observational studies have been organised to
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determine whether this influences the course o f infective endocarditis (Habib et al., 
2009).
6.4 Future perspectives
Future studies should aim to expand on findings from this research and investigate 
other host and pathogen factors that potentially influence susceptibility to infective 
endocarditis (Figure 6.2). For example, platelet receptor polymorphisms may 
influence Staphylococcus- and Streptococcus-platelet interactions under high shear. 
Furthermore, host characteristics such as polymorphisms o f immune system 
components (e.g. toll-like receptors, complement factors and cytokines), variation in 
coagulation and fibrinolytic cascade components (e.g. polymorphisms o f 
plasminogen activator, factor V and protein C), platelet receptor density, plasma 
protein concentration, PMP and IgG titres (Figure 6.2A-E) may modulate the 
outcome o f bacterium-platelet interactions in infective endocarditis (Brouwer et al., 
2009, Dankert et al., 2001, Feng et al., 2001, Foster, 2005, O 'Halloran et al., 2006). 
I f  these factors are found to influence the development o f infective endocarditis, this 
could result in the advent o f treatment modalities such as synthetic cytokine or 
complement analogues, monoclonal antibodies, and the use o f anti-thrombotic or 
fibrinolytic agents in the management o f infective endocarditis (Ballow & Nelson, 
1997, Kleinschnitz et al., 2007, Tricoci & Peterson, 2006).
It is important to remember that like platelets, host antibodies may either contribute 
to or inhibit the pathogenesis o f infective endocarditis. Although binding o f  host 
antibodies against MSCRAMMs to the platelet FcyRIIa receptor facilitates platelet 
aggregation (see Figure 1.7), higher antibody titres may facilitate bacterial 
opsonisation in addition to blocking MSCRAMM ligand-binding sites, preventing 
platelet activation (Fitzgerald et al., 2006a, Ford et al., 1997, Sjobring et a l ,  2002, 
Sullam et al., 1988). Furthermore, IgG levels may vary with FcyRIIa H 131R platelet 
receptor genotype, particularly as the H I31 allele has been demonstrated to bind 
human IgG2 and IgG3 with greater affinity (van der Pol & van de Winkel, 1998). It is
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o f paramount importance to determine whether host IgG titres influence S. aureus- 
induced platelet activation, aggregation and the pathogenesis o f  infective 
endocarditis, as this may influence the therapeutic potential o f vaccines against host 
and bacterial components in infective endocarditis.
Future research should also investigate the bacterial factors influencing pathogen 
survival and vegetation formation following bacterial growth in human blood. For 
example, the effect o f growth medium on clfA gene transcription observed in this 
study may extend to other bacterial genes, including those encoding components 
mediating platelet and (sub)-endothelium interactions, tissue invasion and 
destruction, coagulation, nutrient acquisition and evasion o f host innate immunity 
(Figure 6.2F-J). I f  specific bacterial factors are found to be essential for bacterial 
survival or the pathogenesis o f infective endocarditis, novel therapeutics involving 
passive or active immunisation against those components may dramatically improve 
the outcome o f bacteraemia and infective endocarditis.
It is clearly a priority to elucidate the dynamic interactive effects o f  host and 
bacterial components that facilitate bacterial survival in the human host, microbial 
colonisation and invasion o f host valvular tissue, and vegetation formation (Figure 
6.2). For example, the outcome o f interactions between host innate immunity and 
bacterium evasion o f innate defences, exemplified by the interplay o f host platelet 
PMP release and bacterium PMP-resistance (Figure 6.2E-F), may determine the 
outcome o f  bacteraemia. However, such experiments should be performed under 
conditions mimicking those present in vivo, which can be achieved by analysing 
bacterium-platelet-(sub)-endothelium interactions using bacteria grown in blood, 




Rat or rabbit models are often seen as ‘gold standard’ models o f infective 
endocarditis, but do not accurately reflect the human in vivo state. For example, 
animal models routinely involve catheterisation to facilitate artificial induction o f 
valvular endothelial damage, which enables formation o f a sterile thrombus that is 
subsequently infected by bacteria at a high concentration (Piroth et al., 2008, Siboo 
et al., 2005). However, the precise dynamics and timing o f bacterium-platelet-sub- 
(endothelium) interactions contributing to vegetation formation in infective 
endocarditis are still not fully understood (see Section 1.4.3). The structure o f 
cardiac valves also varies amongst different mammals and in comparison to the 
human heart, the rabbit heart has a thinner and shorter intervalvular septum 
(W almsley, 1978). Furthermore, not all animals spontaneously acquire valvular 
heart disease that would otherwise predispose to infective endocarditis in humans 
(Donnelly, 2008). Human platelets also take longer to aggregate in response to S. 
sanguinis than rat or rabbit platelets (Manning et al., 1994), and have been reported 
to release different PMPs as compared to rabbit platelets (Tang et al., 2002).
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6.5 Conclusion
S. aureus infective endocarditis is a life-threatening condition and an urgent public 
health issue. The identification o f contributing host and bacterial factors is crucial to 
enable the development o f novel therapeutics against infective endocarditis. Taken 
together, the results o f this research suggest that the host factors investigated in the 
current study may be o f greater importance than the investigated bacterial factors in 
determining susceptibility to and prognosis in infective endocarditis, as host platelet 
activation and platelet receptor genotype correlated with disease development and 
severity in infective endocarditis. Furthermore, it appears that platelets play a dual 
role in infective endocarditis, which may limit the efficacy o f anti-platelet therapy.
This research has highlighted the necessity o f a unified understanding o f the 
interaction o f  host and bacterial components in the development o f infective 
endocarditis. Such integrated studies will enhance our knowledge o f  the factors 
influencing the pathogenesis o f infective endocarditis, with major implications for 
patient screening and the development o f novel prophylactics and therapeutics 
against this fatal condition.
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Table S5.1. Association of GPIIIa p|A1/A2 genotype with lag time to S.
aureus-induced platelet aggregation.
S. aureus strain GPIIIa P1A1/A2 genotype
and growth
phase A l/A l A1/A2 A2/A2 P value
Newman, 1.92 ± 0 .65  min 1.83 ± 0 .4 7  min 2.63 ± 1.25 min 0.451
stationary
209, stationary 8.60 ± 3.51 min 12.44 ± 7 .28  
min
6.08 ± 1.41 min 0.743
Newman, 6.07 ± 1.41 min 6.60 ± 1.26 min 6.92 ± 1.03 min 0.060
exponential
207, exponential 9.19 ± 3.36 min 9.11 ± 3.62 min 8.31 ± 5 .1 4  min 0.868
209, exponential 1.94 ± 0.64 min 1.84 ± 0 .5 0  min 3.13 ± 1.82 min 0.377
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Table S5.2. Association of GPIIIa p|A1/A2 genotype with rate of platelet
aggregation induced by S. aureus and pharmacological agonists.
Agonist A l/A l
GPIIIa P1A1/A2 genotype 
A1/A2 A2/A2 P value
Newman, 3 4 ±  13 3 7 ±  10 35 ± 14 0.520
stationary
209, stationary 17 ± 5 15 ± 5 13 ± 8 0.709
Newman, 17 ± 7 15 ± 9 20 ± 12 0.481
exponential
207, exponential 11 ± 6 13 ± 5 13 ± 6 0.392
209, exponential 29 ± 12 30 ± 11 26 ± 12 0.646
ADP 47 ± 13 49 ± 12 38 ± 10 0.154
Ristocetin 3 9 ±  12 44 ± 11 51 ± 14 0.146
s f l l r n -n h 2 5 9 ±  14 62 ± 19 68 ± 14 0.395
Only results where platelet aggregation was induced are included
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Table S5.3. Association of GPIIIa p|A1/A2 genotype with maximal 
percentage platelet aggregation induced by S. aureus and 
pharmacological agonists.
Agonist A l/A l
GPIIIa P1A1/A2 genotype 
A1/A2 A2/A2 P value
Newman, 67 ± 10% 69 ± 7 % 66 ± 2 % 0.914
stationary
209, stationary 68 ± 8 % 64 ± 10% 63 ± 33 % 0.060
Newman, 69 ± 12% 60 ± 19% 76 ± 7 % 0.106
exponential
207, exponential 66 ± 15 % 66 ± 13 % 70 ± 16% 0.515
209, exponential 63 ± 9 % 63 ± 14% 67 ± 4 % 0.461
ADP 69 ± 12 % 74 ± 12 % 70 ± 6 % 0.153
Ristocetin 81 ± 7 % 81 ± 8 % 81 ± 10% 0.955
s f l l r n -n h 2 68 ± 12 % 69 ± 13 % 69 ± 7 % 0.929
Only results where platelet aggregation was induced are included
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Table S5.4. Association of GPIIIa p|A1,A2 genotype with lag time to S.
aureus-induced aggregation of washed platelets.
S. aureus strain GPIIIa P1A1/A2 genotype
and growth
phase A l/A l A1/A2 A2/A2 P value
Newman,
stationary
3.00 ±  0.90 min 2.89 ± 1.26 min 9.21 ±  10.56 min 0.034
209, stationary 10.20 ± 8.73  
min
9.10 ± 9.18 min 13.66 ± 7.88 min 0.342
Newman,
exponential
8.65 ± 8.02 min 9.05 ± 9 .1 6  min 21.01 ± 7 .9 9  min 0.059
207, exponential 25 min * 19.24 ± 8 .78  
min
22.93 ± 4 .1 4  min 0.047
209, exponential 7.74 ±  5.48 min 8.74 ±  7.43 min 16.32 ±  10.10 
min
0.176
* Absence of platelet aggregation
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Table S5.5. Association of GPIIIa p|A1/A2 genotype with rate of S.
aureus-induced aggregation of washed platelets.
Agonist A l/A l
GPIIIa PIA1/A2 genotype 
A1/A2 A2/A2 P value
Newman, 50 ± 13 50 ± 13 46 ± 10 0.817
stationary
209, stationary 29 ± 13 41 ± 9 19 ±  18 0.042
Newman, 22 ± 13 29 ± 14 N/A 0.505
exponential
209, exponential 28 ± 12 29 ± 12 34 ±  14 0.778
ADP 30 ± 2 4 30 ± 17 17 ± 18 0.533
Ristocetin 2 8 ±  11 26 ± 6 23 ± 5 0.500
s f l l r n -n h 2 52 ± 2 5 61 ± 18 79 ± 5 1 0.374
Only results where platelet aggregation was induced are included
245
Table S5.6. Association of GPIIIa p|A1/A2 genotype with percentage S.
ai/rei/s-induced aggregation of washed platelets.
Agonist A l/A l
GPIIIa p iA1/A2 genotype 
A1/A2 A2/A2 P value
Newman, 82 ± 4 % 80 ± 6 % 78 ± 5 % 0.431
stationary
209, stationary 73 dz 12% 77 ± 7 % 73 ± 17% 0.601
Newman, 66 ± 16% 75 ± 6 % N/A 0.408
exponential
209, exponential 71 ± 12% 72 ± 8 % 75 ± 1 % 0.928
ADP 29 ± 20 % 36 ± 17% 12 ± 16% 0.062
Ristocetin 67 ± 7 % 70 ± 7 % 73 ± 6 % 0.273
s f l l r n -n h 2 71 ± 19% 75 ± 5 % 64 ± 22 % 0.622
Only results where platelet aggregation was induced are included
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Table S5.7. Association of GPIIIa p|A1/A2 genotype with percentage of
platelets bound to S. aureus.
S. aureus strain 
and growth 
phase A l/A l
GPIIIa P1A,/A2 genotype 
A1/A2 A2/A2 P value
Newman, 84 ± 21  % 85 ± 26 % 91 ± 8 % 0.928
stationary
209, stationary 86 ± 22 % 86 ± 23 % 92 ± 8 % 0.989
Newman, 58 ± 27 % 53 ± 26 % 70 ± 3 1  % 0.516
exponential
207, exponential 78 ± 25 % 74 ± 28 % 77 ± 20 % 0.745
209, exponential 57 ± 25 % 52 ± 28 % 58 ± 19 % 0.808
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Table S5.8. Association of GPIIIa p|A1/A2 genotype with percentage of S.
aureus cells bound to platelets.
.S', aureus strain 
and growth 
phase A l/A l
GPIIIa P1A,/A2 genotype 
A1/A2 A2/A2 P value
Newman, 49 ± 10% 44 ± 15 % 56 ± 9 % 0.318
stationary
209, stationary 44 ± 12% 38 ± 12% 48 ± 12% 0.257
Newman, 22 ± 12% 18 ± 11 % 25 ± 8 % 0.508
exponential
207, exponential 24 ± 10% 21 ± 8 % 23 ± 3 % 0.566
209, exponential 18 ± 11 % 14 ±  7 % 17 ± 3  % 0.669
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Table S5.9. Association of GPIIIa p|A1/A2 genotype with absolute levels
of P-selectin expression induced by S. aureus and SFLLRN-NH2.
Agonist A l/A l
GPIIIa P1A1/A2 genotype 
A1/A2 A2/A2 P value
Newman, 55 ± 29 % 49 ± 25 % 43 ± 33 % 0.842
stationary
209, stationary 26 ± 11 % 18 ± 11 % 24 ± 6 % 0.191
Newman, 36 ± 20 % 40 ± 19% 31 ±  16% 0.709
exponential
207, exponential 24 ± 15 % 18 ± 12% 25 ± 11 % 0.562
209, exponential 28 ± 17% 20 ± 12% 21 ± 4 % 0.282
s f l l r n -n h 2 82 ± 14% 83 ± 6 % 78 ± 14% 0.730
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Table S5.10. Association of GPlb Kozak sequence genotype with lag
time to S. aureus-induced platelet aggregation.
G Plb Kozak sequence genotype
S. aureus strain and
growth phase T/T T/C P value
Newman, stationary 1.94 ±  0.65 min 2.01 ±  0.88 min 0.898
209, stationary 8.79 ± 4.20 min 8.78 ± 3 .1 9  min 0.952
Newman, exponential 6.09 ± 1.37 min 6.65 ± 1.24 min 0.021
207, exponential 9.23 ± 3.33 min 9.20 ± 3.62 min 0.775
209, exponential 2.05 ± 1.01 min 1.99 ± 0.78 min 0.678
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Table S5.11. Association of GPlb Kozak sequence genotype with rate
of platelet aggregation induced by S. aureus and pharmacological
agonists.
Agonist
GPlb Kozak sequence genotype 
T/T T/C P value
Newman, stationary 35 ± 11 3 5 ±  13 0.851
209, stationary 14 ± 6 14 ± 4 0.706
Newman, exponential 17 ± 9 15 ± 6 0.186
207, exponential 12 ± 6 12 ± 5 0.613
209, exponential 29 ± 12 30 ± 11 0.494
ADP 47 ± 11 48 ± 14 0.914
Ristocetin 40 ± 12 41 ± 12 0.988
s f l l r n -n h 2 61 ± 16 60 ± 14 0.978
Only results where platelet aggregation was induced are included
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Table S5.12. Association of GPlb Kozak sequence genotype with
maximal percentage platelet aggregation induced by S. aureus and
pharmacological agonists.
G Plb Kozak sequence genotype
A gonist T/T T/C P value
Newman, stationary 67 ± 8 % 67 ±  10% 0.313
209, stationary 64 ± 12 % 69 ±  8 % 0.033
Newman, 67 ± 16% 67 ± 12% 0.400
exponential
207, exponential 64 ± 17% 66 ±  12 % 0.878
209, exponential 62 ± 10% 63 ±  10 % 0.700
ADP 71 ± 12% 69 ±  13 % 0.911
Ristocetin 82 ±  7 % 80 ±  7 % 0.246
s f l l r n -n h 2 69 ± 12% 65 ± 14 % 0.258
Only results where platelet aggregation was induced are included
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Table S5.13. Association of GPlb Kozak sequence genotype with lag
time to S. aureus-induced aggregation of washed platelets.
GPlb Kozak sequence genotype
S. aureus strain and
growth phase T/T T/C P value
Newman, stationary 4.21 ± 5.15 min 3.08 ± 0.96 min 0.747
209, stationary 9.98 ± 8.36 min 10.95 ± 9 .3 4  min 0.948
Newman, exponential 8.31 ± 7.67 min 14.07 ± 10.59 min 0.328
207, exponential 22.27 ± 6.56 min 24.25 ± 2.49 min 0.536
209, exponential 7.70 ± 5.55 min 11.75 ± 8 .9 4  min 0.332
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Table S5.14. Association of GPlb Kozak sequence genotype with rate
of S. aureus-induced aggregation of washed platelets.
GPlb Kozak sequence genotype 
Agonist T/T T/C P value
Newman, stationary 49 ± 13 51 ±11 0.839
209, stationary 3 0 ±  15 35 ± 12 0.457
Newman, exponential 23 ± 13 27 ± 14 0.417
209, exponential 28 ± 13 30 ± 8 0.956
ADP 25 ±21 38 ± 19 0.059
Ristocetin 26 ± 6 28 ± 13 0.880
s f l l r n -n h 2 54 ± 2 3 66 ± 3 6 0.547
Only results where platelet aggregation was induced are included
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Table S5.15. Association of GPlb Kozak sequence genotype with
maximal percentage S. aureus-induced aggregation of washed
platelets.
Agonist
G Plb Kozak sequence genotype 
T/T T/C P value
Newman, stationary 81 ± 6 % 81 ± 3  % 0.840
209, stationary 72 ± 13 % 78 ± 5 % 0.653
Newman, 69 ± 14% 72 ± 15 % 0.356
exponential
209, exponential 71 ± 13 % 74 ± 3 % 0.911
ADP 30 ± 21  % 26 ± 18% 0.730
Ristocetin 70 ± 7 % 67 ± 6 % 0.244
s f l l r n -n h 2 69 ± 12% 73 ± 8 % 0.490
Only results where platelet aggregation was induced are included
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Table S5.16. Association of GPlb Kozak sequence genotype with
percentage of platelets bound to S. aureus.
GPlb Kozak sequence genotype
S. aureus strain and
growth phase T/T T/C P value
Newman, stationary 86 ±21 % 84 ± 22 % 0.561
209, stationary 88 ± 22 % 85 ± 20 % 0.989
Newman, exponential 61 ± 3 2 % 54 ± 25 % 0.516
207, exponential 80 ± 25 % 72 ± 25 % 0.745
209, exponential 58 ± 28 % 50 ± 16 % 0.808
256
Table S5.17. Association of GPlb Kozak sequence genotype with
percentage of S. aureus bound to platelets.
S. aureus strain and 
growth phase
GPlb Kozak sequence genotype 
T /T  T /C P value
Newman, stationary 47 ± 13 % 50 ± 11 % 0.747
209, stationary 41 ± 13 % 45 ± 11 % 0.401
Newman, 21 ± 13 % 21 ± 8 % 0.813
exponential
207, exponential 23 ± 10% 23 ± 4 % 0.983
209, exponential 17 ± 11 % 17 ± 4 % 0.566
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Table S5.18. Association of GPlb Kozak sequence genotype with 
absolute levels of P-selectin expression induced by S. aureus and
s f l l r n -n h 2.
GPlb Kozak sequence genotype 
Agonist T/T T/C P value
Newman, stationary 49 ± 25 % 57 ± 3 1  % 0.417
209, stationary 24 ± 12% 23 ± 8 % 0.808
Newman, exponential 38 ± 2 0 % 34 ± 18 % 0.776
207, exponential 23 ± 16% 21 ± 8 % 1.000
209, exponential 25 ± 16% 24 ± 12% 1.000
s f l l r n -n h 2 84 ± 8 % 78 ± 16% 0.378
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Table S5.19. Association of GPlb HPA-2 genotype with lag time to S.
aureus-induced platelet aggregation.
S. aureus  strain 
and growth 
phase
G Plb HPA-2 genotype 
2a/2a 2a/2b 2b/2b * P value
Newman, 1.96 ± 0.78 min 1.98 ± 0.62 min 2.41 min 0.603
stationary
209, stationary 8.76 ±  4.14 min 8.97 ± 2 .88  min 6.89 min 0.746
Newman, 6.37 ± 1.36 min 5.96 ± 1.30 min 7.17 min 0.394
exponential
207, exponential 9.10 ± 3 .4 7  min 9.65 ± 3.37 min 9.02 min 0.755
209, exponential 2.01 ± 0.92 min 1.95 ±  0.65 min 2.95 min 0.364
* One individual had the HPA-2b/2b genotype
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Table S5.20. Association of GPlb HPA-2 genotype with rate of platelet
aggregation induced by S. aureus and pharmacological agonists.
Agonist 2a/2a
G Plb HPA-2 genotype 
2a/2b 2b/2b * P value
Newman, 3 5 ±  11 3 4 ±  13 49 0.402
stationary
209, stationary 14 ± 5 15 ± 5 15 0.371
Newman, 16 ± 8 18 ± 9 20 0.261
exponential
207, exponential 12 ± 5 13 ± 6 14 0.577
209, exponential 29 ± 12 28 ± 13 49 0.253
ADP 49 ± 13 43 ±  11 41 0.142
Ristocetin 40 ± 12 42 ± 14 35 0.127
s f l l r n -n h 2 61 ± 15 59 ± 17 65 0.310
* One individual had the HPA-2b/2b genotype
Only results where platelet aggregation was induced are included
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Table S5.21. Association of GPlb HPA-2 genotype with maximal
percentage platelet aggregation induced by S. aureus and
pharmacological agonists.
Agonist 2 a/2 a
G Plb HPA-2 genotype 
2a/2b 2b/2b * P value
Newman, 67 ± 9 % 67 ± 8 % 7 4 % 0.553
stationary
209, stationary 65 ± 11 % 69 ± 9 % 7 7 % 0.304
Newman, 67 ± 15 % 68 ± 11 % 7 0 % 0.883
exponential
207, exponential 64 ± 16% 66 ± 15% 75 % 0.640
209, exponential 62 ± 11 % 66 ± 8 % 6 2 % 0.502
ADP 70 ± 12% 73 ± 13 % 6 7 % 0.354
Ristocetin 81 ± 7 % 80 ± 8 % 7 0 % 0.668
s f l l r n -n h 2 68 ± 12% 68 ± 16% 5 0 % 0.836
* One individual had the HPA-2b/2b genotype
Only results where platelet aggregation was induced are included
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Table S5.22. Association of GPlb variable number of tandem repeat







B/D C/C C/D D/D* P value
Newman, 2.76 1.96 ± 1.88 ± 1.92 ± 2.22 ± 1.22 0.487
stationary min 0.64 min 0.11 min 0.78
min
0.79 min min
209, 9.27 9.05 ± 8.51 ± 8.78 ± 8.46 ± 7.97 1.000
stationary min 2.64 min 4.25 min 4.45
min
2.88 min min
Newman, 8.27 6.17 ± 5.51 ± 6.43 ± 5.81 ± 5.30 0.395
exponential min 1.22 min 1.40 min 1.38
min
1.32 min min
207, 11.26 8.52 ± 13.76 ± 9.18 ± 9.56 ± 9.18 0.725
exponential min 3.25 min 7.23 min 3.51
min
2.49 min min
209, 2.52 1.96 ± 2.00 ± 2.05 ± 1.93 ± 1.22 0.867
exponential min 0.71 min 0.38 min 0.99
min
0.49 min min
* A/D and D/D genotypes were present in one individual each
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Table S5.23. Association of GPlb variable number of tandem repeat
(VNTR) genotype with rate of platelet aggregation induced by S. aureus
and pharmacological agonists.
GPlb VNTR genotype 
Agonist A/D* B/C B/D C/C C/D D/D* P value
Newman,
stationary
22 35 ± 14 46 ± 2 36 ± 11 31 ± 15 34 0.324
209,
stationary
16 15 ± 4 22 ± 4 14 ± 6 13 ±  4 10 0.233
Newman,
exponential
4 19 ± 7 22 ± 18 15 ±  8 17 ± 9 17 0.314
207,
exponential
8 13 ± 6 17 ± 2 11 ± 5 12 ± 6 10 0.282
209,
exponential
19 30 ± 11 47 ± 14 29 ± 12 29 ± 13 30 0.375
ADP 33 43 ± 11 46 ± 3 49 ± 12 47 ± 15 45 0.323
Ristocetin 42 41 ± 13 59 ± 8 40 ± 12 39 ± 9 46 0.382
SFLLRN-
n h 2
46 62 ± 18 5 8 ±  16 62 ± 16 5 5 ±  13 49 0.512
* A/D and D/D genotypes were present in one individual each 
Only results where platelet aggregation was induced are included
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Table S5.24. Association of GPlb variable number of tandem repeat
(VNTR) genotype with maximal percentage platelet aggregation induced
by S. aureus and pharmacological agonists.
Agonist A/D*
G Plb VNTR genotype 
B/C B/D C/C C/D D/D* P
value
Newman, 6 4 % 67 ± 8 % 74 ± 3 68 ± 9 % 62 ± 13 61 % 0.476
stationary % %
209, 7 7 % 68 ± 8 % 83 ± 7 64 ± 12 70 ± 9 % 61 % 0.030
stationary % %
Newman, 43 % 69 ± 9 % 73 ± 14 68 ± 15 61 ±  16 5 4 % 0.104
exponential % % %
207, 6 7 % 66 ±  16 71 ± 4 65 ±  15 63 ± 2 0 61 % 0.708
exponential % % % %
209, 6 4 % 66 ± 6 % 65 ± 4 62 ± 11 60 ± 14 55 % 0.326
exponential % % %
ADP 51 % 73 ±  13 78 ± 7 70 ±  11 69 ± 16 7 7 % 0.412
% % % %
Ristocetin 8 8 % 77 ± 6 % 89 ± 1 82 ± 8 % 83 ± 7 % 73 % 0.016
%
SFLLRN- 73 % 66 ± 16 79 ± 5 69 ± 11 63 ±  16 6 0 % 0.293
n h 2 % % % %
* A/D and D/D genotypes were present in one individual each 
Only results where platelet aggregation was induced are included
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Table S5.25. Association of FcyRlla H131R genotype with lag time to S.
aureus-induced platelet aggregation.
S. aureus  strain 
and growth 
phase
FcyRIIa H131R genotype 
H/H H/R R/R P value
Newman, 1.82 ± 0.58 min 1.94 ± 0.68 min 2.02 ± 0.69 min 0.384
stationary
209, stationary 8.02 ± 3.69 min 8.31 ± 3.85 min 9.91 ± 4.00 min 0.287
Newman, 5.90 ± 1.61 min 6.67 ± 1.29 min 5.92 ± 1.07 min 0.077
exponential
207, exponential 9.28 ± 3.64 min 9.18 ± 3.60 min 8.87 ± 3.23 min 0.765
209, exponential 1.86 ± 0.51 min 1.92 ± 0.64 min 2.16 ± 1.01 min 0.401
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Table S5.26. Association of FcyRIla H131R genotype with rate of
platelet aggregation induced by S. aureus and pharmacological
agonists.
FcyRIla H131R genotype
Agonist H/H H/R R/R P value
Newman, 37 ± 10 36 ±  11 31 ±  14 0.244
stationary
209, stationary 15 ±  4 15 ± 5 11 ± 5 0.038
Newman, 16 ±  6 16 ± 9 16 ±  7 0.945
exponential
207, exponential 13 ± 5 12 ± 6 11 ± 5 0.355
209, exponential 31 ± 9 31 ± 12 25 ± 14 0.207
ADP 45 ± 11 47 ± 13 50 ± 13 0.745
Ristocetin 43 ± 1 4 39 ± 13 41 ± 9 0.452
s f l l r n -n h 2 59 ±  15 62 ± 18 61 ±  14 0.275
Only results where platelet aggregation was induced are included
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Table S5.27. Association of FcyRIla H131R genotype with maximal
percentage platelet aggregation induced by S. aureus and
pharmacological agonists.
FcyRIIa H131R genotype
Agonist H/H H/R R/R P value
Newman, 69 ±  9 % 68.0 ± 8% 65 ±  10 % 0.351
stationary
209, stationary 68 ± 9 % 67 ± 10% 64 ± 14 % 0.611
Newman, 70 ± 14% 65 ± 17% 66 ± 9  % 0.285
exponential
207, exponential 69 ± 10% 64 ± 17% 66 ± 13 % 0.576
209, exponential 65 ±  6 % 65 ± 8 % 57 ±  15 % 0.043
ADP 73 ±  11 % 70 ±  13 % 69 ± 11 % 0.206
Ristocetin 82 ± 7 % 82 ± 7 % 80 ± 8 % 0.729
s f l l r n -n h 2 65 ± 15 % 70 ± 12% 68 ±  9 % 0.275
Only results where platelet aggregation was induced are included
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Table S5.28. Association of FeyRlla H131R genotype with lag time to S.
aureus-induced aggregation of washed platelets.
S. aureus strain FcyRIIa H131R genotype
and growth
phase H/H H/R R/R P value
Newman, 3.26 ± 0.66 min 3.19 ± 1.18 min 5.42 ± 7.96 0.949
stationary min
209, stationary 9.00 ± 8.18 min 9.59 ± 8.13 min 12.81 ± 10.31 
min
0.948
Newman, 11.98 ± 10.44 8.74 ± 8 .1 9  min 12.61 ± 10.42 0.328
exponential min min
207, exponential 23.62 ±3 .38 22.85 ± 5 .98 22.82 ± 6 .1 8 0.536
min min min




Table S5.29. Association of FcyRIla H131R genotype with rate of S.
aureus-induced aggregation of washed platelets.
Agonist
FcyRIIa H131R genotype 
1I/H H/R R/R P value
Newman, stationary 55 ± 9 49 ± 14 47 ± 12 0.616
209, stationary 32 ± 11 31 ±  17 32 ±  10 0.948
Newman, 25 ± 17 27 ± 12 16 ±  12 0.248
exponential
209, exponential 36 ± 7 28 ± 13 25 ±  12 0.171
ADP 31 ± 16 31 ± 2 5 23 ±  12 0.738
Ristocetin 3 2 ±  17 25 ± 6 27 ± 5 0.834
s f l l r n -n h 2 67 ± 3 6 52 ± 2 6 62 ± 2 8 0.603
Only results where platelet aggregation was induced were included
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Table S5.30. Association of FcyRIla H131R genotype with maximal
percentage aggregation of washed platelets induced by S. aureus and
pharmacological agonists.
FcyRIIa H131R genotype
Agonist H/H H/R R/R P value
Newman, 81 ± 3  % 79 ± 5 % 85 ± 4 % 0.066
stationary
209, stationary 75 ± 6 % 73 ± 14 % 77 ± 8 % 0.385
Newman, 69 ± 5 % 75 ± 5 % 56 ± 22 % 0.207
exponential
209, exponential 76 ± 3 % 69 ± 13 % 74 ± 5 % 0.251
ADP 33 ±31 % 29 ± 16% 26 ± 19% 0.877
Ristocetin 67 ± 6 % 68 ± 7 % 72 ± 7 % 0.520
s f l l r n -n h 2 75 ± 7 % 71 ± 7 % 68 ± 18 % 0.622
Only results where platelet aggregation was induced were included
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Table S5.31. Association of FcyRIla H131R genotype with binding of
platelets to S. aureus






H/R R/R P value
Newman, 87 ± 23 % 87 ± 18 % 80 ± 26 % 0.456
stationary
209, stationary 84 ± 28 % 90 ± 16% 82 ± 25 % 0.544
Newman, 56 ± 30 % 60 ± 29 % 57 ± 34 % 0.964
exponential
207, exponential 75 ±31  % 81 ± 21  % 70 ± 27 % 0.476
209, exponential 51 ± 2 7 % 59 ± 23 % 51 ± 3 0 % 0.730
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Table S5.32. Association of FcyRlla H131R genotype with binding of S.
aureus to platelets
S. aureus  strain 
and growth 
phase
FcyRIIa H131R genotype 
H/H H/R R/R P value
Newman, 52 ± 9 % 48 ± 13 % 47 ± 14% 0.768
stationary
209, stationary 47 ± 13 % 42 ± 12 % 40 ± 12% 0.550
Newman, 21 ± 6 % 22 ± 14% 19 ± 9 % 0.896
exponential
207, exponential 20 ± 6 % 25 ± 10% 22 ± 7 % 0.699
209, exponential 17 ± 1 % 18 ± 11 % 15 ± 5 % 0.591
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Table S5.33. Association of FcyRIla H131R genotype with S. aureus-
induced platelet activation
Agonist
FcyRIIa H131R genotype 
H/H Il/R R/R P value
Newman, 64 ± 29 % 54 ± 27 % 40 ± 25 % 0.294
stationary
209, stationary 27 ± 12% 22 ± 12% 23 ± 9 % 0.834
Newman, 49 ± 24 % 38 ± 16% 25 ± 15% 0.059
exponential
207, exponential 31 ± 2 2 % 19 ± 11 % 22 ± 1 0% 0.450
209, exponential 34 ± 23 % 23 ± 14% 21 ± 6 % 0.410
s f l l r n -n h 2 78 ± 23 % 84 ± 6 % 79 ± 11 % 0.473
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